




(12) **DEMANDE DE BREVET CANADIEN**
CANADIAN PATENT APPLICATION
(13) **A1**

(86) Date de dépôt PCT/PCT Filing Date: 2018/04/24	(51) Cl.Int./Int.Cl. <i>C07K 14/525</i> (2006.01), <i>A61K 33/24</i> (2019.01), <i>A61K 39/00</i> (2006.01), <i>A61K 48/00</i> (2006.01), <i>C07K 14/54</i> (2006.01), <i>C12N 15/113</i> (2010.01), <i>C12N 15/86</i> (2006.01), <i>C12N 7/00</i> (2006.01), <i>C12N 7/04</i> (2006.01)
(87) Date publication PCT/PCT Publication Date: 2018/11/01	(71) Demandeur/Applicant: IMPERIAL INNOVATIONS LIMITED, GB
(85) Entrée phase nationale/National Entry: 2019/10/24	(72) Inventeurs/Inventors: HAJITOU, AMIN, GB; SUWAN, KEITTISAK, GB; ALBAHRANI, MARIAM, GB; WARAMIT, SAJEE, GB
(86) N° demande PCT/PCT Application No.: GB 2018/051070	(74) Agent: RIDOUT & MAYBEE LLP
(87) N° publication PCT/PCT Publication No.: 2018/197859	
(30) Priorité/Priority: 2017/04/24 (GB1706451.0)	

(54) Titre : TRAITEMENT DU CANCER
(54) Title: CANCER TREATMENT

Figure 2



**Phagemid/Adeno-associated
Virion (PAAV)**

(57) **Abrégé/Abstract:**
The present invention provides phagemid vectors and associated phagemid particles for cancer treatment, and in particular, to the use of novel phagemid particles and associated expression systems for the treatment, prevention, amelioration, or management of cancer. In particular, the invention relates to the use of phagemid particles and expression systems for the delivery of transgenes encoding cytokines, for the treatment, prevention, amelioration, or management of cancer. The invention also extends to the use of phagemid particles and expression systems for the delivery of transgenes, and for the combination of such treatment with the use of adoptively transferred T cells, for the treatment, prevention, amelioration, or management of cancer.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
01 November 2018 (01.11.2018)



(10) International Publication Number
WO 2018/197859 A1

(51) International Patent Classification:

C07K 14/525 (2006.01) *C12N 7/04* (2006.01)
C07K 14/54 (2006.01) *A61K 33/24* (2006.01)
C12N 15/113 (2010.01) *A61K 39/00* (2006.01)
C12N 15/86 (2006.01) *A61K 48/00* (2006.01)
C12N 7/00 (2006.01)

(21) International Application Number:

PCT/GB2018/051070

(22) International Filing Date:

24 April 2018 (24.04.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

1706451.0 24 April 2017 (24.04.2017) GB

(71) Applicant: IMPERIAL INNOVATIONS LIMITED
[GB/GB]; 52 Princes Gate, London SW7 2PG (GB).

(72) Inventors: HAJITOU, Amin; c/o Imperial College London, Hammersmith Campus, Burlington Danes Building, Du Cane Road London W12 0NN (GB). SUWAN, Keittisak; c/o Imperial College London, Hammersmith Campus, Burlington Danes Building, Du Cane Road London W12 0NN (GB). ALBAHRANI, Mariam; c/o Imperial College

London, Hammersmith Campus, Burlington Danes Building, Du Cane Road London W12 0NN (GB). **WARMIT, Sajee**; c/o Imperial College London, Hammersmith Campus, Burlington Danes Building, Du Cane Road London W12 0NN (GB).


(74) Agent: HUTTER, Anton; Venner Shipley LLP, The Surrey Technology Centre, The Surrey Research Park, 40 Occam Road Guildford Surrey GU2 7YG (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

(54) Title: CANCER TREATMENT

Figure 2



(57) **Abstract:** The present invention provides phagemid vectors and associated phagemid particles for cancer treatment, and in particular, to the use of novel phagemid particles and associated expression systems for the treatment, prevention, amelioration, or management of cancer. In particular, the invention relates to the use of phagemid particles and expression systems for the delivery of transgenes encoding cytokines, for the treatment, prevention, amelioration, or management of cancer. The invention also extends to the use of phagemid particles and expression systems for the delivery of transgenes, and for the combination of such treatment with the use of adoptively transferred T cells, for the treatment, prevention, amelioration, or management of cancer.

WO 2018/197859 A1



EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*

CANCER TREATMENT

The present invention relates to cancer treatment, and in particular, to the use of novel phagemid particles and associated expression systems for the treatment, prevention, amelioration, or management of cancer. In particular, the invention relates to the use
5 of phagemid particles and expression systems for the delivery of transgenes encoding cytokines, for the treatment, prevention, amelioration, or management of cancer. The invention also extends to the use of phagemid particles and expression systems for the delivery of transgenes, and for the combination of such treatment with the use of adoptively transferred T cells, for the treatment, prevention, amelioration, or
10 management of cancer.

Paediatric high-grade gliomas are a heterogeneous group of tumours that accounts for 15%–20% of all paediatric central nervous system (CNS) tumours in children. Tumours can originate from any site within the CNS. When arising from the brainstem,
15 specifically the pons, they are referred to as DIPG. Diagnosis is based on imaging and histological appearance. Despite many clinical trials, prognosis remains poor with 2-year survival rates being less than 10%, making it one of the major causes of brain cancer-related deaths in children. Given its location, the tumour is inoperable and conventional fractionated radiation remains the mainstay treatment to provide
20 temporary benefit, with no other treatment showing any efficacy over conventional radiotherapy. Poor response to conventional treatment in DIPG therefore warrants innovative treatment approaches.

In recent years, efforts have been focused on researching gene therapy as a biological
25 mechanism-based technique to specifically target tumour cells and cause anti-tumour activity. Gene therapy has traditionally been conceived for the treatment of congenital diseases, but has increasingly been used in cancer treatment to improve efficiencies of co-administered treatments such as chemotherapy and radiotherapy, and directly induce death in tumour cells. Considering the many side effects that arise from
30 conventional cancer treatments lacking discrimination between healthy and tumour tissue, delivery of therapeutic genes via targeted vectors offer more specificity and safety.

Various cytokine genes are suitable for use in cancer immune-gene therapy such as
35 interleukins (IL-4, IL-12 and IL-15) and the Tumour Necrosis factor Alpha (TNF α) and TNF-related apoptosis-inducing ligand (TRAIL). TRAIL, a member of the TNF family,

- 2 -

induces apoptosis in various cancer cell lines, with high tolerance and minimal toxicity to normal tissue. Both local and systemic injection of TRAIL protein exerts antitumor effects on human tumour xenografts in mice. However, the rapid clearance of TRAIL following systemic administration and large dose required to achieve tumour regression have limited the TRAIL effectiveness in patients. The presently disclosed particles are ideal and cost-effective for the efficient delivery and sustained expression of the TRAIL gene in cancer. IL-4 was efficacious in the induction of antitumour effect, in mouse models of cancer. Moreover, a phase I clinical trial was initiated to determine the safety and tolerability of IL-4 in recurrent human malignant glioma when injected intratumorally by convection enhanced delivery (CED). No histological evidence of neurotoxicity to normal brain was identified in any patient and no drug-related systemic toxicity was evident in any treated patients. Six of nine patients showed glioma necrosis, and one remained disease free for >18 months after the procedure. Yet, again, the large protein dose and cost required to achieve efficacy, and the invasiveness of intracranial delivery places important limitations.

During the past two decades, IL-12 has emerged as one of the most potent cytokines in mediating antitumor activity in a variety of preclinical models. Through pleiotropic effects on different immune cells that form the tumour microenvironment, IL-12 establishes a link between innate and adaptive immunity that involves different immune effector cells and cytokines depending on the type of tumour or the affected tissue. Although IL-12 has no direct effect on tumour cells, it improves activation of cytotoxic T and NK effector cells which mediates tumour lysis. IL-12, moreover, improves the Th1 cell response, induces a panel of cytokines including IFN- γ , and exhibits antiangiogenesis. In mice, local intratumoral adenoviral vector delivery of IL-12 gene was completed safely, significantly prolonged animal survival and induced dramatic regression of tumour size.

Recently, intracranial injection of recombinant rAAV vector encoding the IL-12 was used for brain tumour gene therapy in a rat model, and resulted in antitumour effects associated with increased induction of activated microglia cells. Finally, The TNF α displays powerful anti-tumour cell effects, directly by apoptosis or indirectly by immunomodulatory activity; it also targets and destroys tumour neovascularization.

Interleukin 15 participates in the development of important immune antitumor mechanisms. It activates CD8⁺ T cells, natural killer (NK) cells, NK T cells, and can

- 3 -

promote the formation of antitumor antibodies. IL-15 can also protect T effector cells from the action of T regulatory cells and reverse tolerance to tumour associated antigens.

5 The advantages of IL-15 in tumour immunotherapy result from its unique ability to activate important mechanisms of antitumor immunity, including development and activity of both NK cells and CD8+ T cells, and promoting a persistent immune response through its action on memory T cells. What is more, IL-15 is less toxic and less effective in inducing Treg cell activity, as compared with IL-2, and in certain
10 circumstances it can even protect human effector T cells from the action of Treg cells. IL-15 is at the top of the National Cancer Institute's list of agents with the greatest potential use in tumor immunotherapy, and the first clinical study of recombinant human IL-15 in adults with refractory metastatic melanoma and metastatic renal cell cancer is currently recruiting patients ([http://clinicaltrials.gov/ct2/show/](http://clinicaltrials.gov/ct2/show/NCT01021059)
15 [NCT01021059](http://clinicaltrials.gov/ct2/show/NCT01021059)).

Survival of colon carcinoma-bearing mice has been significantly improved by treatment with IL-15 and was further improved by programmed death ligand1 (PD-L1) blockade. Still, the greatest therapeutic effects have been achieved with combination modality
20 treatment based on application of IL- 15 and blockade of both PD-L1 and cytotoxic T-lymphocyte antigen 4 (CTLA-4).

Unfortunately, in spite of high expectations, while IL-15 shows efficacy in treatment of metastatic malignancy its lack of in vivo biochemical stability is a key limiting issue.
25 The systemic rhIL-15 cytokine in clinical trials has a very short plasma half-life (<1 h) and rapid renal clearance, which easily results in impedance of efficacy. Furthermore, systemic administration of rhIL15 has the potential to cause toxic side effects, including the induction of autoimmunity.

30 Delivery of IL-15 directly into the tumour instead of systemic administration would be ideal to decrease toxicity and increase efficacy. However, direct injection into the tumour mass or incorporation of IL-15 as a transgene in adoptive cell transfer is difficult to implement. The presence of multiple metastatic sites or excessive growth and potential leukemic transformation of transduced cells may in fact limit therapeutic
35 relevance.

- 4 -

Another solution to lengthen the time window of IL-15 bioavailability was found in gene therapy approaches. The advantages of gene therapy include loco-regional production, ability to generate fusion constructs and versatility for combination strategies.

Unfortunately, systemic delivery using eukaryotic viruses has had limited success due
5 to undesired uptake by the liver and reticulo endothelial system, insertional
mutagenesis, immunogenicity arising from reactions with the complement system or
pre-existing antibodies, and broad tropism for mammalian cells . Viral tropism may be
modified by the addition of tissue-specific ligands to viral capsid proteins to mediate a
ligand-receptor interaction on the target tissue. However, addition of these ligands to
10 eukaryotic viruses can alter the structure of the viral capsid, which can reduce efficacy
and diminish targeting properties of the peptides themselves.

Thus, while the cytokines described above are suitable for use in cancer immune-
therapy, the majority of clinical trials involving cytokines fail to show sustained
15 antitumor responses because of the lack of tumour selectivity resulting in systemic
toxicity.

There is, therefore, a need for improved methods for delivery of cytokines in immune-
oncotherapy.

20 In a first aspect, there is provided a recombinant phagemid particle for expressing a
transgene in a target tumour cell transduced with the particle, for use in a method for
treating, preventing, or ameliorating cancer, wherein the phagemid particle comprises
at least one transgene expression cassette comprising a nucleic acid sequence encoding
25 one or more cytokine, and comprises a genome which lacks at least 50% of its
bacteriophage genome, and wherein the method comprises delivering the nucleic acid
sequence to at least adjacent to the tumour cell, such that one or more cytokine is
expressed.

30 In a preferred embodiment, the transgene expression cassette may encode a cytokine
which may have the effect of apoptosis induction in the tumour cell, alternation of the
tumour cell to promote endogenous anti-tumour responses, alternation of the tumour
cell to facilitate other therapies, or alternation of the tumour microenvironment to
facilitate therapy.

35

- 5 -

In a particular preferred embodiment, the cytokine may be IL-4, IL-12, IL-15, TNF α , TRAIL, IFN- γ , or any combination thereof. Preferably, the cytokine is IL-15. Preferably, the cytokine is IL-4. Preferably, the cytokine is IL-12. Preferably, the cytokine is TRAIL. Preferably, the cytokine is IFN- γ . In one preferred embodiment, the cytokine is not
5 TNF α .

However, in another preferred embodiment, the cytokine is TNF α . Preferably, the cytokine is a hybrid TNF α comprising a non-endogenous signal peptide configured to increase expression and/or secretion of TNF α . Preferably, the signal peptide is a
10 cytokine signal peptide other than that of TNF α . For example, the signal peptide is preferably the IL-2 signal peptide.

Thus, in one embodiment the transmembrane domain of TNF α is replaced with a cytokine signal peptide other than that of TNF α , preferably the IL-2 signal peptide. In
15 another embodiment, a signal peptide different to any other cytokine of the invention, preferably the IL-2 signal peptide, is combined with any other cytokine of the invention, such that the expression and/or secretion of the resulting hybrid cytokine is increased. In particular, the hybrid cytokine may be any one of a hybrid IL-4, IL-12, IL-
15, TRAIL or IFN- γ .

20 The hybrid IL-2-TNF α sequence relates to replacement of the transmembrane domain of TNF α , leaving the sequence encoding the secreted form of TNF α , with the signal peptide of IL-2, such that a hybrid TNF α produced that displays greater expression and/or secretion.

25 The skilled person would understand that “signal peptide sequence” can relate to an N-terminal sequence that functions to direct the translocation of a protein to the cellular membrane, and regulates secretion of the protein.

30 In particular, the skilled person would understand that “non-endogenous signal peptide sequence” can relate to a cytokine signal peptide, such as an interleukin, that is different to that of the cytokine being expressed.

The skilled person would understand that “hybrid cytokine” can relate to a cytokine
35 that comprises a non-endogenous signal peptide sequence.

- 6 -

In one embodiment, the full length TNF α comprising the transmembrane domain has the amino acid sequence provided herein as SEQ ID No: 12, as follows:

5' 5
MSTESMIRDVELAEEALPKKTGGPQGSRRCLFSLFSFLIVAGATTLEFCLLHFGVIGPQR
EEFPRDLSLISPLAQAVRSSSRTPSDKPVAHVVANPQAEGQLQWLNRRANALLANGVELR
DNQLVVPSEGLYLIYSQVLFKGQGPCSTHVLLTHTISRIAVSYQTKVNLLSAIKSPCQRETPEG
AEAKPWYEPIYLGGVFQLEKGDRLSAEINRPDYLDFAESGQVYFGIIAL 3'

10 [SEQ ID No: 12]

The nucleic acid sequence encoding full length TNF α comprising the transmembrane domain may be represented herein, as follows:

15 5'
ATGAGCACTGAAAGCATGATCCGGGACGTGGAGCTGGCCGAGGAGGCGCTCCCCAAGAAGACAG
GGGGGCCCCAGGGCTCCAGGCGGTGCTTGTTCTCAGCCTCTTCTCCTTCCTGATCGTGGCAGG
CGCCACCACGCTCTTCTGCCTGCTGCACTTTGGAGTGATCGGCCCCCAGAGGGAAGAGTTCCCC
AGGGACCTCTCTCTAATCAGCCCTCTGGCCCAGGCAGTCAGATCATCTTCTCGAACCCCGAGTG
20 ACAAGCCTGTAGCCCATGTTGTAGCAAACCCTCAAGCTGAGGGGCAGCTCCAGTGGCTGAACCG
CCGGGCCAATGCCCTCCTGGCCAATGGCGTGGAGCTGAGAGATAACCAGCTGGTGGTGCCATCA
GAGGGCCTGTACCTCATCTACTCCCAGGTCCTCTTCAAGGGCCAAGGCTGCCCCTCCACCCATG
TGCTCCTCACCCACACCATCAGCCGCATCGCCGTCTCCTACCAGACCAAGGTCAACCTCCTCTC
TGCCATCAAGAGCCCCTGCCAGAGGGAGACCCAGAGGGGGCTGAGGCCAAGCCCTGGTATGAG
25 CCCATCTATCTGGGAGGGGTCTTCCAGCTGGAGAAGGGTGACCGACTCAGCGCTGAGATCAATC
GGCCCGACTATCTCGACTTTGCCGAGTCTGGGCAGGTCTACTTTGGGATCATTGCCCTGTGA
3'

[SEQ ID No: 13]

30

In one embodiment, the secreted form of TNF α has the amino acid sequence provided herein as SEQ ID No: 18, as follows:

35 VRSSSRTPSDKPVAHVVANPQAEGQLQWLNRRANALLANGVELRDNQLVVPSEGLYLIYS
QVLFKGQGPCSTHVLLTHTISRIAVSYQTKVNLLSAIKSPCQRETPEGAEAKPWYEPIYL

- 7 -

GGVFQLEKGDRLSAEINRPDYLDFAESGQVYFGIIAL

[SEQ ID No: 18]

In one embodiment, the nucleic acid sequence encoding the secreted form of TNF α
 5 may be represented herein, as follows:

5'
 GTCAGATCATCTTCTCGAACCCCGAGTGACAAGCCTGTAGCCCATGTTGTAGCAAACCCTCAAG
 CTGAGGGGCAGCTCCAGTGGCTGAACCGCCGGGCCAATGCCCTCCTGGCCAATGGCGTGGAGCT
 10 GAGAGATAACCAGCTGGTGGTGCCATCAGAGGGCCTGTACCTCATCTACTCCCAGGTCCTCTTC
 AAGGGCCAAGGCTGCCCCCTCCACCCATGTGCTCCTCACCCACACCATCAGCCGCATCGCCGTCT
 CCTACCAGACCAAGGTCAACCTCCTCTCTGCCATCAAGAGCCCCCTGCCAGAGGGAGACCCAGAG
 GGGGGCTGAGGCCAAGCCCTGGTATGAGCCCATCTATCTGGGAGGGGTCTTCCAGCTGGAGAAG
 GGTGACCGACTCAGCGCTGAGATCAATCGGCCCGACTATCTCGACTTTGCCGAGTCTGGGCAGG
 15 TCTACTTTGGGATCATTGCCCTGTGA 3'

[SEQ ID No: 19]

In one embodiment, the IL-2 signal peptide has the amino acid sequence provided
 20 herein as SEQ ID No: 20, as follows:

MYRMQLLSICIALSLALVTNS

[SEQ ID No: 20]

25 In one embodiment, the nucleic acid sequence encoding the IL-2 signal peptide may be
 represented herein as SEQ ID No: 21, as follows:

5' ATGTACAGAATGCAACTCCTGTCTTGTATTGCACTAAGTCTCGCACTTGTACAAACAGT
 3'
 30

[SEQ ID No: 21]

Accordingly, in one embodiment, the hybrid IL-2- TNF α has the amino acid sequence
 provided herein as SEQ ID No 22, as follows:

35 MYRMQLLSICIALSLALVTNSESVRSSSRTPSDKPVAHVVANPQAEGQLQWLNRRANALLA

- 8 -

NGVELRDNQLVVPSEGLYLIYSQVLFGQGCPSTHVLLTHTISRIAVSYQTKVNLLSAIK
 SPCQRETPEGAEAKPWYEPIYLGGVFQLEKGDRLSAEINRPDYLDFAESGQVYFGIIAL

5

[SEQ ID No: 22]

Accordingly, in one embodiment, the nucleic acid sequence encoding hybrid IL-2-TNF α may be represented herein as SEQ ID No: 23, as follows:

10

5'

ATGTACAGAATGCAACTCCTGTCTTGTATTGCACTAAGTCTCGCACTTGTCACAAACAGTGAAT
 TCGTCAGATCATCTTCTCGAACCCCGAGTGACAAGCCTGTAGCCCATGTTGTAGCAAACCCTCA
 AGCTGAGGGGCAGCTCCAGTGGCTGAACCGCCGGGCCAATGCCCTCCTGGCCAATGGCGTGGAG
 CTGAGAGATAACCAGCTGGTGGTGCCATCAGAGGGCCTGTACCTCATCTACTCCCAGGTCCTCT
 TCAAGGGCCAAGGCTGCCCCCTCCACCCATGTGCTCCTCACCCACACCATCAGCCGCATCGCCGT
 CTCCTACCAGACCAAGGTCAACCTCCTCTCTGCCATCAAGAGCCCCTGCCAGAGGGAGACCCCA
 GAGGGGGCTGAGGCCAAGCCCTGGTATGAGCCCATCTATCTGGGAGGGGTCTTCCAGCTGGAGA
 AGGGTGACCGACTCAGCGCTGAGATCAATCGGCCCGACTATCTCGACTTTGCCGAGTCTGGGCA
 GGTCTACTTTGGGATCATTGCCCTGTGA 3'

20

[SEQ ID No: 23]

Thus, in one embodiment, the one or more cytokine comprises an amino acid sequence of any one of SEQ ID Nos: 12, 18, 20 and 22 or a fragment or variant thereof.

25

Preferably, the one or more cytokine comprises an amino acid sequence as substantially set out in SEQ ID No: 22 or a fragment or variant thereof.

30

Thus, in one embodiment, the nucleic acid sequence encoding the one or more cytokine comprises any one of SEQ ID Nos: 13, 19, 21, and 23 or a fragment or variant thereof.

Preferably, the nucleic acid sequence encoding the one or more cytokine comprises SEQ ID No: 23 or a fragment or variant thereof.

35

In a second aspect, there is provided a method of treating, preventing, or ameliorating cancer in a subject, the method comprising administering, to a subject in need of such

- 9 -

treatment, a therapeutically effective amount of the recombinant phagemid particle according to the first aspect.

5 The method of the second aspect may be used for the management of cancer in a subject.

10 In an embodiment, the recombinant phagemid particle is for use in treating, preventing or ameliorating paediatric brain tumours. In other embodiments, the recombinant phagemid particle is for use in treating, preventing or ameliorating diffuse intrinsic pontine glioma (DIPG) or medulloblastoma.

In a third aspect, there is provided a system for producing a recombinant phagemid particle from a prokaryotic host, the system comprising:-

15 (i) a first vector configured to persist inside a prokaryotic host, and comprising at least one transgene expression cassette comprising a nucleic acid sequence encoding one or more cytokine, and a packaging signal for enabling replication of the vector into single-stranded DNA; and

20 (ii) a second vector comprising nucleic acid encoding structural proteins required for packaging the single-stranded DNA, resulting in the formation and extrusion of a recombinant phagemid particle from the prokaryotic host.

In a fourth aspect, there is provided a method for producing a recombinant phagemid particle from a prokaryotic host, the method comprising:-

25 (i) introducing, into a prokaryotic host cell, a first vector configured to persist inside the prokaryotic host, and comprising at least one transgene expression cassette comprising a nucleic acid sequence encoding one or more cytokine, and a packaging signal for enabling replication of the vector into single-stranded DNA;

30 (ii) introducing, into the host, a helper phage comprising nucleic acid encoding bacteriophage structural proteins; and

(iii) culturing the host under conditions which result in the single-stranded DNA being packaged by the structural proteins to form and extrude a recombinant phagemid particle from the prokaryotic host.

35 In a fifth aspect, there is provided a method for producing a recombinant phagemid particle from a prokaryotic host, the method comprising:-

- 10 -

- 5 (i) introducing into a prokaryotic host cell: (a) a first vector configured to persist inside the prokaryotic host, and comprising at least one transgene expression cassette comprising a nucleic acid sequence encoding one or more cytokine, and a packaging signal for enabling replication of the vector into single-stranded DNA, and (b) a second vector comprising nucleic acid encoding structural proteins required for packaging the single-stranded DNA; and
- 10 (ii) culturing the host under conditions which result in the single-stranded DNA being packaged by the structural proteins to form and extrude a recombinant phagemid particle from the prokaryotic host.

15 In a sixth aspect of the invention, there is provided a pharmaceutical composition comprising the recombinant phagemid viral particle produced by the system according to the third aspect, or produced by the methods of the fourth or fifth aspect, and a pharmaceutically acceptable vehicle.

20 The invention also provides, in a seventh aspect, a process for making the pharmaceutical composition according to the sixth aspect, the process comprising contacting a therapeutically effective amount of the recombinant phagemid particle produced by the system according to the third aspect, or produced by the methods of the fourth or fifth aspect, and a pharmaceutically acceptable vehicle.

25 In another aspect of the invention there is provided a recombinant phagemid particle for expressing a transgene in a target tumour cell transduced with the particle, wherein the phagemid particle comprises at least one transgene expression cassette comprising a nucleic acid sequence encoding one or more cytokine, and comprises a genome which lacks at least 50% of its bacteriophage genome, and wherein, in use, the particle is configured to deliver the nucleic acid sequence to at least adjacent to the tumour cell, such that one or more cytokine is expressed, and wherein the cytokine is any one of IL-4, IL-12, IL-15, TRAIL, IFN- γ , hybrid TNF α or any combination thereof.

30

Preferably, the cytokine is IL-15, Preferably, the cytokine is IL-4. Preferably, the cytokine is IL-12. Preferably, the cytokine is TRAIL. Preferably, the cytokine is IFN- γ .

35 Preferably, the cytokine is a hybrid TNF α comprising a non-endogenous signal peptide configured to increase expression and/or secretion of TNF α . Preferably, the signal

- 11 -

peptide is a cytokine signal peptide other than that of TNF α . For example, the signal peptide is preferably the IL-2 signal peptide.

5 In another embodiment, a signal peptide different to any other cytokine of the invention, preferably the IL-2 signal peptide, is combined with any other cytokine of the invention, such that the expression and/or secretion of the resulting hybrid cytokine is increased. In particular, the hybrid cytokine may be any one of a hybrid IL-4, IL-12, IL-15, TRAIL or IFN- γ .

10 In a preferred embodiment, the transgene expression cassette may encode a cytokine which may have the effect of apoptosis induction in the tumour cell, alternation of the tumour cell to promote endogenous anti-tumour responses, alternation of the tumour cell to facilitate other therapies, or alternation of the tumour microenvironment to facilitate therapy

15 In a further aspect, there is provided a recombinant phagemid particle for expressing a transgene in a target tumour cell transduced with the particle, wherein the phagemid particle comprises at least one transgene expression cassette comprising a nucleic acid sequence encoding one or more cytokine, and comprises a genome which lacks at least
20 50% of its bacteriophage genome, and wherein, in use, the particle is configured to deliver the nucleic acid sequence to at least adjacent to the tumour cell, such that one or more cytokine is expressed, and wherein the cytokine is any one of IL-4, IL-12, IL-15, TRAIL, IFN- γ , hybrid TNF α or any combination thereof, for use in therapy or diagnosis.

25 Preferably, the cytokine is IL-15. Preferably, the cytokine is IL-4. Preferably, the cytokine is IL-12. Preferably, the cytokine is TRAIL. Preferably, the cytokine is IFN- γ .

30 Preferably, the cytokine is a hybrid TNF α comprising a non-endogenous signal peptide configured to increase expression and/or secretion of TNF α . Preferably, the signal peptide is a cytokine signal peptide other than that of TNF α . For example, the signal peptide is preferably the IL-2 signal peptide.

35 In another embodiment, a signal peptide different to any other cytokine of the invention, preferably the IL-2 signal peptide, is combined with any other cytokine of the invention, such that the expression and/or secretion of the resulting hybrid

- 12 -

cytokine is increased. In particular, the hybrid cytokine may be any one of a hybrid IL-4, IL-12, IL-15, TRAIL or IFN- γ .

5 There is, also a need for improved methods for treating cancer, for use with adoptive transfer therapy, such as CAR T cell therapy. The inventors have shown in the Examples that it is possible to use the particles described herein for decorating or labelling tumour cells with antigens which are recognisable by CAR T cells, and the like.

10 Thus, according to an eighth aspect of the invention, there is provided a recombinant phagemid particle for expressing at least one antigen in a target tumour cell transduced with the particle, the phagemid particle comprising at least one transgene expression cassette comprising a nucleic acid sequence encoding one or more antigen that is recognised by one or more adoptively transferred T cell, and comprising a genome which lacks at least 50% of its bacteriophage genome, and wherein, in use, the particle
15 is configured to deliver the nucleic acid sequence to at least adjacent to the target tumour cell, such that the one or more antigen is expressed, and recognised by one or more adoptively transferred T cell.

20 In a ninth aspect, there is provided the recombinant phagemid particle according to the eighth aspect, for use in therapy or diagnosis.

In a tenth aspect, there is provided the recombinant phagemid particle according to the eighth aspect, for use in treating, preventing or ameliorating cancer.

25 Advantageously, using the particles of the present invention to target the delivery and expression of cytokines and antigens to tumour cells results in greater tumour killing efficacies, and reduced off target effects that are associated with conventional therapies. The inventors have developed novel vectors and systems (a so-called “hybrid phagemid viral vector system”) that are particularly advantageous for the delivery of antigens or
30 cytokines to tumour cells. There is provided a so-called phagemid particle being referred to as Phagemid/Adeno-associated Virion (i.e. PAAV). Another name used by the inventors for the novel vectors they have created is “phasmid”. Provided herein is a bacteriophage guided cytokine therapy. Also provided herein is a bacteriophage-guided CAR T cell therapy.

35

- 13 -

Unlike the prior art AAVP genome (*Nature protocols* **2**, 523-531 (2007); *Cell* **125**, 385-398 (2006)), which consists of a rAAV cassette inserted into the filamentous phage genome, the PAAV genome of the invention does not contain any structural bacteriophage (phage) genes, and so a prokaryotic helper phage virus is required to facilitate vector assembly in the host. This is advantageous as AAVP still has certain inherent limitations of bacteriophage and thus leaves room for significant improvement of AAVP or phage vectors in general. For instance, AAVP are a hybrid between two virus species (i.e. bacteriophage and AAV), AAVP vectors contain the genome of both the eukaryotic and prokaryotic viruses. Despite being essential for AAVP viral reproduction, the prokaryotic genome is functionally or therapeutically irrelevant. Inclusion of the phage viral genome thus deleteriously affects vector efficiency and the production method, and ultimately leads to AAVP's relatively low gene transduction efficacy when compared to mammalian viruses.

Advantageously, re-engineering hybrid viral vectors (e.g. AAV or lentivirus) into the phagemid particle according to the eighth or any above aspect, substantially lacking the phage genome from which the particle is derived, dramatically enhances the functional properties of the resultant vector (i.e. the phagemid particle). Altering the viral expression system to a phagemid-based system according to the invention expands the possibility of applying phagemid viral vectors in a much broader context. By eliminating at least 50% of the bacteriophage genome, which constitutes over 50% of the genome size, from the particle's genome, the resultant particle size of the phagemid particle is dramatically reduced.

The term "phagemid particle" can refer to a hybrid phagemid genome encapsulated by phage-derived coat proteins. The hybrid phagemid genome is a "phagemid genome" (i.e. a genetic construct containing two origins of replication – one from bacteriophage (e.g. F1), and one from bacteria (e.g. pUC1)). In one embodiment, the phagemid genome may contain an incorporated "recombinant transgene cassette from AAV" (rAAV), and is therefore a hybrid and not a conventional phagemid genome with a normal (i.e. generic, non-viral) recombinant transgene expression cassette. The phagemid particle can refer to the hybrid phagemid genome (i.e. the invention) that has been encapsulated by phage proteins derived from a trans-acting agent (such as a helper phage).

35

- 14 -

While allowing additional capacities to incorporate very large or multiple transgene cassettes, these smaller phagemid particles also display added advantages in enhanced gene transfer, production yield, biodistribution and evasion from eukaryotic cellular barriers. Another significant advantage of using the phagemid particle of the invention
5 is that they have the ability to accommodate extremely large and numerous transgene cassettes or gene inserts, such as genes of the three plasmids used for recombinant virus (e.g. rAAV or lentivirus) production by transfection, as described hereinafter. Hence, by combining the genetic components for viral production in a single or multiple phagemid vector(s), an efficient commercial-scale virus-producing gene
10 delivery system has been designed. Preferably, therefore, the particle comprises multiple transgene cassettes.

In an embodiment, the recombinant phagemid particle is for use in treating a subject that has not been exposed to the delivered one or more antigen, for example by prior
15 vaccination.

In one embodiment, the phagemid particle is preferably configured to deliver the transgene expression cassette to a cell that is adjacent to the target tumour cell, such that the nucleic acid sequence is expressed, thereby producing the or each antigen or
20 cytokine, the antigen can then associate with, or become attached to, the target the tumour cell.

However, in a preferred embodiment, the phagemid particle is configured to deliver the transgene expression cassette to the target tumour cell. Preferably, the or each antigen
25 is a peptide or protein which is expressed on the cell surface of the target tumour cell. Preferably, the or each antigen is a peptide or protein that, when expressed by the tumour cell, would be accessible to a CAR T cell. The peptide or protein may be such that, when expressed by the tumour cell, it is present as a folded peptide protein at or on the cell-surface.

30 In an eleventh aspect of the invention, there is provided a recombinant phagemid particle for expressing at least one antigen in a target tumour cell transduced with the particle, the phagemid particle comprising at least one transgene expression cassette comprising a nucleic acid sequence encoding one or more cytokine, and comprising a
35 genome which lacks at least 50% of its bacteriophage genome, and wherein, in use, the

- 15 -

particle is configured to deliver the nucleic acid sequence to at least adjacent to the target tumour cell, such that the one or more cytokine is expressed.

5 In a twelfth aspect, there is provided the recombinant phagemid particle according to the eleventh aspect, for use in therapy or diagnosis.

In a thirteenth aspect, there is provided the recombinant phagemid particle according to the eleventh aspect, for use in treating, preventing or ameliorating cancer.

10 In a fourteenth aspect, there is provided a method of treating, preventing, or ameliorating cancer in a subject, the method comprising administering, to a subject in need of such treatment, a therapeutically effective amount of the recombinant phagemid particle according to the eleventh aspect.

15 In a fifteenth aspect, there is provided use of a helper phage comprising nucleic acid encoding viral vector structural proteins to produce the recombinant phagemid particle according to the eleventh aspect from a prokaryotic host.

20 In a sixteenth aspect, there is provided a recombinant phagemid viral particle according to the eleventh aspect, produced by the system according to the third aspect, produced by the methods of the fourth or fifth aspect, or produced according to the use of the fifteenth aspect, wherein the recombinant phagemid particle is for production of a recombinant viral vector comprising or derived from the viral genome within the genome of the phagemid particle, wherein the recombinant viral vector is used for
25 delivering the nucleic acid sequence encoding one or more antigen, to at least adjacent to the tumour cell, such that one or more cytokine is expressed.

30 In a seventeenth aspect, there is provided a recombinant vector comprising rAAV, rep-cap, adenohelper genes, and a nucleic acid sequence encoding one or more antigen or cytokine, for use in the treatment, prevention, or amelioration of cancer.

In an eighteenth aspect, there is provided a recombinant phagemid particle comprising the vector of the seventeenth aspect, for use in a method for the treatment, prevention, or amelioration of cancer.

35

The or each antigen may be a known target for existing CAR T cells suitable for use in humans. For example, the or each antigen may be selected from a group consisting of: MUC1; PSMA; CD19; CD20; estrogen-related receptor beta type 2 (ErRB2); or any combination thereof. The or each antigen may be MUC1 or PSMA.

5

In one embodiment, a nucleic acid sequence encoding the suitable antigen (e.g. MUC1.CD28.IL4) may be represented herein, as follows:

ATGGCTCTCCCAGTGACTGCCCTACTGCTTCCCCTAGCGCTTCTCCTGCATGCAACCGCCCCCTCCAGCCC
 10 ACGGAGTGACCAGCGCCCCCTGACACCCGGCCTGCTCCTGGAAGCACAGCTCCACCTGCCCACGGCGTTAC
 CTCTGCACCAGATACTAGGCCTGCTCCAGGCTCCATCGAGGTGATGTACCCCCCCCCCTACCTGGACAAC
 GAGAAGAGCAACGGCACCATCATCCACGTGAAGGGCAAGCACCTGTGCCCCAGCCCCCTGTTCCCCGGCC
 CCAGCAAGCCCTTCTGGGTGCTGGTGGTGGTGGGCGGCGTGCTGGCCTGCTACAGCCTGCTGGTGACCGT
 GGCTTCATCATCTTCTGGGTGCGGAGCAAGAGGAGAAAGCGCAGCGGTTCCGGCGAGGGCCGGGGCAGC
 15 CTGCTGACCTGCGGCGACGTGGAGGAGAACCCCGGCCCTATGGGCCTGACCAGCCAGCTTCTGCCCCCCC
 TGTTCTTCCTGCTGGCCTGCGCCGGCAACTTCGTGCACGGCCACAAGTGCGACATCACCTGCAGGAGAT
 CATCAAGACCCTGAACAGCCTGACCGAGCAGAAGACCCTGTGCACCGAGCTGACCGTGACCGACATCTTC
 GCCGCCAGCAAGAACACCACCGAGAAGGAGACCTTCTGCCGGGCGGCCACCGTGCTGCGGCAGTTCTACA
 GCCACCACGAGAAGGACACCCGGTGCTGGGCGCCACCGCCCAGCAGTTCCACCGGCACAAGCAACTGAT
 20 CCGGTTCTGTAAGCGGCTGGACCGGAACCTGTGGGGCCTGGCCGGCCTGAACAGTTGCCCCGTGAAGGAG
 GCCAACCAGAGCACCTGGAGAACTTCCTGGAGCGGCTGAAGACCATCATGCGGGAGAAGTACAGCAAGT
 GCAGCAGCTAG

[SEQ ID NO:14]

25

In another embodiment, a nucleic acid sequence encoding the antigen (e.g. MUC1.GPI.IL4) may be represented herein, as follows:

ATGGCTCTCCCAGTGACTGCCCTACTGCTTCCCCTAGCGCTTCTCCTGCATGCAACCGCCCCCTCCAGCCC
 ACGGAGTGACCAGCGCCCCCTGACACCCGGCCTGCTCCTGGAAGCACAGCTCCACCTGCCCACGGCGTTAC
 30 CTCTGCACCAGATACTAGGCCTGCTCCAGGCTCCCCCAACAAGGGCAGCGGCACAACCAGCGGAACCACC
 AGGCTGTTGAGCGGCCACACCTGCTTCACCCTGACAGGCCTGCTGGGCACCCTGGTGACAATGGGCCTGC
 TGACCAGGAGAAAGCGCAGCGGTTCCGGCGAGGGCCGGGGCAGCCTGCTGACCTGCGGCGACGTGGAGGA
 GAACCCCGGCCCTATGGGCCTGACCAGCCAGCTTCTGCCCCCCCCTGTTCTTCCTGCTGGCCTGCGCCGGC
 AACTTCGTGCACGGCCACAAGTGCGACATCACCTGCAGGAGATCATCAAGACCCTGAACAGCCTGACCG
 35 AGCAGAAGACCCTGTGCACCGAGCTGACCGTGACCGACATCTTCGCCGCCAGCAAGAACACCACCGAGAA
 GGAGACCTTCTGCCGGGCGGCCACCGTGCTGCGGCAGTTCTACAGCCACCACGAGAAGGACACCCGGTG
 CTGGGCGCCACCGCCCAGCAGTTCCACCGGCACAAGCAACTGATCCGGTTCCTGAAGCGGCTGGACCGGA

- 17 -

ACCTGTGGGGCCTGGCCGGCCTGAACAGTTGCCCCGTGAAGGAGGCCAACCAGAGCACCCCTGGAGAACTT
CCTGGAGCGGCTGAAGACCATCATGCGGGAGAAGTACAGCAAGTGCAGCAGCTAG

[SEQ ID NO:15]

- 5 In yet another embodiment, a nucleic acid sequence encoding the antigen (e.g. PSMA) may be represented herein, as follows:

ATGTGGAACCTGCTGCACGAGACTGACAGCGCCGTGGCAACCGCACGGAGACCCCGGTGGCTGTGCGCTG
GCGCACTGGTGCTGGCCGGCGGGTTCTTTCTGCTGGGGTTCCTGTTTGGATGGTTTATCAAAAGCTCCAA
10 CGAGGCCACCAATATTACACCTAAGCACAATATGAAAGCATTCTCTGGATGAACTGAAGGCCGAGAACATC
AAGAAATTCTGTACAACCTTTACTCAGATTCCACATCTGGCTGGCACCGAGCAGAACTTTCAGCTGGCAA
AACAGATCCAGAGCCAGTGAAGGAATTCGGGCTGGACTCCGTGGAGCTGGCCCACTACGATGTCCTGCT
GAGTTATCCAAATAAGACACATCCCAACTATATCTCAATCATTAACGAAGACGGAAATGAGATTTTCAAC
ACTTCACTGTTTGAACCCCTCCACCCGGCTACGAGAACGTGAGCGACATCGTCCCTCCATTCTCAGCCT
15 TTAGCCACAGGGAATGCCTGAGGGGGATCTGGTGTACGTCAATTATGCTCGCACCGAAGACTTCTTTAA
GCTGGAGCGAGATATGAAAATCAACTGTAGCGGCAAGATCGTGATTGCCAGATACGGCAAAGTGTTTCGC
GGGAATAAGGTCAAAAACGCTCAGCTGGCCGGGGCTAAGGGAGTGATTCTGTACTCTGACCCCGCTGATT
ATTTGCGACCTGGAGTGAAGAGTTATCCAGACGGATGGAATCTGCCAGGAGGAGGAGTGCAGCGAGGAAA
CATCCTGAACCTGAATGGGGCCGGAGATCCTCTGACCCAGGATACCCCGCCAACGAATACGCTTATAGG
20 CGAGGAATTGCAGAGGCAGTGGGACTGCCTTCCATCCCAGTCCACCCCATTTGGCTACTATGACGCCCAGA
AGCTGCTGGAGAAAATGGGAGGCTCTGCTCCCCCTGATTCTAGTTGGAGAGGCAGTCTGAAGGTGCCTTA
CAATGTCGGCCCAGGGTTCACAGGGAACCTTTTCAACTCAGAAGGTGAAAATGCACATCCATAGCACTAAT
GAAGTGACCAGGATCTATAACGTCATTGGAACCTCTGCGAGGCGCCGTGGAGCCTGACAGATACGTCATTCT
TGGGGGGACACCGCGACTCCTGGGTGTTTGGCGGGATCGATCCACAGTCTGGCGCCGCTGTGGTCCATGA
25 AATTGTGCGGTCTTTTCGGCACACTGAAGAAAGAGGGGTGGAGACCCCGACGGACTATCCTGTTTGCAAGT
TGGGATGCCGAGGAATTCGGCCTGCTGGGGAGTACAGAATGGGCCGAGGAAAATTCACGGCTGCTGCAGG
AGAGAGGGGTGGCTTACATCAATGCAGACTCAAGCATTGAAGGAACTATACACTGCGGGTGGATTGCAC
TCCCCTGATGTACAGCCTGGTCCACAACCTGACCAAGGAGCTGAAATCCCCTGACGAGGGATTCTGAAGGC
AAAAGCCTGTATGAATCCTGGACAAAGAAAAGTCCATCACCCGAGTTTAGCGGAATGCCTCGAATCTCTA
30 AGCTGGGAAGTGGCAATGATTTTGAAGTGTTCTTTTTCAGAGACTGGGGATTGCCTCCGGAAGAGCTAGGTA
CACCAAAAATTGGGAGACAAACAAGTTCTCCGGCTACCCACTGTATCACAGCGTGTACGAGACTTATGAA
CTGGTTCGAGAAATTCTACGACCCCATGTTTAAGTATCATCTGACCGTGGCACAGGTCAGGGGAGGCATGG
TGTTTGAGCTGGCCAATTCCATCGTCCTGCCATTCTGACTGTAGAGATTATGCTGTGGTCTGAGGAAGTA
CGCAGACAAAATCTATAGCATTTCCATGAAACATCCCCAGGAGATGAAGACCTACTCTGTGAGTTTCGAT
35 TCCCTGTTTTTCTGCCGTCAAAAACCTTCACAGAAATCGCTAGTAAGTTTTTCAGAGCGCCTGCAGGACTTCG
ATAAGTCTAATCCCATTGTGCTGAGGATGATGAACGACCAGCTGATGTTTCTGGAACGCGCCTTTATCGA
CCCTCTGGGGCTGCCTGATCGCCCTTCTACCGACACGTGATCTACGCACCTTCCTCTCATAACAAGTAC
GCCGGAGAGTCTTTTCCAGGCATCTATGACGCTCTGTTTCGATATTGAATCAAAGGTCGATCCCAGCAAAG

- 18 -

CATGGGGCGAGGTCAAGAGACAGATCTACGTGGCAGCCTTCACCGTCCAGGCTGCAGCCGAAACACTGAG
CGAGGTGGCCTGA

[SEQ ID NO:16]

- 5 Thus, preferably the transgene comprises a nucleic acid sequence substantially as set out in any one of SEQ ID No: 14-16, or a fragment or variant thereof.

In yet another embodiment, the antigen may comprise or be derived from an amino acid sequence (e.g. MUC1, Genbank accession number: P15941), substantially as set out
10 in SEQ ID No:17, or a fragment or variant thereof:

mtpgtqspff lllllltvltv vtgsghasst pggeketsat qrssvpsste knavsmtssv
lsshspgsgs sttggqdvltl apatepasgs aatwgqdvts vpvtrpalgs ttpahdvts
apdnkpapgs tappahgvts apdtrpapgs tappahgvts apdtrpapgs tappahgvts
15 apdtrpapgs tappahgvts apdtrpapgs tappahgvts apdtrpapgs tappahgvts
apdtrpapgs tappahgvts apdtrpapgs tappahgvts apdtrpapgs tappahgvts
apdtrpapgs tappahgvts apdtrpapgs tappahgvts apdtrpapgs tappahgvts
apdtrpapgs tappahgvts apdtrpapgs tappahgvts apdtrpapgs tappahgvts
20 apdtrpapgs tappahgvts apdtrpapgs tappahgvts apdtrpapgs tappahgvts
apdtrpapgs tappahgvts apdtrpapgs tappahgvts apdtrpapgs tappahgvts
apdtrpapgs tappahgvts apdtrpapgs tappahgvts apdtrpapgs tappahgvts
apdtrpapgs tappahgvts apdtrpapgs tappahgvts apdtrpapgs tappahgvts
25 apdtrpapgs tappahgvts apdtrpapgs tappahgvts apdtrpapgs tappahgvts
apdtrpapgs tappahgvts apdtrpapgs tappahgvts apdtrpapgs tappahgvts
apdtrpapgs tappahgvts apdtrpapgs tappahgvts apdtrpapgs tappahgvts
apdtrpapgs tappahgvts apdtrpapgs tappahgvts apdtrpapgs tappahgvts
30 ykqggflgls nikfrpgsvv vqltlaftreg tinvhdivetq fnqykteaas rynltisdvs
vsdvfpfisa qsgagvpgwg iallvlvcl valaivylia lavcqcrrkn ygqldifpar
dtyhpmseyp tyhthgryvp psstdrspye kvsagnggss lsytnpavaa tsanl

[SEQ ID NO:17]

- 35 In some embodiments, one antigen type or species, or cytokine is delivered to at least adjacent to the target tumour cell. In other embodiments, two or more antigen types or species, or cytokine are delivered to at least adjacent to the tumour cell. The two or more antigens or cytokines may be delivered by the same recombinant phagemid

- 19 -

particle, or they may be delivered separately by two or more recombinant phagemid particles.

5 In one embodiment, the or each antigen may be a self-antigen to which a CAR T cell has been developed. A self antigen may be considered to be an antigen expressed by non-tumour tissues of the subject, and such antigens have been utilised as targets for CAR T cells and are suitable for use with the present invention.

10 In a preferred embodiment, however, the or each antigen may be a wholly non-self antigen to which a CAR T cell has been developed. A non-self antigen may include neo-antigens that are newly expressed by tumours, and these neo-antigens have also been utilised as targets for CAR T cells and are also suitable for use with the present invention. A non-self antigen may include foreign antigens, not expressed by any tissues of the subject, to which a CAR T cell has been developed. Such foreign antigens
15 may be advantageous because the therapy may result in fewer “off-target” effects caused by targeting of non-tumour tissues expressing the target antigen.

In an embodiment, the or each antigen may be derived from the dengue virus or derived from yellow fever virus.

20

In a preferred embodiment, the recombinant phagemid particle is for use in a method that further comprises the use of adoptively transferred T cells. The adoptively transferred T cells may be specific for the or each antigen introduced by the recombinant phagemid particle into the target tumour cell. Preferably, more than one
25 type of T cell is adoptively transferred. Preferably, the more than one type of T cell is specific for the same antigen or for different antigens.

Preferably, the adoptively transferred T cell which recognises the one or more antigen expressed at least adjacent to the target tumour cell is selected from a group consisting
30 of a chimeric antigen receptor (CAR) T cell; a T cell receptor (TCR) transgenic T cell; and a tumour infiltrating lymphocyte (TIL). The TCR transgenic T cell may be specific for an epitope associated with the or each introduced antigen. The TIL may originate from a tissue known to contain lymphocytes with a specificity to a known antigen.

- 20 -

Most preferably, however, the adoptively transferred T cell is a chimeric antigen receptor (CAR) T cell. The CAR T cell may be specific for the or each antigen introduced by the recombinant phagemid particle into the tumour cell.

- 5 In a most preferred embodiment, the recombinant phagemid particle is for use in a method that comprises the specific targeting of tumour cells by the recombinant phagemid particle and subsequent delivery to a tumour cell of one or more sequence encoding one or more antigen or cytokine for expression by the tumour cell, and in relation to the antigen, the transfer of CAR T cells with a specificity for the one or more
10 delivered antigen, and subsequent cytotoxic activity against the tumour cells for the treatment, prevention, or amelioration of cancer.

In an embodiment, the CAR T cell may be a dual specificity CAR T cell, which may have specificity for one or more antigen delivered by one or more recombinant phagemid
15 particle. For instance, a single type or species of recombinant phagemid particle may deliver two or more antigens for recognition by a single type of dual-specificity CAR T cell.

Preferably, the phagemid particle comprises a virion. One preferred embodiment of the
20 genome of the recombinant phagemid particle is illustrated on Figure 3, with preferred components being shown on Figures 4-6.

Preferably, the genome of the recombinant phagemid particle comprises a packaging signal for enabling replication of the phagemid genome into single-stranded DNA,
25 which can subsequently be packaged into the phagemid particle inside a prokaryotic host. The packaging signal may preferably comprise an origin of replication. For example, the origin of replication preferably comprises an F1 ori, more preferably from an F1 bacteriophage. The DNA sequence of one embodiment of the F1 ori is represented herein as SEQ ID No: 1, as follows:

30
ACGCGCCCTGTAGCGGCGCATTAAGCGCGGCGGGTGTGGTGGTTACGCGCAGCGTGACCGCTACACTTGC
CAGCGCCCTAGCGCCCGCTCCTTTTCGCTTTCTTCCCTTCTCTCGCCACGTTTCGCCGGCTTTCCCCGT
CAAGCTCTAAATCGGGGGCTCCCTTTAGGGTTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAAC
TTGATTTGGGTGATGGTTCACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTTGGA
35 GTCCACGTTCTTTAATAGTGGACTCTTGTTCCAAACCTGGAACAACACTCAACCCTATCTCGGGCTATTCT

TTTGATTTATAAGGGATTTTGCCGATTTTCGGCCTATTGGTTAAAAAATGAGCTGATTTAACAAAAATTTA
ACGCGAATTTTAACAAAATATTAACGTTTACAATTT

[SEQ ID NO:1]

5

Preferably, the genome of the recombinant phagemid particle comprises an origin of replication for enabling replication of double-stranded vector inside a prokaryotic host. Preferably, the origin of replication enables high copy number replication of the vector inside the host. Preferably, the origin of replication comprises a pUC ori. The DNA
10 sequence of one embodiment of the pUC ori is represented herein as SEQ ID No: 2, as follows:

TTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAACCACCGCTACCAGCGGTGGTT
TGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAAGTGGCTTCAGCAGAGCGCAGATACCAA
15 ATACTGTCCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCT
CGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCA
AGACGATAGTTACCGGATAAGGCGCAGCGGTTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGG
AGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGG
GAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGG
20 GGAAACGCCTGGTATCTTTATAGTCCTGTCTGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGAT
GCTCGTCAGGGGGGCGGAGCCTATGGAAA

[SEQ ID NO:2]

Alternatively, in another embodiment, the phagemid particle may be designed such
25 that it integrates into the genome of a host cell. In this case, nucleic acid sequences, which favour targeted integration (e.g. by homologous recombination) of the particle's genome are envisaged. Hence, the genome of the recombinant phagemid particle may comprise one or more DNA sequence, which favours targeted integration into a host genome.

30

In another embodiment, preferably the phagemid particle may be used as a recombinant vector for the delivery of the transgene to a tissue specific target (e.g. tumour tissue), irrespective of whether the vector is administered systemically or locally to a subject *in vivo*.

35

Preferably, the at least one transgene expression cassette comprises a viral transgene expression cassette, more preferably a mammalian viral transgene expression cassette.

For example, the at least one transgene expression cassette may, in one preferred embodiment, comprise a lentivirus transgene expression cassette. The at least one transgene expression cassette is preferably an adeno-associated virus (AAV) transgene expression cassette.

5

The transgene expression cassette may comprise any nucleic acid encoding the or each antigen or cytokine, which is expressed in the target tumour cell or tissue. In one embodiment of the invention, the nucleic acid may be DNA, which may be genomic DNA or cDNA. Non-naturally occurring cDNA may be preferred in some embodiments.

10

In another embodiment, the nucleic acid may be RNA, such as antisense RNA or shRNA.

15

As shown in the illustrative Example 7, the phagemid may be used to deliver a gene to tumour cells. In this example, down-regulation of mTOR expression in tumour cells (e.g. medulloblastoma cells) may be achieved with treatment with RGD4C-phagemid carrying a sequence encoding the mTOR/shRNA (RGD4C-mTOR/ shRNA). Example 7 provides another illustrative example of the use of the phagemid to deliver genes to tumour cells. As shown in Example 7, RGD4C-phagemid can successfully deliver TNF α to DIPG (diffuse intrinsic pontine glioma) in a selective manner, resulting in apoptosis induction. Therefore, the RGD4C-phagemid has therapeutic potential for use in targeted therapy against DIPG using cytokines

20

However, it will be appreciated that the type of tumour cell, which is targeted by the recombinant phagemid particle depends on the type of cell-targeting ligand, which may be expressed on the surface of the particle. Cell-targeting ligands are discussed below.

25

The transgene expression cassette may comprise one or more functional elements required for expression of the nucleic acid in the target tumour cell. For example, preferably the transgene expression cassette comprises a promoter, such as the CMV promoter. The DNA sequence of one embodiment of the CMV promoter is represented herein as SEQ ID No: 3, as follows:

30

35

```
ACGCGTGGAGCTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCC
GCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTTGACGTCAAT
AATGACGTATGTTCCCATAGTAACGTCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGG
TAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACG
```

- 23 -

GTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTA
 CGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTT
 GACTCACGGGGATTTCCTCAAGTCTCCACCCCATGACGTCAATGGGAGTTTGTTTTGCACCAAAATCAACG
 GGACTTTCCAAAATGTCGTAACAACCTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAG
 5 GTCTATATAAGCAGAGCTCGTTTAGTGAACCGTCAGATCGCCTGGAGACGCCATCCACGCTGTTTTGACC
 TCCATAGAAGACACCGGGACCGATCCAGCCTCC

[SEQ ID NO:3]

In another preferred embodiment, the transgene expression cassette comprises a
 10 promoter which is only active in the target tumour cell. The promoter may therefore be
 tumour-activated and/or temozolomide-induced.

In an embodiment, the promoter may be multidrug resistant promoter (MDR), which is
 highly active in cancer cells. This promoter can be activated by cancer drugs to produce
 15 the P-gp and ABC transporter to efflux the drug out from the cell. This promoter may
 be used for gene therapy in combination with cancer drugs.

In another embodiment, the promoter may be human telomerase reverse transcriptase
 (hTERT) promoter. This promoter is exclusively active in tumour cells, but not in
 20 normal proliferating cells. Hence, this promoter can be used as a tumour-specific
 promoter.

In preferred embodiment, the transgene expression cassette comprises a grp78
 promoter. The nucleic acid sequence of one embodiment of the grp78 promoter is
 25 represented herein as SEQ ID No: 8, as follows:

CCCGGGGGCCCCAACGTGAGGGGAGGACCTGGACGGTTACCGGCGGAAACGGTTTCCAGGTGAGAGGTCAC
 CCGAGGGACAGGCAGCTGCTCAACCAATAGGACCAGCTCTCAGGGCGGATGCTGCCTCTCATTGGCGGCC
 GTTAAGAATGACCAGTAGCCAATGAGTCGGCTGGGGGGCGCGTACCAGTGACGTGAGTTGCGGAGGAGGC
 30 CGCTTCGAATCGGCAGCGGCCAGCTTGGTGGCATGAACCAACCAGCGGCCTCCAACGAGTAGCGAGTTCA
 CCAATCGGAGGCCTCCACGACGGGGCTGCGGGGAGGATATATAAGCCGAGTCGGCGACCGGCGCGCTCGA
 TACTGGCTGTGACTACACTGACTTGGAC

[SEQ ID NO: 8]

35 Preferably, the transgene expression cassette comprises nucleic acid for encoding a
 polyA tail attachable to the or each expressed antigen or cytokine. The DNA sequence of
 one embodiment of the nucleic acid for encoding a polyA tail is represented herein as
 SEQ ID No: 4, as follows:

- 24 -

ACGGGTGGCATCCCTGTGACCCCTCCCCAGTGCCTCTCCTGGCCCTGGAAGTTGCCACTCCAGTGCCAC
 CAGCCTTGTCTAATAAAAATTAAGTTGCATCATTTTGTCTGACTAGGTGTCCTTCTATAATATTATGGGG
 TGGAGGGGGGTGGTATGGAGCAAGGGGCAAGTTGGGAAGACAACCTGTAGGGCCTGCGGGGTCTATTGGG
 AACCAAGCTGGAGTGCAGTGGCACAATCTTGGCTCACTGCAATCTCCGCCTCCTGGGTTCAAGCGATTCT
 5 CCTGCCTCAGCCTCCCGAGTTGTTGGGATTCCAGGCATGCATGACCAGGCTCAGCTAATTTTTGTTTTT
 TGGTAGAGACGGGGTTTCACCATATTGGCCAGGCTGGTCTCCAACCTCCTAATCTCAGGTGATCTACCCAC
 CTTGGCCTCCCAAATTGCTGGGATTACAGGCGTGAACCACTGCTCCCTTCCCTGTCCTT

[SEQ ID NO:4]

10 Preferably, the transgene expression cassette comprises left and/or right Inverted
 Terminal Repeat sequences (ITRs). An ITR can be specific to an AAV or Long Terminal
 Repeats Sequences (LTRs) specific to a lentivirus serotype, and can be any sequence, so
 long as it forms a hairpin loop in its secondary structure. For example, the AAV
 serotype may be AAV1-9, but is preferably AAV1, AAV2, AAV5, AAV6 or AAV8. The
 15 DNA sequence of one embodiment (left ITR from a commercially available AAV
 plasmid) of the ITR is represented herein as SEQ ID No: 5, as follows:

CCTGCAGGCAGCTGCGCGCTCGCTCGCTCACTGAGGCCGCCGGGCGTGGGCGACCTTTGGTCGCCCCG
 CCTCAGTGAGCGAGCGAGCGCGCAGAGAGGGAGTGGCCAACTCCATCACTAGGGGTTCT

20 [SEQ ID NO:5]

The DNA sequence of another embodiment (right ITR from a commercially available
 AAV plasmid) of the ITR is represented herein as SEQ ID No: 6, as follows:

25 AGGAACCCCTAGTGATGGAGTTGGCCACTCCCTCTCTGCGCGCTCGCTCGCTCACTGAGGCCGGGCGACC
 AAAGGTCGCCCCGACGCCCGGGCTTTGCCCGGGCGGCCTCAGTGAGCGAGCGAGCGCGCAGCTGCCTGCAG
 G

[SEQ ID NO:6]

30 Preferably, the genome of the recombinant phagemid particle comprises a selection
 marker, which will depend on the host cell in which the vector is harboured, for
 example for conferring ampicillin resistance in a host cell, preferably a bacterium. The
 marker provides selection pressure during production of the phagemid particle in the
 host cell.

35 Preferably, the recombinant phagemid particle comprises one or more capsid minor
 coat protein. The recombinant phagemid particle may comprise a pIII capsid minor

- 25 -

coat protein that is configured to display a cell-targeting ligand for enabling delivery of the particle to the target tumour cell. Preferably, the recombinant phagemid particle comprises one or more capsid major coat protein. The recombinant phagemid particle may comprise at least one pVIII capsid major coat protein that is configured to display
5 a foreign peptide thereon.

The recombinant phagemid particle may comprise a modification of the capsid structure, for example by treatment, or chemical or biochemical conjugation. Examples of suitable modifications may include cross-linking peptide residues on to the
10 phagemid particle. In another embodiment, the recombinant phagemid particle may comprise one or functional peptide attached to the capsid thereof. For example, a functional peptide may comprise a nuclear translocation signal. The phagemid particle may therefore be multifunctional, and use features disclosed in WO 2014/184528.

15 In another embodiment, the recombinant phagemid particle may be combined with a cationic polymer to form a complex having a net positive charge, as described in WO 2014/184529. The cationic polymer may be selected from a group consisting of: chitosan; poly-D-lysine (PDL); diethylaminoethyl (DEAE); diethylaminoethyl-dextran (DEAE.DEX); polyethyleneimine (PEI); polybrene; protamine sulphate; and a cationic
20 lipid. Preferably, the cationic lipid is selected from the group consisting of fugene®, lipofectamine®, and DOTAP (N-[1-(2,3-Dioleoyloxy)propyl]-N,N,N-trimethylammonium methyl-sulfate). Preferably, the cationic polymer comprises DEAE, more preferably DEAE.DEX.

25 Preferably, the phagemid particle comprises a genome which substantially lacks the phage genome from which the particle is derived. Preferably, the genome of the recombinant phagemid particle lacks at least 60%, more preferably at least 70%, and even more preferably at least 80% of the bacteriophage genome from which it is derived. More preferably, the genome of the recombinant phagemid particle lacks at
30 least 90%, more preferably at least 95%, and even more preferably at least 99% of the bacteriophage genome from which it is derived. Preferably, the genome of the recombinant phagemid particle lacks all of the bacteriophage genome from which it is derived. As discussed above, however, the genome of the phagemid viral particle may, in some embodiments, comprise the bacteriophage origin of replication for enabling
35 replication of the particle into single-stranded DNA, i.e. F1 bacteriophage ori.

- 26 -

Preferably, the phagemid particle comprises a genome which has a relative genome size of less than 14 Kb. The relative genome size may be less than about 13 Kb, less than about 12 Kb, less than about 11 Kb, less than about 10Kb, less than about 9 Kb, less than about 8 Kb, or less than about 7 Kb. The relative genome size may be between 3 Kb and 9 Kb, 4 Kb and 8 Kb, 5 Kb and 7 Kb, or preferably approximately 6 Kb.

Preferably, the phagemid particle lacks bacteriophage structural genes in its genome required for the formation, packaging or extrusion of the particle from a prokaryotic host. Such structural genes encode the capsid proteins etc. Preferably, the phagemid particle comprises a genome which lacks a gene encoding a minor or major coat protein from which the particle is derived. Preferably, the phagemid particle comprises a genome which lacks a pIII capsid minor coat protein, or which lacks a pVIII capsid major coat protein. Most preferably, the phagemid particle comprises a genome which lacks both a pIII capsid minor coat protein, and a pVIII capsid major coat protein.

Thus, the recombinant phagemid particle preferably comprises a replication-deficient, virus-like-particle or virion constructed from, and displaying, the structural components, including but not limited to proteins and other conjugated compounds, derived from a bacteriophage, despite the genome of the particle not containing the structural genes of a bacteriophage from which it is derived.

Accordingly, given that the genome of the recombinant phagemid particle of the eighth or any above aspect lacks the derivative phage genome, including the structural genes, an alternative system is required in order to provide the necessary structural (i.e. capsid) genes that are required to package the recombinant phagemid genome in a bacteriophage capsid to produce the particle of the invention. Accordingly, the inventors have devised a novel system for producing the particles of the eighth or any above aspect, involving the use of a separate so-called "helper virus" vector. In effect, therefore, the particle of the eighth or any above aspect is a hybrid phagemid vector, which includes components of a phagemid and a eukaryotic virus.

Hence, in a nineteenth aspect, there is provided a system for producing a recombinant phagemid particle from a prokaryotic host, the system comprising:-
(i) a first vector configured to persist inside a prokaryotic host, and comprising at least one transgene expression cassette comprising a nucleic acid sequence encoding one or more cytokine, or one or more antigen that is recognised by one or more adoptively

- 27 -

transferred T cell, and a packaging signal for enabling replication of the vector into single-stranded DNA; and

- (ii) a second vector comprising nucleic acid encoding structural proteins required for packaging the single-stranded DNA, resulting in the formation and extrusion of a recombinant phagemid particle from the prokaryotic host.

Advantageously, separating the reproductive elements of the phagemid particle into the first “therapeutic” vector carrying the transgene encoding the or each antigen recognised by the or each adoptively transferred T cell or cytokine, and the second separate “helper” vector carrying the viral structural genes substantially decreases the genome/vector size, and thereby significantly increases transgene capacity. The phagemid particle is used therapeutically (e.g. in CAR-T cell therapy) and the increased transgene capacity is a particularly useful advantage for gene therapy applications of the new system. Consequently, this results in an enhanced production yield, gene transduction efficiency and flexibility of the vector system for other applications.

The novelty of the system of the nineteenth aspect is its ability to package the genome of eukaryotic viruses (such as AAV or lentivirus), which is provided by the first vector, into a prokaryotic virus capsid (i.e. bacteriophage), which is provided by the second vector. Thus, while the prior art system (i.e. AAVP) is a chimera of two genomes, the system of the nineteenth aspect (i.e. PAAV) is a chimera between prokaryotic viral phenotypes and a eukaryotic viral genotype.

The antigen may be any as disclosed herein. In a preferred embodiment, the or each antigen is a peptide or protein which is expressed on the cell surface of the target tumour cell. Preferably, the or each antigen is a peptide or protein that, when expressed by the tumour cell, would be accessible to a CAR T cell. The peptide or protein may be such that, when expressed by the tumour cell, it is present as a folded peptide protein at or on the cell-surface. The or each antigen may be a known target for existing CAR T cells suitable for use in humans. For example, the or each antigen may be selected from a group consisting of: MUC1; PSMA; CD19; CD20; estrogen-related receptor beta type 2 (ErRB2); or any combination thereof. In an embodiment, the or each antigen may be dengue virus or yellow fever vaccine antigens.

Preferably, the system of the nineteenth aspect is used to produce the recombinant phagemid particle of the eighth aspect. Preferably, the first vector therefore comprises

- 28 -

the genome of the recombinant phagemid particle. The packaging signal of the first vector may preferably comprise an origin of replication. Preferably, the origin of replication in the first vector comprises an F1 ori, more preferably from an F1 bacteriophage.

5

Preferably, the first vector comprises a second origin of replication for enabling replication of double-stranded vector inside a prokaryotic host. Preferably, the origin of replication enables high copy number replication of the vector inside the host.

Preferably, the origin of replication comprises a pUC ori. Alternatively, the first vector
10 may comprise one or more DNA sequence, which favours targeted integration into a host genome, thus removing the requirement for any origin of replication.

The transgene expression cassette comprises a viral transgene expression cassette, more preferably a mammalian viral transgene expression cassette. For example, the at
15 least one transgene expression cassette may comprise a lentivirus transgene expression cassette or a AAV transgene expression cassette. An AAV transgene expression cassette is preferred.

One preferred example of the second vector is illustrated in Figure 7, with preferred
20 components being shown in Figure 8. The second vector or “helper phage” is preferably a bacteriophage engineered specifically for rescuing the phagemid particles carrying the first vector (i.e. the phagemid particle’s genome) from prokaryotic hosts, an embodiment of which is shown in Figure 3. The second vector (i.e. the helper phage) is therefore provided to lend its proteins and polypeptides to the first vector (i.e. the
25 phagemid particle’s genome), or any other DNA entity that contains a functional packaging signal and/or a single stranded origin of replication. The second vector is most preferably replication-defective. Preferably, the second vector comprises a disrupted packaging signal, which significantly deters its ability to package itself into phage particles. Preferably, the second vector comprises a disrupted origin of
30 replication. In one embodiment, the disrupted origin of replication is a medium copy number origin, such as p15a. In another embodiment, the disrupted origin of replication is a low copy number origin, such as a pMB1. Preferably, the first vector (i.e. the phagemid particle’s genome) is configured to outcompete with the second vector (i.e. the helper phage) in both replication and packaging.

35

- 29 -

The genome of the second vector may be engineered to give the resultant recombinant phagemid particle targeting properties (or multifunctional properties as described in WO 2014/184528). Hence, it provides the structural capsid proteins for phagemid particle assembly. Preferably, the second vector comprises nucleic acid encoding one or
 5 more capsid minor coat proteins, or one or more capsid major coat proteins. All capsid proteins may either be wild type or recombinant, present in single or multiple copies, and modified to display chimeric or synthetic peptides. This includes the display of antigens of other viruses for peptide vaccine delivery or as an adjuvant in the case that a DNA vaccine (delivered by the phagemid particle of the eighth aspect) is desired.

10

In one example, therefore, the second vector may comprise a first nucleic acid sequence encoding a pIII minor coat protein that is configured to display a cell-targeting ligand for enabling delivery of the recombinant phagemid particle to the target cell (e.g. a tumour). Therefore, it may be desired to induce a 9-amino acid mutation in the pIII
 15 minor coat protein of the recombinant phagemid particle in order to confer its specificity to tumour cells and angiogenic tumour-associated endothelial cells that express $\alpha_v\beta_3$ and $\alpha_v\beta_5$ integrins. Thus, the genome of the second vector may comprise the RGD4C targeting peptide (CDCRGDCFC – SEQ ID No: 7).

20 In another example, the second vector may comprise a second nucleic acid sequence encoding at least one pVIII capsid major coat protein that is configured to display a foreign peptide thereon. Thus, it may be desired to induce a mutation in the wild pVIII major coat protein of the recombinant phagemid particle in order to display a short peptide, for example less than 10 amino acids long. The short peptide may be a
 25 targeting moiety and/or have inherent biological/chemical functionality *in vivo* or *in vitro*. For example, immune stimulation *in vivo* via antigen display, wherein the peptide displayed on the pVIII coat protein may be processed through the exogenous pathway and presented on the MHC II of the target cell, thus presenting another target for adoptively transferred T cells. Alternatively, the at least one pVIII major coat
 30 protein might have binding functionality, for instance to nanoparticles (e.g. gold) *in vitro* via displaying a gold-binding peptide.

The first vector may be a member of the Retroviridae family, or of the Orthoretrovirinae Sub-family. The first vector may be a member of the Lentivirus genus. Preferably, the
 35 first vector is a member of the Parvoviridae family or sub-family. Preferably, the first vector is a member of the Dependoparvovirus, or adeno-associated virus species.

Once the first vector (i.e. the phagemid particle's genome) and the second vector (i.e. the Helper phage) have been constructed, they are used together to produce, in a prokaryotic host, the recombinant phagemid particle of the eighth or any above aspect.

5 It will be appreciated that the packaging signal (e.g. the origin of replication) of the first vector, which is for enabling replication of the phagemid genome into single-stranded DNA, functions to signal the second vector (i.e. the helper phage) structural proteins to package the phagemid genome (i.e. they work together in trans in the host) to create the particle used in the eighth or any above aspect.

10

In one preferred embodiment, the first vector (phagemid particle genome) comprises a nucleic acid sequence substantially as set out in SEQ ID No: 9, or a fragment or variant thereof, wherein SEQ ID No: 9 is represented as follows, wherein "N" is a transgene.:

15 CCTGCAGGCAGCTGCGCGCTCGCTCGCTCACTGAGGCCGCCCGGGCGTCCGGGCGACCTTTGGTCGCCCCGG
CCTCAGTGAGCGAGCGAGCGCGCAGAGAGGGAGTGGCCAACTCCATCACTAGGGGTTCTGCGGCCGCNA
GGAACCCCTAGTGATGGAGTTGGCCACTCCCTCTCTGCGCGCTCGCTCGCTCACTGAGGCCGGGCGACCA
AAGGTCGCCCCGACGCCCGGGCTTTGCCCGGGCGGCCTCAGTGAGCGAGCGAGCGCGCAGCTGCCTGCAGG
GGCGCCTGATGCGGTATTTTCTCCTTACGCATCTGTGCGGTATTTACACCCGCATACGTCAAAGCAACCA
20 TAGTACGCGCCCTGTAGCGGCGCATTAAGCGCGGCGGGTGTGGTGGTTACGCGCAGCGTGACCGCTACAC
TTGCCAGCGCCCTAGCGCCCGCTCCTTTTCGCTTTCTTCCCTTCCCTTTCTCGCCACGTTTCGCCGGCTTTCC
CCGTCAAGCTCTAAATCGGGGGCTCCCTTTAGGGTTCCGATTTAGTGCTTTACGGCACCTCGACCCCCAAA
AACTTGATTTGGGTGATGGTTCACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTTCGCCCTTTGACGT
TGGAGTCCACGTTCTTTAATAGTGGACTCTTGTTCCAAACTGGAACAACACTCAACCCTATCTCGGGCTA
25 TTCTTTTGATTTATAAGGGATTTTGGCGATTTTCGGCCTATTGGTTAAAAAATGAGCTGATTTAACAAAA
TTTAACGCGAATTTTAACAAAATATTAACGTTTACAATTTTATGGTGCACCTCTCAGTACAATCTGCTCTG
ATGCCGCATAGTTAAGCCAGCCCCGACACCCGCCAACACCCGCTGACGCGCCCTGACGGGCTTGTCTGCT
CCCGGCATCCGCTTACAGACAAGCTGTGACCGTCTCCGGGAGCTGCATGTGTGTCAGAGGTTTTACCGTCA
TCACCGAAACGCGCGAGACGAAAGGGCCTCGTGATACGCCTATTTTTTATAGGTTAATGTCATGATAATAA
30 TGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTA
AATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGG
AAGAGTATGAGTATTCAACATTTCCGTGTGCGCCCTTATTCCTTTTTTTCGCGCATTTTGCCTTCTGTTT
TTGCTCACCCAGAAACGCTGGTGAAAGTAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACAT
CGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTTCGCCCCGAAGAACGTTTTTCCAATGATGAGC
35 ACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTATTGACGCCGGGCAAGAGCAACTCGGTCCGC
GCATACACTATTCTCAGAAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCAT
GACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACA
ACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACCTCGCCTTGATC
GTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGTAGCAATGGC
40 AACAACGTTGCGCAAACCTATTAACCTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGG
ATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATA
AATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCG
TATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATA
GGTGCCTCACTGATTAAGCATTGGTAACCTGTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTAA
45 AACTTCATTTTTTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTTGATAATCTCATGACCAAAATCCCTTA
ACGTGAGTTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTT
TTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAACCACCGCTACCAGCGGTGGTTTGTGTTGCCGGATC
AAGAGCTACCAACTCTTTTTCCGAAGGTAACCTGGCTTCAGCAGAGCGCAGATACCAAATACTGTCTTCT
AGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATC
50 CTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTAC

CGGATAAGGCGCAGCGGTTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTA
 CACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGAC
 AGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGT
 ATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGG
 5 GCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCT
 CACATGT

[SEQ ID No: 9]

10 In one preferred embodiment, the second vector (helper phage with RGD sequence)
 comprises a nucleic acid sequence substantially as set out in SEQ ID No: 10, or a
 fragment or variant thereof, wherein SEQ ID No: 10 is represented as follows:

AACGCTACTACTATTAGTAGAATTGATGCCACCTTTTCAGCTCGCGCCCCAAATGAAAATATAGCTAAAC
 15 AGGTTATTGACCATTTGCGAAATGTATCTAATGGTCAAACCTAAATCTACTCGTTCGCAGAATTGGGAATC
 AACTGTTACATGGAATGAACTTCCAGACACCGTACTTTAGTTGCATATTTAAAACATGTTGAGCTACAG
 CACCAGATTCAGCAATTAAGCTCTAAGCCATCCGCAAAAATGACCTCTTATCAAAGGAGCAATTAAAGG
 TACTCTCTAATCCTGACCTGTTGGAGTTTGCTTCCGGTCTGGTTCGCTTTGAAGCTCGAATTAAAACGCG
 ATATTTGAAGTCTTTTCGGGCTTCTCTTAATCTTTTTGATGCAATCCGCTTTGCTTCTGACTATAATAGT
 20 CAGGGTAAAGACCTGATTTTTGATTTATGGTCATTCTCGTTTTCTGAACTGTTTAAAGCATTTGAGGGGG
 ATTCAATGAATATTTATGACGATTCCGCGAGTATTGGACGCTATCCAGTCTAAACATTTTACTATTACCCC
 CTCTGGCAAACTTCTTTTGCAAAAGCCTCTCGCTATTTTGGTTTTTATCGTCGTCTGGTAAACGAGGGT
 TATGATAGTGTGCTCTTACTATGCCTCGTAATTCCTTTTGGCGTTATGTATCTGCATTAGTTGAATGTG
 GTATTCCTAAATCTCAACTGATGAATCTTCTACCTGTAATAATGTTGTTCCGTTAGTTTCGTTTTATTAA
 25 CGTAGATTTTTCTTCCCAACGTCCTGACTGGTATAATGAGCCAGTTCTTAAAATCGCATAAGGTAATTCA
 CAATGATTAAAGTTGAAATTAAACCATCTCAAGCCCAATTTACTACTCGTTCCTGGTGTTCCTCGTCAGGG
 CAAGCCTTATTCACTGAATGAGCAGCTTTGTTACGTTGATTTGGGTAATGAATATCCGGTTCTTGTCAAG
 ATTACTCTTGATGAAGGTCAGCCAGCCTATGCGCCTGGTCTGTACACCGTTCATCTGTCTCTTTCAAAG
 TTGGTCAGTTCCGGTTCCTTATGATTGACCGTCTGCGCCTCGTTCGCGCTAAGTAACATGGAGCAGGTCG
 30 CGGATTTTCGACACAATTTATCAGGCGATGATACAAATCTCCGTTGTACTTTGTTTTCGCGCTTGGTATAAT
 CGCTGGGGGTCAAAGATGAGTGTTTTAGTGTATTCTTTTCGCTCTTTTCGTTTTAGGTTGGTGCCTTCGTA
 GTGGCATTACGTATTTTACCCGTTTAAATGGAACTTCCCTCATGAAAAAGTCTTTAGTCCTCAAAGCCTCT
 GTAGCCGTTGCTACCCCTCGTTCGGATGCTGTCTTTTCGCTGCTGAGGGTGACGATCCCGCAAAAGCGGCCT
 TTAACCTCCCTGCAAGCCTCAGCGACCGAATATATCGGTTATGCGTGGGCGATGGTTGTTGTCAATTGTGCG
 35 CGCAACTATCGGTATCAAGCTGTTTAAGAAATTCACCTCGAAAGCAAGCTGATAAACCGATACAATTAAA
 GGCTCCTTTTGGAGCCTTTTTTTTTTGGAGATTTTCAACGTGAAAAAATTATTATTTCGAATTCCTTTAGT
 TGTTCCTTTCTATTCTCACTCCGCTTGTGATTGTAGGGGGGATTGTTTTTGTGAAACTGTTGAAAGTTGT
 TTAGCAAAACCCCATACAGAAAATTCATTTACTAACGTCTGGAAAGACGACAAAACCTTTAGATCGTTACG
 CTAACCTATGAGGGTTGTCTGTGGAATGCTACAGGCGTTGTAGTTTGTACTGGTGACGAAACTCAGTGTTA
 40 CGGTACATGGGTTCCCTATTGGGCTTGCTATCCCTGAAAATGAGGGTGGTGGCTCTGAGGGTGGCGGTTCT
 GAGGGTGGCGGTTCTGAGGGTGGCGGTACTAAACCTCCTGAGTACGGTGATACACCTATTCCGGGCTATA
 CTTATATCAACCCTCTCGACGGCACTTATCCGCCTGGTACTGAGCAAAACCCCGCTAATCCTAATCCTTC
 TCTTGAGGAGTCTCAGCCTCTTAATACTTTTCATGTTTCAGAATAATAGGTTCCGAAATAGGCAGGGGGCA
 TTAACCTGTTTATACGGGCACTGTTACTCAAGGCACTGACCCCGTTAAACTTATTACCAGTACACTCCTG
 45 TATCATCAAAGCCATGTATGACGCTTACTGGAACGGTAAATTCAGAGACTGCGCTTTCCATTCTGGCTT
 TAATGAGGATCCATTCGTTTGTGAATATCAAGGCCAATCGTCTGACCTGCCTCAACCTCCTGTCAATGCT
 GGCGGCGGCTCTGGTGGTGGTTCTGGTGGCGGCTCTGAGGGTGGTGGCTCTGAGGGTGGCGGTTCTGAGG
 GTGGCGGCTCTGAGGGAGGCGGTTCCGGTGGTGGCTCTGGTTCCGGTGATTTTGATTATGAAAAGATGGC
 AAACGCTAATAAGGGGGCTATGACCGAAAATGCCGATGAAAACGCGCTACAGTCTGACGCTAAAGGCAAA
 50 CTTGATTCTGTGCTACTGATTACGGTGCTGCTATCGATGGTTTCATTGGTGACGTTTCCGGCCTTGCTA
 ATGGTAATGGTGCTACTGGTGATTTTGCTGGCTCTAATTCCTCAAATGGCTCAAGTCGGTGACGGTGATAA
 TTCACCTTTAATGAATAATTTCCGTCAATATTTACCTTCCCTCCCTCAATCGGTTGAATGTGCGCCCTTTT
 GTCTTTAGCGCTGGTAAACCATATGAATTTTCTATTGATTGTGACAAAATAAACTTATTCCGTGGTGTCT
 TTGCGTTTCTTTTATATGTTGCCACCTTTATGTATGTATTTTCTACGTTTGCTAACATACTGCGTAATAA
 55 GGAGTCTTAATCATGCCAGTTCTTTTGGGTATTCCGTTATTATTGCGTTTCCCTCGGTTTCTTCTGGTAA
 CTTTGTTCGGCTATCTGCTTACTTTTCTTAAAAAGGGCTTCGGTAAGATAGCTATTGCTATTTTCATTGTT
 TCTTGCTCTTATTATTGGGCTTAACTCAATTCTTGTGGGTATCTCTCTGATATTAGCGCTCAATTACCC

TCTGACTTTGTTTCAGGGTGTTTCAGTTAATTCTCCCGTCTAATGCGCTTCCCTGTTTTTATGTTATTCTCT
 CTGTAAAGGCTGCTATTTTTCATTTTTGACGTTAAACAAAAAATCGTTTCTTATTTGGATTGGGATAAATA
 ATATGGCTGTTTATTTTGTAACTGGCAAATTAGGCTCTGGAAAGACGCTCGTTAGCGTTGGTAAGATTCA
 GGATAAAATTGTAGCTGGGTGCAAAATAGCAACTAATCTTGATTTAAGGCTTCAAAACCTCCCGCAAGTC
 5 GGGAGGTTTCGCTAAAACGCCTCGCGTTCTTAGAATACCGGATAAGCCTTCTATATCTGATTTGCTTGCTA
 TTGGGCGCGGTAATGATTCCCTACGATGAAAATAAAAACGGCTTGCTTGTTCTCGATGAGTGCGGTACTTG
 GTTTAATACCCGTTCTTGGAATGATAAGGAAAGACAGCCGATTATTGATTGGTTTCTACATGCTCGTAAA
 TTAGGATGGGATATTATTTTTCTTGTTTCAGGACTTATCTATTGTTGATAAACAGGCGCGTTCTGCATTAG
 CTGAACATGTTGTTTATTGTCGTCGTCTGGACAGAATTACTTTACCTTTTGTTCGGTACTTTATATTCTCT
 10 TATTACTGGCTCGAAAATGCCTCTGCCTAAATTACATGTTGGCGTTGTTAAATATGGCGATTCTCAATTA
 AGCCCTACTGTTGAGCGTTGGCTTTTACTGGTAAGAATTTGTATAACGCATATGATACTAAACAGGCTT
 TTTCTAGTAATTATGATTCCGGTGTTTATTCTTATTTAACGCCTTATTTATCACACGGTCGGTATTTCAA
 ACCATTAAATTTAGGTCAGAAGATGAAATTAATAAATAATTTGAAAAAGTTTTCTCGCGTTCTTTGT
 CTTGCGATTGGATTTGCATCAGCATTACATATAGTTATATAACCCAACCTAAGCCGGAGGTTAAAAAGG
 15 TAGTCTCTCAGACCTATGATTTTGATAAATTCATATTGACTCTTCTCAGCGTCTTAATCTAAGCTATCG
 CTATGTTTTCAAGGATTCTAAGGGAAAAATTAATTAATAGCGACGATTTACAGAAGCAAGGTTATTCACTC
 ACATATATTGATTTATGTACTGTTTCCATTAAAAAAGGTAATTCAAATGAAATTGTTAAATGTAATTAAT
 TTTGTTTTCTTGATGTTTGTTTCATCATCTTCTTTTGCTCAGGTAATTGAAATGAATAATTCGCCTCTGC
 GCGATTTTGTAACCTGGTATTCAAAGCAATCAGGCGAATCCGTTATTGTTTCTCCCGATGTAAAAGGTAC
 20 TGTTACTGTATATTCATCTGACGTTAAACCTGAAAATCTACGCAATTTCTTTATTTCTGTTTTACGTGCT
 AATAATTTTGATATGGTTGGTTCAATTCCTTCCATAATTCAGAAGTATAATCCAAACAATCAGGATTATA
 TTGATGAATTGCCATCATCTGATAATCAGGAATATGATGATAATTCCGCTCCTTCTGGTGGTTTCTTTGT
 TCCGCAAAATGATAATGTTACTCAAACCTTTTAAAAATTAATAACGTTTCGGGCAAAGGATTTAATACGAGTT
 GTCGAATTGTTTGTAAGTCTAATACTTCTAAATCCTCAAATGTATTATCTATTGACGGCTCTAATCTAT
 25 TAGTTGTTAGTGCACCTAAAGATATTTTAGATAACCTTCCTCAATTCCTTTCTACTGTTGATTTGCCAAC
 TGACCAGATATTGATTGAGGGTTTGATATTTGAGGTTTCAGCAAGGTGATGCTTTAGATTTTTTCATTTGCT
 GCTGGCTCTCAGCGTGGCACTGTTGCAGGCGGTGTTAATACTGACCGCCTCACCTCTGTTTTATCTTCTG
 CTGGTGGTTTCGTTTCGGTATTTTTTAATGGCGATGTTTTAGGGCTATCAGTTTCGCGCATTAAGACTAATAG
 CCATTCAAAAATATTGTCTGTGCCACGTATTCTTACGCTTTCAGGTCAGAAGGGTTCTATCTCTGTTGGC
 30 CAGAATGTCCCTTTTATTACTGGTCGTGTGACTGGTGAATCTGCCAATGTAAATAATCCATTTACAGACGA
 TTGAGCGTCAAAATGTAGGTATTTCCATGAGCGTTTTTCCTGTTGCAATGGCTGGCGGTAATATTGTTCT
 GGATATTACCAGCAAGGCCGATAGTTTGAGTTCTTCTACTCAGGCAAGTGATGTTATTACTAATCAAAGA
 AGTATTGCTACAACGGTTAATTTGCGTGATGGACAGACTCTTTTACTCGGTGGCCTCACTGATTATAAAA
 ACACTTCTCAAGATTCTGGCGTACCGTTCCTGTCTAAAATCCCTTTAATCGGCCTCCTGTTTAGCTCCCG
 35 CTCTGATTCCAACGAGGAAAGCACGTTATACGTGCTCGTCAAAGCAACCATAGTACGCGCCCTGTAGCGG
 CGCATTAAGCGCGGCGGGTGTTGTTGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCC
 GCTCCTTTTCGCTTTCTTCCCTTCCTTTCTCGCCACGTTTCGCCGGCTTTCCCCGTCAAGCTCTAAATCGGG
 GGCTCCCTTTAGGGTTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAACTTGATTTGGGTGATGG
 TTCACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTTGGAGTCCACGTTCTTTAAT
 40 AGTGGACTCTTGTTCCAAACTGGAACAACACTCAACCCTATCTCGGGACGGATCGCTTCATGTGGCAGGA
 GAAAAAAGGCTGCACCGGTGCGTCAGCAGAATATGTGATACAGGATATATTCCGCTTCCTCGCTCACTGA
 CTCGCTACGCTCGGTGCTTCGACTGCGGCGAGCGGAAATGGCTTACGAACGGGGCGGAGATTTCTTGAA
 GATGCCAGGAAGATACTTAACAGGGAAGTGAGAGGGCCGCGGCAAAGCCGTTTTTCCATAGGCTCCGCCC
 CCCTGACAAGCATCACGAAATCTGACGCTCAAATCAGTGGTGGCGAAACCCGACAGGACTATAAAGATAC
 45 CAGGCGTTTTCCCCCTGGCGGCTCCCTCGTGCGCTCTCCTGTTCTGCTTTTCGGTTTACCGGTGTCATTC
 CGCTGTTATGGCCGCGTTTGTCTCATTCCACGCCTGACACTCAGTTCCGGGTAGGCAGTTTCGCTCCAAGC
 TGGACTGTATGCACGAACCCCCCGTTTCAGTCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTC
 CAACCCGGAAAGACATGCAAAAGCACCCTGGCAGCAGCCACTGGTAATTGATTTAGAGGAGTTAGTCTT
 GAAGTCATGCGCCGGTTAAGGCTAAACTGAAAGGACAAGTTTTGGTGACTGCGCTCCTCCAAGCCAGTTA
 50 CCTCGGTTCAAAGAGTTGGTAGCTCAGAGAACCTTCGAAAAACCGCCCTGCAAGGCGGTTTTTTTCGTTTT
 CAGAGCAAGAGATTACGCGCAGACCAAAACGATCTCAAGAAGATCATCTTATTAAGGGGTCTGACGCTCA
 GTGGAACGAAAACCTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTT
 TTAATTAATAAATGAAGTTTTTAAATCAATCTAAAGTATATATGAGTAACTTGGTCTGACAGTTACCAAT
 GCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTTCGTTTCATCCATAGTTGCCTGACTCCCCGT
 55 CGTGTAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCA
 CGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGATTTCGAGCTCGCCCCGGGGATCGACCA
 GTTGGTGATTTTGAACCTTTTGCTTTGCCACGGAACGGTCTGCGTTGTTCGGGAAGATGCGTGATCTGATCC
 TTCAACTCAGCAAAAGTTTCGATTTATTCAACAAAGCCCGTCCCGTCAAGTCAGCGTAATGCTCTGCCA
 GTGTTACAACCAATTAACCAATTCTGATTAGAAAAACTCATCGAGCATCAAATGAAACTGCAATTTATTC

- 33 -

ATATCAGGATTATCAATACCATATTTTTGAAAAAGCCGTTTCTGTAATGAAGGAGAAAACTCACCGAGGC
 AGTTCCATAGGATGGCAAGATCCTGGTATCGGTCTGCGATTCCGACTCGTCCAACATCAATACAACCTAT
 TAATTTCCCCTCGTCAAAAATAAGGTTATCAAGTGAGAAATCACCATGAGTGACGACTGAATCCGGTGAG
 AATGGCAAAAGCTTATGCATTTCTTTCCAGACTTGTTCAACAGGCCAGCCATTACGCTCGTCATCAAAAT
 5 CACTCGCATCAACCAAACCGTTATTCATTTCGTGATTGCGCCTGAGCGAGACGAAATACGCGATCGCTGTT
 AAAAGGACAATTACAAACAGGAATCGAATGCAACCGGCGCAGGAACACTGCCAGCGCATCAACAATATTT
 TCACCTGAATCAGGATATTCTTCTAATACCTGGAATGCTGTTTTCCCGGGGATCGCAGTGGTGAGTAACC
 ATGCATCATCAGGAGTACGGATAAAATGCTTGATGGTCGGAAGAGGCATAAATTCGTCAGCCAGTTTAG
 TCTGACCATCTCATCTGTAACATCATTGGCAACGCTACCTTTGCCATGTTTCAGAAACAACCTCTGGCGCA
 10 TCGGGCTTCCCATAACAATCGATAGATTGTTCGCACCTGATTGCCCCGACATTATCGCGAGCCCCATTTATACC
 CATATAAATCAGCATCCATGTTGGAATTTAATCGCGGCCTCGAGCAAGACGTTTCCCGTTGAATATGGCT
 CATAACACCCCTTGTATTACTGTTTATGTAAGCAGACAGTTTTATTGTTTCATGATGATATATTTTTATCT
 TGTGCAATGTAACATCAGAGATTTTGAGACACAACGTGGCTTTCCCCCCCCCCCCCTGCAGGTCTCGGGC
 TATTCTTTTGATTTATAAGGGATTTTGCCGATTTCCGGCCTATTGGTTAAAAAATGAGCTGATTTAACAAA
 15 AATTTAACGCGAATTTTAACAAAATATTAACGTTTACAATTTAAATATTTGCTTATACAATCTTCCTGTT
 TTTGGGGCTTTTCTGATTATCAACCGGGGTACATATGATTGACATGCTAGTTTTACGATTACCGTTCATC
 GATTCTCTTGTGTTGCTCCAGACTCTCAGGCAATGACCTGATAGCCTTTGTAGACCTCTCAAAAATAGCTA
 CCCTCTCCGGCATGAATTTATCAGCTAGAACGGTTGAATATCATATTGATGGTGATTTGACTGTCTCCGG
 CCTTTCTCACCCCTTTTGAATCTTTACCTACACATTACTCAGGCATTGCATTTAAAAATATATGAGGGTTCT
 20 AAAAATTTTTATCCTTGCGTTGAAATAAAGGCTTCTCCCGCAAAAGTATTACAGGGTCATAATGTTTTTG
 GTACAACCGATTTAGCTTTATGCTCTGAGGCTTTATTGCTTAATTTTGCTAATTCTTTGCCTTGCCTGTA
 TGATTTATTGGATGTT

[SEQ ID No: 10]

25 In one preferred embodiment, the second vector (helper phage without RGD sequence)
 comprises a nucleic acid sequence substantially as set out in SEQ ID No: 11, or a
 fragment or variant thereof, wherein SEQ ID No: 11 is represented as follows:

AACGCTACTACTATTAGTAGAATTGATGCCACCTTTTCAGCTCGCGCCCCAAATGAAAATATAGCTAAAC
 30 AGGTTATTGACCATTTGCGAAATGTATCTAATGGTCAAACATAATCTACTCGTTTCGCAGAATTGGGAATC
 AACTGTTACATGGAATGAACTTCCAGACACCGTACTTTAGTTGCATATTTAAAACATGTTGAGCTACAG
 CACCAGATTCAGCAATTAAGCTCTAAGCCATCCGCAAAAATGACCTCTTATCAAAAGGAGCAATTAAAGG
 TACTCTCTAATCCTGACCTGTTGGAGTTTGCTTCCGGTCTGGTTTCGCTTTGAAGCTCGAATTAAAACGCG
 ATATTTGAAGTCTTTTCGGGCTTCTCTTAATCTTTTTGATGCAATCCGCTTTGCTTCTGACTATAATAGT
 35 CAGGGTAAAGACCTGATTTTTGATTTATGGTCATTCTCGTTTTCTGAACTGTTTAAAGCATTTGAGGGGG
 ATTCAATGAATATTTATGACGATTCCGCAGTATTGGACGCTATCCAGTCTAAACATTTTACTATTACCCC
 CTCTGGCAAACTTCTTTTGCAAAAGCCTCTCGCTATTTTGGTTTTTATCGTCGTCTGGTAAACGAGGGT
 TATGATAGTGTGCTCTTACTATGCCTCGTAATTCCTTTTGGCGTTATGTATCTGCATTAGTTGAATGTG
 GTATTCCATAATCTCAACTGATGAATCTTTCTACCTGTAATAATGTTGTTCCGTTAGTTTCGTTTTATTAA
 40 CGTAGATTTTTCTTCCCAACGTCCTGACTGGTATAATGAGCCAGTTCTTAAAAATCGCATAAGGTAATTCA
 CAATGATTAAAGTTGAAATTAACCATCTCAAGCCCAATTTACTACTCGTTCTGGTGTTTCTCGTCAGGG
 CAAGCCTTATTCAGTGAATGAGCAGCTTTGTTACGTTGATTTGGGTAAATGAATATCCGGTTCTTGTCAAG
 ATTACTCTTGATGAAGGTCAGCCAGCCTATGCGCCTGGTCTGTACACCGTTTCATCTGTCCTCTTTCAAAG
 TTGGTCAGTTTCGGTTCCCTTATGATTGACCGTCTGCGCCTCGTTCCGGCTAAGTAACATGGAGCAGGTCG
 45 CGGATTTTCGACACAATTTATCAGGCGATGATACAAATCTCCGTTGTACTTTGTTTTCGCGCTTGGTATAAT
 CGCTGGGGGTCAAAGATGAGTGTTTTAGTGTATTCTTTGCGCTCTTTGTTTTAGGTTGGTGCCTTCGTA
 GTGGCATTACGTATTTTACCCGTTTAAATGGAACTTCCTCATGAAAAAGTCTTTAGTCCTCAAAGCCTCT
 GTAGCCGTTGCTACCCTCGTTCCGATGCTGTCTTTGCTGCTGAGGGTGACGATCCCGCAAAAGCGGCCT
 TTAACCTCCCTGCAAGCCTCAGCGACCGAATATATCGGTTATGCGTGGGCGATGGTTGTTGTCATTGTGCG
 50 CGCAACTATCGGTATCAAGCTGTTTAAGAAATTCACCTCGAAAGCAAGCTGATAAACCGATACAATTAAA
 GGCTCCTTTTGGAGCCTTTTTTTTTTGGAGATTTTCAACGTGAAAAAATTATTATTTCGAATTCCTTTAGT
 GTTTCCTTTCTATTCTCACTCCGCTGAACTGTTGAAAGTTGTTTAGCAAAACCCCATACAGAAAATTCA
 TTTACTAACGTCTGGAAAGACGACAAAACCTTTAGATCGTTACGCTAACTATGAGGGTTGTCTGTGGAATG
 CTACAGGCGTTGTAGTTTGTACTGGTGACGAACTCAGTGTACGGTACATGGGTTCCTATTGGGCTTGC
 55 TATCCCTGAAAATGAGGGTGGTGGCTCTGAGGGTGGCGGTTCTGAGGGTGGCGGTTCTGAGGGTGGCGGT
 ACTAAACCTCCTGAGTACGGTGATACACCTATTCGGGGCTATACTTATATCAACCTCTCGACGGCACTT
 ATCCGCCTGGTACTGAGCAAAACCCCGCTAATCCTAATCCTTCTCTTGAGGAGTCTCAGCCTCTTAATAC

TTTCATGTTTCAGAATAATAGGTTCCGAAATAGGCAGGGGGGCATTAACCTGTTTATACGGGCACTGTTACT
 CAAGGCACTGACCCCGTTAAACTTTATTACCAGTACACTCCTGTATCATCAAAAGCCATGTATGACGCTT
 ACTGGAACGGTAAATTCAGAGACTGCGCTTTCCATTCTGGCTTTAATGAGGATCCATTTCGTTTGTGAATA
 TCAAGGCCAATCGTCTGACCTGCCTCAACCTCCTGTCAATGCTGGCGGGCGGCTCTGGTGGTGGTTCTGGT
 5 GGCGGCTCTGAGGGTGGTGGCTCTGAGGGTGGCGGTTCTGAGGGTGGCGGCTCTGAGGGAGGCGGTTCCG
 GTGGTGGCTCTGGTTCCGGTGATTTTGATTATGAAAAGATGGCAAACGCTAATAAGGGGGCTATGACCGA
 AAATGCCGATGAAAACGCGCTACAGTCTGACGCTAAAGGCAAACCTTGATTCTGTGCTACTGATTACGGT
 GCTGCTATCGATGGTTTCATTGGTGACGTTTCCGGCCTTGCTAATGGTAATGGTGCTACTGGTGATTTTG
 CTGGCTCTAATTCCCAAATGGCTCAAGTCGGTGACGGTGATAATTCACCTTTAATGAATAATTTCCGTCA
 10 ATATTTACCTTCCCTCCCTCAATCGGTTGAATGTCGCCCTTTTGTCTTTAGCGCTGGTAAACCATATGAA
 TTTTCTATTGATTGTGACAAAATAAACTTATTCCGTGGTGTCTTTGCGTTTCTTTTATATGTTGCCACCT
 TTATGTATGTATTTTCTACGTTTGCTAACATACTGCGTAATAAGGAGTCTTAATCATGCCAGTTCTTTTG
 GGTATTCGGTTATTATTGCGTTTCCCTCGGTTTCCCTTCTGGTAACCTTTGTTGCGCTATCTGCTTACTTTTC
 TAAAAAGGGCTTCGGTAAGATAGCTATTGCTATTTCAATTGTTTCTTGCTCTTATTATTGGGCTTAACTC
 15 AATTCTTGTTGGTTATCTCTCTGATATTAGCGCTCAATTACCCTCTGACTTTGTTTCAGGGTGTTCAGTTA
 ATTCTCCCGTCTAATGCGCTTCCCTGTTTTTATGTTATTCTCTCTGTAAAGGCTGCTATTTTTCATTTTTG
 ACGTTAAACAAAAAATCGTTTCTTATTTGGATTGGGATAAATAATATGGCTGTTTATTTTGTAACCTGGCA
 AATTAGGCTCTGGAAAGACGCTCGTTAGCGTTGGTAAGATTCAGGATAAAATTGTAGCTGGGTGCAAAT
 AGCAACTAATCTTGATTTAAGGCTTCAAACCTCCCGCAAGTCGGGAGGTTTCGCTAAAACGCCTCGCGTT
 20 CTTAGAATACCGGATAAGCCTTCTATATCTGATTTGCTTGCTATTGGGCGCGGTAATGATTCCTACGATG
 AAAATAAAAACGGCTTGCTTGTTCTCGATGAGTGCGGTACTTGGTTTAATACCCGTTCTTGGAATGATAA
 GGAAAGACAGCCGATTATTGATTGGTTTCTACATGCTCGTAAATTAGGATGGGATATTATTTTTCTTGTT
 CAGGACTTATCTATTGTTGATAAACAGGCGCGTTCTGCATTAGCTGAACATGTTGTTTATTGTCGTCGTC
 TGGACAGAATTACTTTACCTTTTGTGCGGTACTTTATATTCTCTTATTACTGGCTCGAAAATGCCTCTGCC
 25 TAAATTACATGTTGGCGTTGTTAAATATGGCGATTCTCAATTAAGCCCTACTGTTGAGCGTTGGCTTTAT
 ACTGGTAAGAATTTGTATAACGCATATGATACTAAACAGGCTTTTTCTAGTAATTATGATTCCGGTGTTT
 ATTCTTATTTAACGCCTTATTTATCACACGGTCGGTATTTCAAACCATTAATTTAGGTCAGAAGATGAA
 ATTAATAAAATATATTTGAAAAAGTTTTCTCGCGTTCTTTGTCTTGCGATTGGATTTCATCAGCATTT
 ACATATAGTTATATAACCCAACCTAAGCCGGAGGTTAAAAAGGTAGTCTCTCAGACCTATGATTTTGATA
 30 AATTCACTATTGACTCTTCTCAGCGTCTTAATCTAAGCTATCGCTATGTTTTCAAGGATTCTAAGGGAAA
 ATTAATTAATAGCGACGATTTACAGAAGCAAGGTTATTCACTCACATATATTGATTTATGTACTGTTTCC
 ATTAAAAAAGGTAATTCAAATGAAATTGTTAAATGTAATTAATTTTGTCTTCTGATGTTTGTCTCATCA
 TCTTCTTTTGTCTCAGGTAATTGAAATGAATAATTCGCCCTCTGCGCGATTTTGTAACCTGGTATTCAAAGC
 AATCAGGCGAATCCGTTATTGTTTCTCCCGATGTAAAAGGTACTGTTACTGTATATTCATCTGACGTTAA
 35 ACCTGAAAATCTACGCAATTTCTTTATTTCTGTTTTACGTGCTAATAATTTTGATATGGTTGGTTCAATT
 CCTTCCATAATTCAGAAGTATAATCCAAACAATCAGGATTATATTGATGAATTGCCATCATCTGATAATC
 AGGAATATGATGATAATTCCGCTCCTTCTGGTGGTTTCTTTGTTCCGCAAAATGATAATGTTACTCAAAC
 TTTTAAATTAATAACGTTCCGGGCAAAGGATTTAATAACGAGTTGTGCAATTGTTTGTAAGTCTAATACT
 TCTAAATCCTCAAATGTATTATCTATTGACGGCTCTAATCTATTAGTTGTTAGTGCACCTAAAGATATTT
 40 TAGATAACCTTCCCTCAATTCCTTTCTACTGTTGATTTGCCAACTGACCAGATATTGATTGAGGGTTTGAT
 ATTTGAGGTTTCAGCAAGGTGATGCTTTAGATTTTTCATTTGCTGCTGGCTCTCAGCGTGGCACTGTTGCA
 GGCGGTGTTAATACTGACCGCCTCACCTCTGTTTTATCTTCTGCTGGTGGTTTCGTTCCGGTATTTTTAATG
 GCGATGTTTTAGGGCTATCAGTTTCGCGCATTAAAGACTAATAGCCATTCAAAAATATTGTCTGTGCCACG
 TATTCTTACGTTTTCAGGTCAGAAGGGTTCTATCTCTGTTGGCCAGAATGTCCCTTTTATTACTGGTTCGT
 45 GTGACTGGTGAATCTGCCAATGTAAATAATCCATTTCAAGACGATTGAGCGTCAAAATGTAGGTATTTCCA
 TGAGCGTTTTTCTGTTGCAATGGCTGGCGGTAATATTGTTCTGGATATTACCAGCAAGGCCGATAGTTT
 GAGTTCTTCTACTCAGGCAAGTGATGTTATTACTAATCAAAGAAGTATTGCTACAACGGTTAATTTGCGT
 GATGGACAGACTCTTTTACTCGGTGGCCTCACTGATTATAAAAACACTTCTCAAGATTCTGGCGTACCGT
 TCCTGTCTAAAATCCCTTTAATCGGCCTCCTGTTTAGCTCCCGCTCTGATTCCAACGAGGAAAGCACGTT
 50 ATACGTGCTCGTCAAAGCAACCATAGTACGCGCCCTGTAGCGGCGCATTAAGCGCGGCGGGTGTGGTGGT
 TACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTTCGCTTTCTTCCCTTCCCTT
 CTCGCCACGTTCCCGGCTTTCCCGTCAAGCTCTAAATCGGGGGCTCCCTTTAGGGTTCCGATTTAGTG
 CTTTACGGCACCTCGACCCCAAAAACTTGATTTGGGTGATGGTTACAGTAGTGGGCCATCGCCCTGATA
 GACGGTTTTTTCGCCCTTTGACGTTGGAGTCCACGTTCTTTAATAGTGGACTCTTGTTCCAACTGGAACA
 55 ACACTCAACCTATCTCGGGACGGATCGCTTCATGTGGCAGGAGAAAAAGGCTGCACCGGTGCGTCAGC
 AGAATATGTGATACAGGATATATTCCGCTTCCCTCGCTCACTGACTCGCTACGCTCGGTTCGTTTCGACTGCG
 GCGAGCGGAAATGGCTTACGAACGGGGCGGAGATTTCCCTGGAAGATGCCAGGAAGATACTTAACAGGGAA
 GTGAGAGGGCCGCGGCAAAGCCGTTTTTCCATAGGCTCCGCCCCCTGACAAGCATCACGAAATCTGACG
 CTCAAATCAGTGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGCGGCTCCCTC

- 35 -

GTGCGCTCTCCTGTTCCCTGCCTTTTCGGTTTACCGGTGTCATTCCGCTGTTATGGCCGCGTTTGTCTCATT
 CCACGCCTGACACTCAGTTCCGGGTAGGCAGTTCGCTCCAAGCTGGACTGTATGCACGAACCCCCCGTTC
 AGTCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGAAAGACATGCAAAAGCACC
 ACTGGCAGCAGCCACTGGTAATTGATTTAGAGGAGTTAGTCTTGAAGTCATGCGCCGGTTAAGGCTAAAC
 5 TGAAAGGACAAGTTTTTGGTGACTGCGCTCCTCCAAGCCAGTTACCTCGGTTCAAAGAGTTGGTAGCTCAG
 AGAACCTTCGAAAAACCGCCCTGCAAGGCGGTTTTTTTCGTTTTTCAGAGCAAGAGATTACGCGCAGACCAA
 AACGATCTCAAGAAGATCATCTTATTAAGGGGTCTGACGCTCAGTGGAACGAAAACCTCACGTTAAGGGAT
 TTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAAATCA
 ATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAG
 10 CGATCTGTCTATTTTCGTTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGG
 CTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACCGGCTCCAGATTTATCAGCA
 ATAAACCAGCCAGCCGATTTCGAGCTCGCCCCGGGGATCGACCAGTTGGTGATTTTGAACTTTTGCTTTGC
 CACGGAACGGTCTGCGTTGTGCGGAAGATGCGTGATCTGATCCTTCAACTCAGCAAAAGTTTCGATTTATT
 CAACAAAGCCGCGTCCCGTCAAGTCAGCGTAATGCTCTGCCAGTGTTACAACCAATTAACCAATTCTGA
 15 TTAGAAAAACTCATCGAGCATCAAATGAAACTGCAATTTATTCATATCAGGATTATCAATAACCATATTTT
 TGAAAAAGCCGTTTCTGTAATGAAGGAGAAAACCTCACCGAGGCAGTTCCATAGGATGGCAAGATCCTGGT
 ATCGGTCTGCGATTCCGACTCGTCCAACATCAATACAACCTATTAATTTCCCTCGTCAAAAATAAGGTT
 ATCAAGTGAGAAATCACCATGAGTGACGACTGAATCCGGTGAGAATGGCAAAAGCTTATGCATTTCTTTC
 CAGACTTGTTCAACAGGCCAGCCATTACGCTCGTCATCAAAATCACTCGCATCAACCAAACCGTTATTCA
 20 TTCGTGATTGCGCCTGAGCGAGACGAAATACGCGATCGCTGTTAAAAGGACAATTACAAACAGGAATCGA
 ATGCAACCGGCGCAGGAACACTGCCAGCGCATCAACAATATTTTCACCTGAATCAGGATATTCTTCTAAT
 ACCTGGAATGCTGTTTTCCCGGGGATCGCAGTGGTGAGTAACCATGCATCATCAGGAGTACGGATAAAAT
 GCTTGATGGTCGGAAGAGGCATAAATTCGTCAGCCAGTTTAGTCTGACCATCTCATCTGTAACATCATT
 GGCAACGCTACCTTTGCCATGTTTCAGAAACAACCTCTGGCGCATCGGGCTTCCCATACAATCGATAGATT
 25 GTCGCACCTGATTGCCCCGACATTATCGCGAGCCCATTTATACCCATATAAATCAGCATCCATGTTGGAAT
 TTAATCGCGGCCTCGAGCAAGACGTTTCCCGTTGAATATGGCTCATAACACCCCTTGTATTACTGTTTAT
 GTAAGCAGACAGTTTTATTGTTTCATGATGATATATTTTTATCTTGTGCAATGTAACATCAGAGATTTTGA
 GACACAACGTGGCTTTCCCCCCCCCCCCCTGCAGGTCTCGGGCTATTCTTTTGATTTATAAGGGATTTTG
 CCGATTTTCGGCCTATTGGTTAAAAAATGAGCTGATTTAACAAAAATTTAACGCGAATTTTAACAAAATAT
 30 TAACGTTTACAATTTAAATATTTGCTTATACAATCTTCCTGTTTTTTGGGGCTTTTCTGATTATCAACCGG
 GGTACATATGATTGACATGCTAGTTTTACGATTACCGTTCATCGATTCTCTTGTTTGCTCCAGACTCTCA
 GGCAATGACCTGATAGCCTTTGTAGACCTCTCAAAAATAGCTACCTCTCCGGCATGAATTTATCAGCTA
 GAACGGTTGAATATCATATTGATGGTGATTTGACTGTCTCCGGCCTTTCTCACCTTTTGAATCTTTACC
 TACACATTACTCAGGCATTGCATTTAAATATATGAGGGTTCTAAAAATTTTTATCCTTGCGTTGAAATA
 35 AAGGCTTCTCCCGCAAAAGTATTACAGGGTCATAATGTTTTTGGTACAACCGATTAGCTTTATGCTCTG
 AGGCTTTATTGCTTAATTTTGCTAATCTTTGCCTTGCCTGTATGATTTATTGGATGTT

[SEQ ID No: 11]

40 The system according to the nineteenth aspect can be used to produce a particle for use
 in accordance with any use as disclosed herein. The particle may be for use in
 accordance with the second, ninth or tenth aspect. In an embodiment, the recombinant
 phagemid particle produced is for use in treating a subject that has not been exposed to
 the delivered one or more antigen, for example by prior vaccination.

45

In an embodiment, the recombinant phagemid particle produced by the system of the
 nineteenth aspect is for use in a method that further comprises the use of one or more
 adoptively transferred T cell. Preferably, the adoptively transferred T cell is selected
 from a group consisting of a chimeric antigen receptor (CAR) T cell; T cell receptor
 50 (TCR) transgenic T cell; and tumour infiltrating lymphocyte (TIL). The adoptively
 transferred T cells may be specific for the one or more antigen introduced by the

- 36 -

recombinant phagemid particle into the tumour cell. In a preferred embodiment, the adoptively transferred T cells are CAR T cells.

As described in Example 1, the inventors have devised two alternative approaches (see
 5 Figures 9 and 10) for producing the recombinant phagemid particle of the invention in a prokaryotic host.

Hence, in a twentieth aspect, there is provided a method for producing a recombinant phagemid particle from a prokaryotic host, the method comprising:-

- 10 (i) introducing, into a prokaryotic host cell, a first vector configured to persist inside the prokaryotic host, and comprising at least one transgene expression cassette comprising a nucleic acid sequence encoding one or more cytokine, or one or more antigen that is recognised by one or more adoptively transferred T cell, and a packaging signal for enabling replication
 15 of the vector into single-stranded DNA;
- (ii) introducing, into the host, a helper phage comprising nucleic acid encoding bacteriophage structural proteins; and
- (iii) culturing the host under conditions which result in the single-stranded DNA
 20 being packaged by the structural proteins to form and extrude a recombinant phagemid particle from the prokaryotic host.

Advantageously, this method (as shown in Figure 9) results in very high yields of particles. The first vector (i.e. the phagemid particle's genome) may be introduced into the host cell, for example by infection. The host cell may then be transformed with the
 25 helper phage, which results in the production of the recombinant phagemid particle. Preferably, the method comprises a purification step following the culturing step. Purification may comprise centrifugation and/or filtration.

The antigen may be any as disclosed herein. In a preferred embodiment, the or each
 30 antigen is a peptide or protein which is expressed on the cell surface of the target tumour cell. Preferably, the or each antigen is a peptide or protein that, when expressed by the tumour cell, would be accessible to a CAR T cell. The peptide or protein may be such that, when expressed by the tumour cell, it is present as a folded peptide protein at or on the cell-surface. The or each antigen may be a known target for
 35 existing CAR T cells suitable for use in humans. For example, the or each antigen may be selected from a group consisting of: MUC1; PSMA; CD19; CD20; estrogen-related

- 37 -

receptor beta type 2 (ErRB2); or any combination thereof. In an embodiment, the or each antigen may be dengue virus or yellow fever vaccine antigens.

5 The cytokine may be any as disclosed herein. In particular the cytokine may be IL-4, IL-12, IL-15, TNF α , TRAIL, IFN- γ , or any combination thereof. Preferably, the cytokine is IL-15, Preferably, the cytokine is IL-4. Preferably, the cytokine is IL-12. Preferably, the cytokine is TRAIL. Preferably, the cytokine is IFN- γ .

10 Preferably, the cytokine is not TNF α . Preferably, the cytokine is TNF α . Preferably, the cytokine is a hybrid TNF α comprising a non-endogenous signal peptide configured to increase expression and/or secretion of TNF α . Preferably, the signal peptide is a cytokine signal peptide other than that of TNF α .

15 Preferably, the method of the twentieth aspect is used to produce the recombinant phagemid particle of the eighth aspect. Preferably, the first vector therefore comprises the genome of the recombinant phagemid particle. The packaging signal of the first vector may preferably comprise an origin or replication. Preferably, the origin of replication in the first vector comprises an F1 ori, more preferably from an F1 bacteriophage.

20 The method according to the twentieth aspect can be used to produce a particle for use in accordance with any use as disclosed herein. The particle may be for use in accordance with the second, ninth or tenth aspect. In an embodiment, the recombinant phagemid particle produced is for use in treating a subject that has not been exposed to the delivered one or more antigen, for example by prior vaccination.

30 In an embodiment, the recombinant phagemid particle produced by the method of the twentieth aspect is for use in a method that further comprises the use of one or more adoptively transferred T cell. Preferably, the adoptively transferred T cell is selected from a group consisting of a chimeric antigen receptor (CAR) T cell; T cell receptor (TCR) transgenic T cell; and tumour infiltrating lymphocyte (TIL). The adoptively transferred T cells may be specific for the one or more antigen introduced by the recombinant phagemid particle into the tumour cell. In a preferred embodiment, the adoptively transferred T cells are CAR T cells.

35

- 38 -

In a twenty-first aspect, there is provided a method for producing a recombinant phagemid particle from a prokaryotic host, the method comprising:-

- (i) introducing into a prokaryotic host cell: (a) a first vector configured to persist inside the prokaryotic host, and comprising at least one transgene expression cassette comprising a nucleic acid sequence encoding one or more cytokine, or one or more antigen that is recognised by one or more adoptively transferred T cell, and a packaging signal for enabling replication of the vector into single-stranded DNA, and (b) a second vector comprising nucleic acid encoding structural proteins required for packaging the single-stranded DNA; and
- (ii) culturing the host under conditions which result in the single-stranded DNA being packaged by the structural proteins to form and extrude a recombinant phagemid particle from the prokaryotic host.

Advantageously, this method (as shown in Figure 10) results in improved safety. The second vector (i.e. the helper phage) may be introduced into the host cell, for example by infection. The host cell may then be transformed with the first vector (i.e. the phagemid particle's genome), which results in the production of the recombinant phagemid particle. Preferably, the method comprises a purification step following the culturing step. Purification may comprise centrifugation and/or filtration.

The antigen may be any as disclosed herein. In a preferred embodiment, the or each antigen is a peptide or protein which is expressed on the cell surface of the target tumour cell. Preferably, the or each antigen is a peptide or protein that, when expressed by the tumour cell, would be accessible to a CAR T cell. The peptide or protein may be such that, when expressed by the tumour cell, it is present as a folded peptide protein at or on the cell-surface. The or each antigen may be a known target for existing CAR T cells suitable for use in humans. For example, the or each antigen may be selected from a group consisting of: MUC1; PSMA; CD19; CD20; estrogen-related receptor beta type 2 (ErRB2); or any combination thereof. In an embodiment, the or each antigen may be dengue virus or yellow fever vaccine antigens.

The cytokine may be any as disclosed herein. In particular the cytokine may be IL-4, IL-12, IL-15, TNF α , TRAIL, IFN- γ , or any combination thereof. Preferably, the cytokine is IL-15. Preferably, the cytokine is IL-4. Preferably, the cytokine is IL-12. Preferably, the cytokine is TRAIL. Preferably, the cytokine is IFN- γ .

- 39 -

Preferably, the cytokine is not TNF α . Preferably, the cytokine is TNF α . Preferably, the cytokine is a hybrid TNF α comprising a non-endogenous signal peptide configured to increase expression and/or secretion of TNF α . Preferably, the signal peptide is a
5 cytokine signal peptide other than that of TNF α .

Preferably, the method of the twenty-first aspect is used to produce the recombinant phagemid particle of the eighth aspect. Preferably, the first vector therefore comprises the genome of the recombinant phagemid particle. The packaging signal of the first
10 vector may preferably comprise an origin of replication. Preferably, the origin of replication in the first vector comprises an F1 ori, more preferably from an F1 bacteriophage.

The method of the twenty-first aspect can be used to produce a recombinant phagemid
15 particle for any use as disclosed herein. The particle may be for use in accordance with the second, ninth or tenth aspect. In an embodiment, the recombinant phagemid particle is for use in treating a subject that has not been exposed to the delivered one or more antigen, for example by prior vaccination.

20 In an embodiment, the recombinant phagemid particle produced by the method of the twenty-first aspect is for use in a method that further comprises the use of one or more adoptively transferred T cell. Preferably, the adoptively transferred T cells are selected from a group consisting of chimeric antigen receptor (CAR) T cells; T cell receptor (TCR) transgenic T cells; and tumour infiltrating lymphocytes (TILs). The adoptively
25 transferred T cells may be specific for the one or more antigen introduced by the recombinant phagemid particle into the tumour cell. In a preferred embodiment, the adoptively transferred T cells are CAR T cells.

In an twenty-second aspect, there is provided use of a helper phage comprising nucleic
30 acid encoding viral vector structural proteins to produce the recombinant phagemid particle according to the eighth aspect from a prokaryotic host.

There is provided a host cell comprising the first and/or second vector as defined in the
35 twenty-first aspect.

- 40 -

The host cell is preferably prokaryotic, more preferably a bacterial cell. Examples of suitable host cells include: (i) TG1 (Genotype: K-12 *supE thi-1 Δ(lac-proAB) Δ(mcrB-hsdSM)5, (r_Km_K)*, Plasmids: F' [*traD36 proAB⁺ lacI^q lacZΔM15*]), (ii) DH5αF' IQTM (Genotype: F-φ80lacZΔM15 Δ(lacZYA-argF) U169 recA1 endA1 hsdR17 (rk-, mk+) *phoA supE44 λ- thi-1 gyrA96 relA1*, Plasmids: F' *proAB⁺ lacIqZΔM15 zzf::Tn5 [KmR]*; and (iii) XL1-Blue MRF' (Genotype: Δ(mcrA)183 Δ(mcrCB-hsdSMR-mrr)173 endA1 *supE44 thi-1 recA1 gyrA96 relA1 lac*, Plasmids: F' *proAB lacIqZΔM15 Tn10 (Tetr)*.

10 The particle is used therapeutically or in diagnostic methods, preferably *in vivo*.

The invention may be used for the treatment of a wide variety of cancers due to the target-specific nature and the improved transduction efficiency of the recombinant phagemid particle of the invention. Consequently, the therapeutic opportunities of recombinant bacteriophages used in gene therapy may be significantly increased by the invention due to its ability to carry one or more transgene expression cassettes. The invention may be used prophylactically to prevent cancer, or after the development of a cancer, to ameliorate, manage, and/or treat it.

20 It will be appreciated that the invention may be used to create a variety of different recombinant phagemid particles that can be used for the treatment and/or diagnosis of a variety of cancers depending on the nature of the particles and the displayed foreign proteins (if an antigen). It will be appreciated that cytokine may not be displayed on the tumour cell. The target cell in the gene therapy technique is preferably eukaryotic, and preferably mammalian.

25 The gene therapy technique is used to treat, prevent, ameliorate, or manage cancer. The tumour may be a liquid tumour, such as a blood malignancy or a blood-forming tissue, or a haematological malignancy. The tumour may be a solid tumour. Tumours may be in the brain, e.g. medulloblastoma, glioblastoma, or diffuse intrinsic pontine glioma (DIPG). The recombinant phagemid particle may be used in combination with conventional treatments, such as chemotherapeutic drugs (e.g. doxorubicin, temozolomide, lomustine, cisplatin, vincristine), radiation therapy, or other drugs/xenobiotic compound, including but not limited to inhibitors of histone deacetylases (HDAC inhibitors), proteasome inhibiting drugs (e.g. MG132, borzotemib, 30 carfilzomib) and anticancer products from natural and dietary sources (e.g. genistein, Epigallocatechin gallate(EGCG), resveratrol).

The recombinant phagemid particle may also be used to directly display and express the antigen of interest on the major pVIII coat proteins, thus providing an efficient platform for the simultaneous delivery, by a single phage particle, of numerous
5 antigens , or proteins, or proteins with related biological activities. The subject may be mammalian, and is preferably human.

It will be appreciated that the recombinant phagemid particles and systems according to the invention (i.e. referred to hereinafter as “agents”) may be used in a medicament
10 which may be used in a monotherapy, or as an adjunct to, or in combination with, known therapies for treating, ameliorating, managing, or preventing cancer. For example, a combined therapeutic approach using the phagemid particles and systems of the invention with existing chemotherapeutics, such as Temozolamide, cisplatin, Doxorubicin, vincristine, or Genistein, is preferred.

15 In another preferred embodiment, therapy may comprise the combination of the recombinant phagemid particle and system of the invention with an extracellular matrix degrading agent, such as enzyme or losartan. The inventors believe that extracellular matrix degrading agents should enhance phagemid diffusion in the subject
20 being treated, and especially within a solid tumour.

The agents according to the invention (i.e. the recombinant phagemid particle used in the eighth or any above aspect, or produced by the system according to the nineteenth aspect) may be combined in compositions having a number of different forms
25 depending, in particular, on the manner in which the composition is to be used. Thus, for example, the composition may be in the form of a powder, tablet, capsule, liquid etc. or any other suitable form that may be administered to a person or animal in need of treatment. It will be appreciated that the vehicle of medicaments according to the invention should be one which is well-tolerated by the subject to whom it is given.

30 Medicaments comprising the agents according to the invention may be used in a number of ways. For instance, oral administration may be required, in which case the agents may be contained within a composition that may, for example, be ingested orally in the form of a tablet, capsule or liquid. Compositions comprising
35 agents of the invention may be administered by inhalation (e.g. intranasally).

- 42 -

Compositions may also be formulated for topical use. For instance, creams or ointments may be applied to the skin.

Agents according to the invention may also be incorporated within a slow- or
5 delayed-release device. Such devices may, for example, be inserted on or under the skin, and the medicament may be released over weeks or even months. The device may be located at least adjacent the treatment site. Such devices may be particularly advantageous when long-term treatment with agents used according to the invention is required and which would normally require frequent
10 administration (e.g. at least daily injection).

In a preferred embodiment, agents and compositions according to the invention may be administered to a subject by injection into the blood stream or directly into a site requiring treatment. Injections may be intravenous (bolus or infusion),
15 subcutaneous (bolus or infusion), intradermal (bolus or infusion) or enhanced by convection (convection enhanced delivery – relevant to local injections at disease site).

It will be appreciated that the amount of the agent that is required is determined by
20 its biological activity and bioavailability, which in turn depends on the mode of administration, the physiochemical properties of the agent (i.e. recombinant phagemid viral particle or the system), and whether it is being used as a monotherapy, or in a combined therapy. The frequency of administration will also be influenced by the half-life of the agent within the subject being treated. Optimal
25 dosages to be administered may be determined by those skilled in the art, and will vary with the particular agent in use, the strength of the pharmaceutical composition, the mode of administration, and the advancement of the disease. Additional factors depending on the particular subject being treated will result in a need to adjust dosages, including subject age, weight, gender, diet, and time of
30 administration.

Generally, a daily dose of between 0.01µg/kg of body weight and 500mg/kg of body weight of the agent according to the invention may be used. More preferably, the daily dose is between 0.01mg/kg of body weight and 400mg/kg of body weight,
35 and more preferably between 0.1mg/kg and 200mg/kg body weight.

- 43 -

As discussed in the Examples, the agent may be administered before, during the or after the onset of disease. For example, the agent may be administered immediately after a subject has developed a disease. Daily doses may be given systemically as a single administration (e.g. a single daily injection). Alternatively, the agent may require
5 administration twice or more times during a day. As an example, the agent may be administered as two (or more depending upon the severity of the disease being treated) daily doses of between 25mg and 7000 mg (i.e. assuming a body weight of 70 kg). A patient receiving treatment may take a first dose upon waking and then a second dose in the evening (if on a two dose regime) or at 3- or 4-hourly intervals thereafter.
10 Alternatively, a slow release device may be used to provide optimal doses of agents according to the invention to a patient without the need to administer repeated doses.

Known procedures, such as those conventionally employed by the pharmaceutical industry (e.g. *in vivo* experimentation, clinical trials, etc.), may be used to form specific
15 formulations comprising the particles or systems according to the invention and precise therapeutic regimes (such as daily doses of the agent and the frequency of administration).

Hence, in a twenty-third aspect of the invention, there is provided a pharmaceutical
20 composition comprising the recombinant phagemid viral particle according to the eighth aspect, produced by the system according to the nineteenth aspect, produced by the methods of the twentieth or twenty-first aspect, or produced according to the use of the twenty-second aspect, and a pharmaceutically acceptable vehicle.

The invention also provides, in an twenty-fourth aspect, a process for making the pharmaceutical composition according to the twenty-third aspect, the process comprising contacting a therapeutically effective amount of the recombinant phagemid particle according to the eighth aspect, produced by the system according to the nineteenth aspect, produced by the methods of the twentieth or twenty-first aspect, or
30 produced according to the use of the twenty-second aspect, and a pharmaceutically acceptable vehicle.

A “subject” may be a vertebrate, mammal, or domestic animal. Hence, agents, compositions and medicaments according to the invention may be used to treat any
35 mammal, for example livestock (e.g. a horse), pets, or may be used in other veterinary applications. Most preferably, however, the subject is a human being.

A “therapeutically effective amount” of agent (i.e. recombinant phagemid viral particle) is any amount which, when administered to a subject, is the amount of drug that is needed to treat the target disease, or produce the desired effect, e.g.
5 result in effective delivery of the transgene to a target cell or tissue, such as result in tumour killing.

For example, the therapeutically effective amount of agent used may be from about 0.01 mg to about 800 mg, and preferably from about 0.01 mg to about 500 mg.

10

A “pharmaceutically acceptable vehicle” as referred to herein, is any known compound or combination of known compounds that are known to those skilled in the art to be useful in formulating pharmaceutical compositions.

15 In one embodiment, the pharmaceutically acceptable vehicle may be a solid, and the composition may be in the form of a powder or tablet. A solid pharmaceutically acceptable vehicle may include one or more substances which may also act as flavouring agents, lubricants, solubilisers, suspending agents, dyes, fillers, glidants, compression aids, inert binders, sweeteners, preservatives, dyes, coatings, or tablet-
20 disintegrating agents. The vehicle may also be an encapsulating material. In powders, the vehicle is a finely divided solid that is in admixture with the finely divided active agents according to the invention. In tablets, the active agent (e.g. the particle or system of the invention) may be mixed with a vehicle having the necessary compression properties in suitable proportions and compacted in the shape and size desired. The
25 powders and tablets preferably contain up to 99% of the active agents. Suitable solid vehicles include, for example calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, polyvinylpyrrolidone, low melting waxes and ion exchange resins. In another embodiment, the pharmaceutical vehicle may be a gel and the composition may be in the form of a cream or the like.

30

However, the pharmaceutical vehicle may be a liquid, and the pharmaceutical composition is in the form of a solution. Liquid vehicles are used in preparing solutions, suspensions, emulsions, syrups, elixirs and pressurized compositions. The particles or system according to the invention may be dissolved or suspended in a pharmaceutically
35 acceptable liquid vehicle such as water, an organic solvent, a mixture of both or pharmaceutically acceptable oils or fats. The liquid vehicle can contain other suitable

- 45 -

pharmaceutical additives such as solubilisers, emulsifiers, buffers, preservatives, sweeteners, flavouring agents, suspending agents, thickening agents, colours, viscosity regulators, stabilizers or osmo-regulators. Suitable examples of liquid vehicles for oral and parenteral administration include water (partially containing additives as above, 5 e.g. cellulose derivatives, preferably sodium carboxymethyl cellulose solution), alcohols (including monohydric alcohols and polyhydric alcohols, e.g. glycols) and their derivatives, and oils (e.g. fractionated coconut oil and arachis oil). For parenteral administration, the vehicle can also be an oily ester such as ethyl oleate and isopropyl myristate. Sterile liquid vehicles are useful in sterile liquid form compositions for 10 parenteral administration. The liquid vehicle for pressurized compositions can be a halogenated hydrocarbon or other pharmaceutically acceptable propellant.

Liquid pharmaceutical compositions, which are sterile solutions or suspensions, can be utilized by, for example, intramuscular, intrathecal, epidural, intraperitoneal, 15 intravenous and particularly subcutaneous injection. The particles or system (i.e. hybrid vector) may be prepared as a sterile solid composition that may be dissolved or suspended at the time of administration using sterile water, saline, or other appropriate sterile injectable medium.

20 The recombinant phagemid particle, system and pharmaceutical compositions of the invention may be administered orally in the form of a sterile solution or suspension containing other solutes or suspending agents (for example, enough saline or glucose to make the solution isotonic), bile salts, acacia, gelatin, sorbitan monoleate, polysorbate 80 (oleate esters of sorbitol and its anhydrides copolymerized with ethylene oxide) and 25 the like. The particles and system according to the invention can also be administered orally either in liquid or solid composition form. Compositions suitable for oral administration include solid forms, such as pills, capsules, granules, tablets, and powders, and liquid forms, such as solutions, syrups, elixirs, and suspensions. Forms useful for parenteral administration include sterile solutions, emulsions, and 30 suspensions.

It will be appreciated that adeno-associated virus (AAV) is often the vector of choice for gene therapy. As a gene delivery vector, lentiviral vectors also have key several advantages over other systems. They have a large packaging capacity of at least 8 Kb of 35 DNA, which is an important feature when packaging sizeable expression cassettes of tissue-specific promoters and transgenes. In addition, lentiviral vectors have reduced

- 46 -

immunogenicity compared to adenoviral vectors, making it possible to consider systemic delivery routes. However, barrier of using AAV or lentivirus for laboratory and clinical research include their extremely high production cost and low yields.

5 The inventors have shown that in addition to exhibiting useful applications in gene therapy, the recombinant phagemid particle of the invention can also be used to produce recombinant viral vectors, such as AAV or lentivirus, in vitro or in vivo (including in situ). Phage-guided AAV production utilizes the ability of the phagemid particles to package large amounts of single-stranded ssDNA. A typical AAV
10 production system consists of three major elements: rAAV, rep-cap and adenohelper genes, which function together to produce rAAV particles.

Thus, in a twenty-fifth aspect, there is provided a recombinant phagemid particle according to the eighth aspect, produced according to the system of the nineteenth
15 aspect, produced by the methods of the twentieth or twenty-first aspect, or produced according to the use of the twenty-second aspect, wherein the recombinant phagemid particle is for production of a recombinant viral vector comprising or derived from the viral genome within the genome of the phagemid particle, wherein the recombinant viral vector is used for delivering the nucleic acid sequence encoding one or more
20 antigen or cytokine, to at least adjacent to the tumour cell., when the sequence encodes one or more antigen, the one or more antigen is expressed, and recognisable by one or more adoptively transferred T cell.

A recombinant phagemid particle which can produce a recombinant viral vector which,
25 in turn, encodes an antigen for recognition by an adoptively transferred T cell (such as a CAR T cell) can be advantageous. Figure 16 illustrates the delivery of a nucleic acid sequence to a malignant tumour; the production of the viral vector enables autoinfection of the tumour, such that the nucleic acid sequence is delivered throughout the tumour. This can be advantageous as this enables an antigen for
30 recognition by an adoptively transferred T cell to be delivered throughout a tumour. This synergises with any subsequent adoptive transfer therapy, such as CAR T cell therapy, as it provides a suitable target for the CAR T cells. Furthermore, it may allow a lower concentration of the introduced vector (i.e. the recombinant phagemid particle) to be used.

35

- 47 -

In a preferred embodiment, the or each antigen is a peptide or protein which is expressed on the cell surface of the target tumour cell. Preferably, the or each antigen is a peptide or protein that, when expressed by the tumour cell, would be accessible to a CAR T cell. The peptide or protein may be such that, when expressed by the tumour cell, it is present as a folded peptide protein at or on the cell-surface. The or each antigen may be a known target for existing CAR T cells suitable for use in humans. For example, the or each antigen may be selected from a group consisting of: MUC1; PSMA; CD19; CD20; estrogen-related receptor beta type 2 (ErRB2); or any combination thereof. In an embodiment, the or each antigen may be dengue virus or yellow fever vaccine antigens.

The recombinant phagemid particle according to the twenty-fifth aspect can be for any use as disclosed herein. The particle may be for use in accordance with the second, ninth or tenth aspect. In an embodiment, the recombinant phagemid particle is for use in treating a subject that has not been exposed to the delivered one or more antigen, for example by prior vaccination.

In an embodiment, the recombinant phagemid particle of the twenty-fifth aspect is for use in a method that further comprises the use of one or more adoptively transferred T cell. Preferably, the adoptively transferred T cells are selected from a group consisting of chimeric antigen receptor (CAR) T cells; T cell receptor (TCR) transgenic T cells; and tumour infiltrating lymphocytes (TILs). The adoptively transferred T cells may be specific for the one or more antigen introduced by the recombinant phagemid particle into the tumour cell. In a preferred embodiment, the adoptively transferred T cells are CAR T cells.

There is also provided a method for producing recombinant viral vector, the method comprising introducing into, a eukaryotic host cell, the recombinant phagemid particle according to the eighth aspect, or the system according to the nineteenth aspect, and allowing the host cell to produce recombinant viral vector.

Preferably, the recombinant virus product is a recombinant mammalian virus, such as AAV or lentivirus. Preferably, the viral vector product is rAAV. Preferably, the phagemid viral particle according to the eighth aspect, or the system according to the nineteenth aspect is used in cis and/or trans together with the delivery and/or presence of other genetic elements required for the production of mammalian viruses, as

- 48 -

determined by the phagemid particle's genome, inside the eukaryotic host cell. The method used to assist or enhance gene transfer to the host cell by the phagemid particle includes those described in WO 2014/184528 (i.e. multifunctional) and WO 2014/184529 (i.e. combination with a cationic polymer to form a complex having a net positive charge).

The eukaryotic host cell may be mammalian. The host cell may comprise or be derived from Human Embryonic Kidney Cells (HEK293), *Spodoptera frugiperda* pupal ovarian tissue (Sf9), or Chinese Hamster Ovary (CHO). Insect cells are also envisaged.

In one example, the host cell may be transformed with one or more phagemid particle genome carrying genes selected from the group consisting of: rAAV, lentivirus, capsid, replication, helper protein encoding genes, and any other genes required for the expression and packaging of mammalian viruses.

For example, in hybrid phagemid particle-guided rAAV production, the rAAV gene may be carried by the recombinant phagemid viral particle according to the eighth aspect, as shown in Figure 3, and the adenohelper and rep-cap genes may be carried on separate vectors, or be integrated into the eukaryotic host genome. For example, Figure 12 shows the adenohelper genes on one vector, and Figure 13 shows the rep-cap on a separate vector. Any combinations of the rAAV, rep-cap and adenohelper genes may be carried on one or more vectors, i.e. in cis or trans configurations. Alternatively, rep-cap or adenohelper proteins, in the context of rAAV production, could also be integrated or introduced into the eukaryotic host as a stably expressed accessory DNA (e.g. a plasmid), whereby the hybrid phagemid particle supplies the recombinant viral genome for packaging into a recombinant virus, as determined by the transgene cassette inside the phagemid particle's genome.

In one preferred embodiment, rAAV, rep-cap and adenohelper genes are carried on a single vector, as shown in Figures 14 and 15. The inventors believe that this is the first time that all three sets of genes have been harboured on the same vector.

Hence, in a twenty-sixth aspect, there is provided a recombinant vector comprising rAAV, rep-cap, adenohelper genes, and a nucleic acid sequence encoding one or more cytokine, or one or more antigen for recognition by one or more adoptively transferred T cell, for use in the treatment, prevention, or amelioration of cancer.

The recombinant vector can be for any use or method disclosed herein.

5 In a twenty –seventh aspect, there is provided a recombinant phagemid particle comprising the vector of the twelfth aspect, for use in a method for the treatment, prevention, or amelioration of cancer.

The recombinant phagemid particle can be for any use or method disclosed herein.

10 There is provided use of the vector according to the twenty –sixth aspect or the particle of the twenty-seventh aspect, to produce a recombinant AAV viral vector comprising or derived from the viral genome of the phagemid particle.

15 There is provided a method for producing recombinant AAV viral vector, the method comprising introducing into, a eukaryotic host cell, the vector according to the twenty –sixth aspect or the particle of the twenty-seventh aspect, and allowing the host cell to produce recombinant viral vector.

20 When introduced into the same eukaryotic host cell (see Figures 11 and 14), the rep-cap and adenohelper genes on the vector behave as trans-acting or cis-acting or a combination of both elements that facilitate packaging of the rAAV genome in the AAV virus capsid, in the context of rAAV production. This production process is comparable to transient co-transfection of multiple plasmids, and usually involving three plasmids. However, in this embodiment, the plasmids are replaced with the recombinant
25 phagemid particles of the invention, which are targeted to eukaryotic cells (preferably mammalian cells), which also carry the same elements.

The method may be carried out *in vivo*, *in vitro*, *ex vivo*, or *in situ*. For *in situ* production, the recombinant phagemid particles preferably comprise a targeting
30 moiety for the target eukaryotic cell that is the designated eukaryotic host. Preferably, in the context of *in situ*, *ex vivo* and *in vivo* virus production, the designated eukaryotic host cell type is a diseased cell. Preferably, the diseased cell is a malignant or benign tumour. In the context of *in vitro* virus production, preferably the eukaryotic host is a derivative of any of the eukaryotic hosts listed above. The application of the
35 recombinant phagemid particles and genetic elements required for the production of recombinant virus (as determined by the transgene cassette in the hybrid phagemid

- 50 -

particle), could be in any fashion as indicated earlier, either in cis-acting or trans-acting combinations, inside the eukaryotic host cell.

In a twenty-eighth aspect, there is provided a recombinant phagemid particle for
 5 expressing a transgene in a target tumour cell transduced with the particle, for use in a
 method for treating, preventing or ameliorating cancer, wherein the phagemid particle
 comprises at least one transgene expression cassette comprising a nucleic acid
 sequence encoding one or more cytokine, or antigen recognisable by one or more
 adoptively transferred T cell, and comprises a genome which lacks at least 50% of its
 10 bacteriophage genome, and wherein the method comprises delivering the nucleic acid
 sequence to at least adjacent to the tumour cell, when the nucleic encodes an one or
 more antigen, the one or more antigen is expressed, and recognisable by one or more
 adoptively transferred T cell.

15 It will be appreciated that the invention extends to any nucleic acid or peptide or
 variant, derivative or analogue thereof, which comprises substantially the amino acid or
 nucleic acid sequences of any of the sequences referred to herein, including functional
 variants or functional fragments thereof. The terms “substantially the amino
 acid/polynucleotide/polypeptide sequence”, “functional variant” and “functional
 20 fragment”, can be a sequence that has at least 40% sequence identity with the amino
 acid/polynucleotide/polypeptide sequences of any one of the sequences referred to
 herein, for example 40% identity with the nucleic acids identified herein.

Amino acid/polynucleotide/polypeptide sequences with a sequence identity which is
 25 greater than 65%, more preferably greater than 70%, even more preferably greater than
 75%, and still more preferably greater than 80% sequence identity to any of the
 sequences referred to is also envisaged. Preferably, the amino
 acid/polynucleotide/polypeptide sequence has at least 85% identity with any of the
 sequences referred to, more preferably at least 90% identity, even more preferably at
 30 least 92% identity, even more preferably at least 95% identity, even more preferably at
 least 97% identity, even more preferably at least 98% identity and, most preferably at
 least 99% identity with any of the sequences referred to herein.

The skilled technician will appreciate how to calculate the percentage identity between
 35 two amino acid/polynucleotide/polypeptide sequences. In order to calculate the
 percentage identity between two amino acid/polynucleotide/polypeptide sequences, an

- 51 -

alignment of the two sequences must first be prepared, followed by calculation of the sequence identity value. The percentage identity for two sequences may take different values depending on:- (i) the method used to align the sequences, for example, ClustalW, BLAST, FASTA, Smith-Waterman (implemented in different programs), or
5 structural alignment from 3D comparison; and (ii) the parameters used by the alignment method, for example, local vs global alignment, the pair-score matrix used (e.g. BLOSUM62, PAM250, Gonnet etc.), and gap-penalty, e.g. functional form and constants.

10 Having made the alignment, there are many different ways of calculating percentage identity between the two sequences. For example, one may divide the number of identities by: (i) the length of shortest sequence; (ii) the length of alignment; (iii) the mean length of sequence; (iv) the number of non-gap positions; or (v) the number of
15 equivalenced positions excluding overhangs. Furthermore, it will be appreciated that percentage identity is also strongly length dependent. Therefore, the shorter a pair of sequences is, the higher the sequence identity one may expect to occur by chance.

Hence, it will be appreciated that the accurate alignment of protein or DNA sequences is a complex process. The popular multiple alignment program ClustalW (Thompson et
20 al., 1994, Nucleic Acids Research, 22, 4673-4680; Thompson et al., 1997, Nucleic Acids Research, 24, 4876-4882) is a preferred way for generating multiple alignments of proteins or DNA in accordance with the invention. Suitable parameters for ClustalW may be as follows: For DNA alignments: Gap Open Penalty = 15.0, Gap Extension
Penalty = 6.66, and Matrix = Identity. For protein alignments: Gap Open Penalty =
25 10.0, Gap Extension Penalty = 0.2, and Matrix = Gonnet. For DNA and Protein alignments: ENDGAP = -1, and GAPDIST = 4. Those skilled in the art will be aware that it may be necessary to vary these and other parameters for optimal sequence alignment.

30 Preferably, calculation of percentage identities between two amino acid/polynucleotide/polypeptide sequences is then calculated from such an alignment as $(N/T) \times 100$, where N is the number of positions at which the sequences share an identical residue, and T is the total number of positions compared including gaps but
35 excluding overhangs. Hence, a most preferred method for calculating relative percentage identity between two sequences comprises (i) preparing a sequence alignment using the ClustalW program using a suitable set of parameters, for example,

- 52 -

as set out above; and (ii) inserting the values of N and T into the following formula:-
Sequence Identity = $(N/T) \times 100$.

Alternative methods for identifying similar sequences will be known to those skilled in
5 the art. For example, a substantially similar nucleotide sequence will be encoded by a
sequence which hybridizes to a nucleic acid sequence described herein, or their
complements under stringent conditions. By stringent conditions, we mean the
nucleotide hybridises to filter-bound DNA or RNA in 3x sodium chloride/sodium
citrate (SSC) at approximately 45°C followed by at least one wash in 0.2x SSC/0.1%
10 SDS at approximately 20-65°C. Alternatively, a substantially similar polypeptide may
differ by at least 1, but less than 5, 10, 20, 50 or 100 amino acids from the sequences
shown herein.

Due to the degeneracy of the genetic code, it is clear that any nucleic acid sequence
15 could be varied or changed without substantially affecting the sequence of the protein
encoded thereby, to provide a functional variant thereof. Suitable nucleotide variants
are those having a sequence altered by the substitution of different codons that encode
the same amino acid within the sequence, thus producing a silent change. Other
suitable variants are those having homologous nucleotide sequences but comprising all,
20 or portions of, sequence, which are altered by the substitution of different codons that
encode an amino acid with a side chain of similar biophysical properties to the amino
acid it substitutes, to produce a conservative change. For example small non-polar,
hydrophobic amino acids include glycine, alanine, leucine, isoleucine, valine, proline,
and methionine. Large non-polar, hydrophobic amino acids include phenylalanine,
25 tryptophan and tyrosine. The polar neutral amino acids include serine, threonine,
cysteine, asparagine and glutamine. The positively charged (basic) amino acids include
lysine, arginine and histidine. The negatively charged (acidic) amino acids include
aspartic acid and glutamic acid. It will therefore be appreciated which amino acids may
be replaced with an amino acid having similar biophysical properties, and the skilled
30 technician will know the nucleotide sequences encoding these amino acids.

All of the features described herein (including any accompanying claims, abstract and
drawings), and/or all of the steps of any method or process so disclosed, may be
combined with any of the above aspects in any combination, except combinations
35 where at least some of such features and/or steps are mutually exclusive. For the
avoidance of doubt, reference to cytokine may preferably relate to IL-4, IL-12, IL-15,

TNF α , TRAIL, IFN- γ , or any combination thereof. Preferably, the cytokine is IL-15, Preferably, the cytokine is IL-4. Preferably, the cytokine is IL-12. Preferably, the cytokine is TRAIL. Preferably, the cytokine is IFN- γ .

- 5 However, in another preferred embodiment, the cytokine is TNF α . Preferably, the cytokine is a hybrid TNF α comprising a non-endogenous signal peptide configured to increase expression and/or secretion of TNF α . Preferably, the signal peptide is a cytokine signal peptide other than that of TNF α . For example, the signal peptide is preferably the IL-2 signal peptide.

10

For a better understanding of the invention, and to show how embodiments of the same may be carried into effect, reference will now be made, by way of example, to the accompanying Figures, in which:-

- 15 **Figure 1** is a table showing features of the phagemid-AAV (PAAV) virus particle according to the invention compared to prior art AAVP virus particles;

- Figure 2** shows schematic illustrations of embodiments of a Helper Phage and a Phagemid genome (PAAV) according to the invention, and a phagemid-AAV (PAAV) particle that is created by the Helper and phagemid. Structural genes are integral to packaging of DNA in to virus particles, and are supplied by the replication Helper phage. The phagemid genome is extremely parasitic to the Helper phage. Ultimately, the PAAV particles are produced at yields that far surpass prior art systems;

- 20 **Figure 3** is a schematic representation of one embodiment of a phagemid genome (PAAV);

- 25 **Figure 4** shows the respective locations of f1 ori and pUC ori on the phagemid genome shown in Figure 3;

Figure 5 shows the location of a selection marker gene (AmpR) on a recombinant adeno-associated virus (rAAV) transgene cassette on the phagemid genome shown in Figure 3;

- 30 **Figure 6** shows the rAAV transgene cassette on the phagemid genome shown in Figure 3, which contains a gene of interest (e.g. GFP), the expression of which is driven by a CMV promoter and/or enhancer sequences, and tailed with a polyA signal. The entire transgene cassette is flanked by Inverted Terminal Repeat sequences (ITRs) from AAV;

- Figure 7** shows an embodiment of the Helper phage which is a bacteriophage engineered for rescuing phagemid particles from prokaryotic hosts carrying a phagemid genome, such as that shown in Figure 3;
- 35

Figure 8 shows a section of the genome of the helper phage shown in Figure 5 comprising the RGD4C targeting peptide in the pIII minor coat protein, and as shown in SEQ ID Nos 26 and 27;

Figure 9 shows a first embodiment of a method for producing phagemid-AAV (PAAV) particles;

Figure 10 shows a second embodiment of a method for producing phagemid-AAV (PAAV) particles;

Figure 11 shows one embodiment of a phage-based approach for in vitro AAV production showing the three vectors, (i) phagemid-AAV (PAAV), (ii) Rep-Cap phagemid, and (iii) adenohelper phagemid;

Figure 12 shows the genome map of an embodiment of the adenohelper phagemid vector shown in Figure 11;

Figure 13 shows the genome map of an embodiment of a Rep-Cap phagemid vector shown in Figure 11;

Figure 14 shows an embodiment of a unified adenohelper/Rep-cap/phagemid-AAV (PAAV) vector;

Figure 15 shows the genome map of an embodiment of the unified adenohelper-Rep-Cap phagemid vector shown in Figure 11;

Figure 16 shows an embodiment of in situ AAV production using either the three phagemid vectors shown in Figures 11-13, or the unified adenohelper-Rep-Cap-AAV phagemid vector shown in Figures 14 and 15;

Figure 17 shows Transmission Electron Microscopy (TEM) of known AAVP vectors and PAAV vectors according to the invention. **(A)** RGD.AAVP.GFP filament (pink) is typically 1455.02nm in length. **(B)** RGD. PAAV.GFP filament (blue) is typically 729.96nm in length; helper phage present in virus sample (green) is typically 1186.03nm in length;

Figure 18 shows internalisation of known AAVP vectors and PAAV vectors according to the invention in: **(A)** 293AAV and **(B)** U87 cells after 2 and 4 hours. Flow cytometric analysis was used with gating threshold set at 20000 events of total cell population. (n=3) *=p<0.05, **=p<0.01;

Figure 19 shows quantification of GFP-positive cells 9 days post-transduction in **(A)** 293AAV, **(B)** 293AAV with the addition of DEAE.DEXTRAN, **(C)** U87 and **(D)** U87 with the addition of DEAE.DEXTRAN. Flow cytometric analysis was used with gating threshold set at 20000 events of total cell population. (n=3) *=p<0.05, **=p<0.01;

Figure 20 shows quantification of genome copy numbers of rAAV-GFP from cell lysates following phagemid-guided gene transfer (**A**) or transfection (**B**) of rAAV expression elements. (Experiment A: n=1; Experiment B: n=3);

Figure 21 shows immunofluorescence staining of UW228 and DAOY human medulloblastoma cells to demonstrate expression of α_v , β_3 and β_5 integrin subunits, receptor for RGD4C-phagemid. Tumour cells were stained using primary rabbit anti- α_v , β_3 or β_5 antibodies (diluted 1:50 in PBS-1%BSA), then with goat anti-rabbit AlexaFluor-488 secondary antibody (showed in green) and counterstained with 0.05 μ g/ml DAPI (in blue). Images were taken using a confocal microscope;

Figure 22 shows targeted gene delivery to paediatric medulloblastoma cells by RGD4C-phagemid. Medulloblastoma cells (UW228) were grown on 96 well-plates, then transduced with RGD4C-phagemid vector carrying the Luciferase gene (RGD). Untreated cells or cells treated with the non-targeted vector (M13) were used as negative controls. Luciferase expression was monitored over a time course from day 2 to 4 after transduction;

Figure 23 shows Western blot analyses showing down regulation of mTOR expression in paediatric UW228 and DAOY medulloblastoma cells following treatment with RGD4C-phagemid carrying a sequence encoding the mTOR/shRNA (RGD4C-mTOR/shRNA)). Cell lysates were collected at day 4 post vector treatment, and total proteins were measured by BCA assay. Western blot was probed with a monoclonal antibody to human mTOR (Cell Signalling). Untreated cells (CTR) and cells treated with RGD4C-phagemid, lacking mTOR/shRNA, (RGD4C) were used as negative controls;

Figure 24 shows combination treatment of temozolomide (TMZ) and RGD4C-phagemid carrying a sequence encoding shRNA for mTOR in medulloblastoma. Medulloblastoma cells (UW228 and DAOY) were transduced with RGD4C-phagemid (RGD4C) or RGD4C-phagemid carrying a sequence encoding mTOR/shRNA (RGD4C-mTOR/shRNA). Untreated cells were also used as controls. At day 7 post vector treatment, temozolomide (TMZ, 100 μ M) was added in a few treated wells to assess effect of combination of vectors with chemotherapy. Images were taken at day 8 after vector treatment;

Figure 25 shows treatment of medulloblastoma cells with TNF α phagemid vectors. UW228 cells were treated with RGD4C-phagemid-TNF α (RGD4C/TNF α) and non-targeted (ctr). **A**) Cell viability, using MTT assay, following expression of TNF α . **B**) Expression of TNF α in the medium of vector-treated cells, measured using human TNF α ELISA Max. Error bars: mean $\pm$ SEM;

Figure 26 shows immunofluorescence staining of DIPG cells to demonstrate expression of α_v , β_3 and β_5 integrin subunits, receptor for RGD4C-phagemid. Cells were stained using primary rabbit antibodies then with goat anti-rabbit AlexaFluor-488 secondary antibody. Control cells received secondary antibody alone. Images were
5 taken using a confocal microscope;

Figure 27 shows selective and dose dependent delivery of gene expression to UW228, DAOY, and DIPG cells by RGD4C-phagemid/AAV. Increasing vector dose 1×10^6 or 2×10^6 TU/cell of RGD4C-phagemid-Luc (RGD4C) carrying the reporter Luc (luciferase) gene was used to treat the cells. Luc expression was measured daily. Non-targeted
10 vector lacking RGD4C (ctr) was used as negative control for targeting. Error bars: mean $\pm$ SEM. (A) shows treatment of DIPG cells, (B) shows treatment of UW228, (C) shows treatment of DAOY cells;

Figure 28 shows treatment with RGD4C-phagemid-TNF α of UW288, DAOY, or DIPG cells. DIPG were transduced with 2×10^6 TU/cell RGD4C-phagemid-TNF α (RGD4C) and non-targeted vector as negative control (ctr). UW288 or DAOY cells were
15 transduced with 1×10^6 TU/cell with or without DEAE dextran. Apoptotic activity was measured at day 9 post-vector treatment by measuring the percentage of viable cells or using caspase-Glo assay (caspase 3/7, caspase 8, and caspase9). Error bars: mean $\pm$ SEM. * $P \leq 0.05$, ** $P \leq 0.01$, *** $P \leq 0.001$;

Figure 29 shows luciferase expression after transduction with RGD.PAAV at various transducing units of RGD.PAAV;

Figure 30 shows the percentage of PAAV vectors bound to the cell surface of 293 AAV cells. RGD.PAAV vectors had 58.2% binding efficiency, whereas M13.PAAV vectors had 7.1% binding efficiency relative to their respective controls;

Figure 31 shows schematic diagrams of embodiments of the expression plasmid constructs for bacteriophage-guided CAR T cell therapy; 31a represents MUC1-CD28.IL4 expression plasmid driven by CMV promoter, 31b represents MUC1-GPI.IL4 expression plasmid driven by CMV promoter, 31c represents PSMA expression plasmid driven by CMV promoter, 31d represents MUC1-CD28.IL4 expression plasmid driven
25 by Grp78 promoter, 31e represents MUC1-GPI.IL4 expression plasmid driven by Grp78 promoter and 31f represents PSMA expression plasmid driven by Grp78 promoter.

Figure 32 shows MUC-1.CD28, MUC-1.GPI and PSMA antigen expression on day 6 post-transduction. HEK 293 cells were transduced by either 10^6 TU/cell of RGD targeted PAAV (RGD) or non-targeted PAAV (NT). Untreated HEK 293 cells (Ctrl) and,
30 targeted PAAV transduced-HEK 293 cells with only 488 secondary antibody staining

(Ant.488) were shown as control. **A** represents the MUC-1 or PSMA expression of HEK 293 cells transduced by CMV promoter-driven PAAV vector (construct in figure 31a, 31b and 31c). DEAE-dextran was added. **B** represents the MUC-1 or PSMA expression of HEK 293 cells transduced by CMV promoter-driven PAAV vector (construct in figure 31a, 31b and 31c) without DEAE dextran added. **C** represents the MUC-1 expression of HEK 293 cells transduced by Grp78 promoter-driven PAAV vector (construct in figure 31d and 31e) without DEAE dextran added.;

Figure 33 shows schematic diagrams of the expression plasmid constructs with puromycin resistance gene for stable cell line selection bacteriophage-guided CAR T cell therapy therapy; 33a represents MUC1-CD28.IL4 expression plasmid driven by CMV promoter, 33b represents MUC1-GPI.IL4 expression plasmid driven by CMV promoter, 33c represents PSMA expression plasmid driven by CMV promoter, 33d represents MUC1-CD28.IL4 expression plasmid driven by Grp78 promoter, 33e represents MUC1-GPI.IL4 expression plasmid driven by Grp78 promoter and 33f represents PSMA expression plasmid driven by Grp78 promoter;

Figure 34 shows MUC-1.CD28, MUC-1.GPI and PSMA antigen expression of cancer cells on day 6 post-transduction. Cancer cells were transduced by either 10⁶ TU/cell of RGD targeted PAAV (RGD) or non-targeted PAAV (M13). Untreated cells without any antibody staining (CTRL) were shown as control while untreated cells were stained with primary and secondary antibody (Stain) to checked internal expression of the antigen by FACS. **A** represents the MUC-1 or PSMA expression of A549 cells transduced by CMV promoter-driven PAAV vector. **B** represents the MUC-1 or PSMA expression of Suit2 cells transduced by CMV promoter-driven PAAV vector. **C** represents the MUC-1 expression of UW 228 cells transduced by CMV promoter-driven PAAV vector;

Figure 35 shows MUC-1.CD28, MUC-1.GPI and PSMA antigen expression in stable cancer cells. RGD4C-PAAV-Stably transduced cancer cells expressing MUC1 or PSMA antigen (Stable cell) were selected with puromycin antibiotic, then used to perform FACS analyses for MUC-1 or PSMA expression. Untreated cells without any antibody staining (CTRL) were shown as control while untreated cells were stained with primary and secondary antibody (Stain) to checked internal expression of the antigen. **A** represents the MUC-1 or PSMA expression of A549 cells. **B** represents the MUC-1 or PSMA expression of Suit2 cells. **C** represents the MUC-1 expression of UW 228 cells;

Figure 36 shows treatment and comparison of DIPG cell killing in vitro between PAAV carrying either the transmembrane tmTNF α or secreted sTNF α . DIPG cells were treated with either RGD4C-PAAV-tmTNF α or RGD4C-PAAV-sTNF α (RGD4C and non-targeted M13 [ctr]) and cell viability was measured at day 7 post-vector treatment. The

RGD4C-PAAV-sTNF α particle carrying the secreted sTNF α was more potent in inducing DIPG cell killing than the RGD4C-PAAV-tmTNF α , even in a transient transduction context where only a small population of cells are transduced by the vector;

5 **Figure 37** shows schematic diagrams of embodiments of the plasmid constructs used by the presently disclosed methods; 37a represents PAAV-CMV-IRES GFP plasmid, 37b represents PAAV.Grp78.IRES.GFP;

Figure 38 shows expression of TNF α after PAAV-tm.TNF α transduction. (A) UW228 and Daoy were seeded in 96-well plate and transduced with 1×10^6 TU/cell with DEAE dextran, the supernatant was collected at day 6 and TNF α in the supernatant was
10 determined by ELISA. . Data are represented as mean $\pm$ SEM.

Figure 39 shows the effect of TNF α and cisplatin combination treatment in UW228 cells. Cell viability was measured at different time points using sulphorodamine B assay. Stably transduced UW228 were treated with 1 μ M and 5 μ M cisplatin
15 chemotherapy 48 hrs after seeding the cells. . Data are represented as mean $\pm$ SEM. ***P $\leq$ 0.001. The figure shows that a combination with cisplatin (cis) chemotherapy increases tmTNF α cytokine gene therapy against medulloblastoma;

Figure 40 shows expression of TNF after PAAV-sTNF transduction. DIPG were seeded in 96-well plate and transduced with 2×10^6 TU/cell with DEAE dextran, the
20 supernatant was collected at day 3 and TNF α in the supernatant was determined by ELISA;

Figure 41 shows the generation of PAAV-CMV-tmTNF α ;

Figure 42 shows the generation of PAAV-sTNF α ;

Figure 43 shows a targeted PAAV vector, showing RGD-4C ligand displayed on pIII coat proteins of the M13 filamentous phage. The hybrid genome shows important gene
25 fragments that are necessary for expression of the desired gene;

Figure 44 shows a schematic for producing RGD pVIII helper viruses;

Figure 45 shows a schematic for producing RGD pVIII PAAV-GFP and RGD pVIII PAAV-lucia, which are used in in vitro transduction experiments to assess efficiency of
30 vector and level of gene expression;

Figure 46 shows a schematic for producing PAAV-hTRAIL (image from SnapGene);

Figure 47 shows fluorescent microscopic images of DIPG cells incubated with a primary anti-phage antibody and Alexa Fluor-488 labelled secondary antibody (green) to assess integrin (α v/ β 3/ β 5) expression. Images of control cells with no antibodies or
35 secondary antibodies only were taken to account for background fluorescence. Nuclei were stained with DAPI (blue);

Figure 48 shows theorised constructs of RGD-4C ligands as displayed on pIII (left) or pVIII (right) coat proteins of the M13 filamentous phage;

Figure 49 shows fluorescent microscopic images of HEK293T cells incubated with un-targeted, RGD pIII PAAV-GFP or RGD pVIII PAAV-GFP vectors at 0.1m TU, 0.5m TU and 1m TU at day 6 post-transduction. GFP expression is highest in RGD pIII PAAV-GFP at all TUs;

Figure 50 shows RLU of HEK293T cells incubated with un-targeted, RGD pIII PAAV-lucia or RGD pVIII PAAV-lucia vectors at 0.1m TU, 0.5m TU and 1m TU at Day 6 post-transduction. RLU is highest in RGD pIII PAAV-lucia at all TUs. Error bars are +/- 1 standard error;

Figure 51 shows RLU of HEK293T cells incubated with vectors at Day 4 post-transduction. RLU is highest in H5W RGD pIII PAAV-lucia at all TUs. Error bars are +/- 1 standard error. (Sajee Waramit, unpublished data);

Figure 52 shows RLU of DIPG cells incubated with un-targeted, RGD pIII PAAV-lucia or H5W RGD pIII PAAV-lucia vectors at 1m TU and 2m TU at Day 3 post-transduction. RLU is highest in H5W RGD pIII PAAV-lucia at all TUs. Error bars are +/- 1 standard error;

Figure 53 Microscopic images of DIPG cells transfected with PAAV-hTRAIL and control PAAV-GFP plasmids at 0.2ng, 0.4ng and 0.6ng DNA. Images were taken at 18 hours post-transfection. Cell viability is lower in cells transfected with PAAV-hTRAIL at all DNA concentrations;

Figure 54 shows a Bar graph showing IL-12 concentration of media collected on day 6 post transduction with PAAV-CMV-IL-12 normalised to 1µg of protein. Controls of transduction with a targeted and untargeted empty vector with a CMV promoter and mock transduction are shown. The outer selection bar designates analysis of IL-12 production data of all vector titres and controls by 2-way ANOVA. The inner selection bars designate comparison between vectors and controls at each titre by unpaired t-test. The experiment was performed in triplicate;

Figure 55 shows a line graph showing mouse IL-12 concentration of media sampled at various days post transduction with PAAV-CMV-mIL-12. Controls of transduction with a targeted and untargeted empty vector with a CMV promoter and mock transduction are shown. The outer selection bar designates analysis of mouse IL-12 production data from all sampled days for vectors and controls by 2-way ANOVA. The asterisks over specific data points designate comparison between vectors and controls at each specified day by unpaired t-test;

- 60 -

Figure 56 shows a bar graph showing the mean tumour size in mm³ of B16-F10 murine melanoma tumours in C57BL/6 mice over seven days after treatment with RGD-4C-targeted PAAV-CMV-mIL-12 (n=4) with RGD-4C-targeted PAAV-CMV with no transgene (n=4) and no treatment controls (n=4). Three doses of 5×10^{10} TU vector were administered intravenously on days 0, 2 and 5. Data were analysed by 2-way ANOVA with a Tukey's multiple comparisons test;

Figure 57 shows the IL2 signal sequence;

Figure 58 shows the Il-2/TNF α construct;

Figure 59 shows cell killing efficiency of RGD4C-sTNF α and RGD4C-tmTNF α in DIPG. DIPG cells were transduced with PAAV targeted (RGD4C) or non-targeted (M13) carrying either secreted or transmembrane TNF α (sTNF α) transgene. The cells were seeded in 96-well plate. Two day later, the cells were transduced with 2×10^6 TU/cell with 40ng/ μ g of protein DEAE dextran. The viability was measured with sulforhodamine B (SRB) assay. Statistical significance was determined by student's t-test Data are represented as mean $\pm$ SEM. *P $\leq$ 0.05, **P $\leq$ 0.01;

Figure 60 shows expression of TNF α after transduction with PAAV-sTNF α and PAAV-tmTNF α . DIPG cells were seeded in 6-well plate and transduced with RGD4C and M13 carrying either secreted or transmembrane form of TNF α transgene. A) RNA was extracted and expression of TNF α was determined by qRT-PCR. B) The supernatant was collected and TNF α in the supernatant was determined by ELISA. Data are represented as mean $\pm$ SEM. **P $\leq$ 0.01 ***P $\leq$ 0.001. Statistical significance was determined by student's t-test;

Background

The development of gene delivery technologies is instrumental to successful translation of basic research to the society. In the past decade, a number of viral and non-viral vectors have emerged as potential delivery vectors for industrial and therapeutic applications. An important property of vectors, in addition to being efficient at delivering genes, is that it must also be easily produced and commercially viable. In 2006, Hajitou et al. attempted to fulfil the need for such vectors by creating a hybrid between recombinant adeno-associated virus (rAAV) and filamentous bacteriophage (phage), called the adeno-associated Virus/Phage (AAVP) (*Nature protocols* 2, 523-531 (2007); *Cell* 125, 385-398 (2006)). The resulting AAVP vector possesses favourable characteristics of mammalian and prokaryotic viruses, but does not suffer from the disadvantages that those individual vectors normally carry. However, there are certain

- 61 -

aspects of the AAVP vector that still leaves room for significant improvement. Above all, this includes the genetic design of the vector, which carries ramifications in its production and therapeutic properties. Ultimately, this leads to AAVP's relatively low gene transduction efficacy when compared to mammalian viruses.

5

The research described herein relates to the design of the most advanced version of phage gene delivery vectors and their superiority to the known and existing phage vector, AAVP, by using a so-called "phagemid system", with the new phagemid vector being referred to as Phagemid/Adeno-associated Virion Phagemid (i.e. PAAV). Unlike
 10 the AAVP genome, which consists of a rAAV cassette inserted in to the filamentous phage genome, the PAAV genome does not contain any structural phage genes – a prokaryotic helper virus is required to facilitate vector assembly (*Mol Ther* 3, 476-484; *Pharmaceutical research* 27, 400-420 (2010)). Separating the reproductive and therapeutic elements of the virus in to a therapeutic vector carrying the transgene and a
 15 separate helper virus carrying the structural genes substantially decreases the genome/vector size and thereby significantly increases transgene capacity, a useful advantage for gene therapy applications of the new system. Consequently, this results in the encapsidation of a eukaryotic virus genome into the capsid of a prokaryotic virus, resulting in a vector as hybrid between eukaryotic genome and prokaryotic capsid with
 20 enhanced production yield, gene transduction efficiency and flexibility of the vector system for other applications.

As described in the Examples below, the inventors have:-

- 25 1. Designed and constructed a hybrid Phagemid - AAV Vector (PAAV) particle expression system;
2. Characterised and determined whether the phagemid/AAV vector (PAAV) is more efficient at gene transduction than the known AAVP system at various stages, including but not limited to:
 - 30 a. Binding to the cell surface,
 - b. Internalisation of the vector from the cell surface,
 - c. Recombinant transgene expression.
3. Determined whether the hybrid phagemid PAAV vector system is capable of producing rAAV from a mammalian producer cell-line.
- 35 4. Demonstrated that the system can be used in CAR-T therapy for cancer treatment.

- 62 -

5. Demonstrated that the system can be used to deliver the cytokines IL-12, TRAIL and hybrid TNF α to target cells for cancer treatment.
6. Designed and constructed a phagemid particle comprising a hybrid TNF α construct.
- 5 7. Demonstrated that a hybrid TNF α constructs show increased expression, secretion and cell killing efficiency when compared to full length TNF α .

Referring first to Figure 1, there is shown a table comparing features of the phagemid-AAV (PAAV) particles according to the invention (i.e. virions) with the prior art AAVP viral particles. As can be seen, the PAAV particles (6kb) of the invention are much
 10 smaller than the known AAVP particles (14kb), i.e. 42% less DNA, and 50% shorter viral particles, and the PAAV particles are produced at yields that far surpass prior art systems (100X) the yield of AAVP). As a result, PAAV particles of the invention can carry larger payloads, which is very useful for delivering multiple transgenes in gene
 15 therapy approaches. The inventors have therefore demonstrated that the modified bacteriophage expression system (PAAV) can be used as a highly viral vector for gene therapy, or for large-scale production of viral vectors.

Example 1 – Phagemid - AAV Vector (PAAV) Construction

20 Referring to Figure 2, there is shown an embodiment of a Helper Phage genome and a Phagemid genome (PAAV DNA) according to the invention, which are used together upon expression in a prokaryote to produce the phagemid-AAV (PAAV) particle, also shown in Figure 1. Structural genes are integral to packaging of DNA in to virus particles, and are supplied by the replication-defective Helper phage, which is
 25 discussed in detail below. The phagemid genome is extremely parasitic to the Helper phage, meaning it outcompetes the replication-defective helper phage in both replication and packaging.

A) Phagemid/AAV Vector

30 Referring now to Figure 3, there is shown one embodiment of the phagemid genome which is a plasmid containing two origins of replication and two other genetic elements. Phagemid genomes require two origins of replication to facilitate both its replication inside the prokaryotic (e.g. bacterial) host and packaging into phagemid particles when rescued by a helper virus.

35

- 63 -

Referring to Figure 4, the first origin of replication (ori) is a high-copy number origin of replication (pUC ori) that enables replication of the double-stranded phagemid (dsDNA) inside the prokaryotic host at large quantities. The second origin of replication is a phage origin of replication (f1 ori) that enables replication of the plasmid into single-stranded DNA, which can subsequently be packaged into a phagemid vector particle (PAAV).

Referring to Figure 5, the phagemid genome includes a selection marker gene. In order for the phagemid genome to replicate efficiently inside the prokaryotic host, a selection marker (e.g. ampicillin resistance) is used to ensure expression and provides selective pressure to prevent loss of the phagemid genome in the form of an antibiotic resistance gene (with its own promoter). This ensures expression (and replication) of the phagemid genome when the prokaryotic host is cultured in the presence of the antibiotic that the selection marker confers resistance to.

Referring to Figure 6, the phagemid genome further includes a recombinant (adeno-associated virus, AAV) transgene cassette which contains a transgene of interest. This can include, but is not limited to, polypeptides/proteins, short hairpin/small interfering/short guiding RNAs, or a combination of both. By way of example only, the transgene shown in Figure 6 encodes GFP and human Beta-globin. Expression of the transgene is driven by a viral promoter (e.g. CMV) and/or enhancer sequences, and tailed with a polyA signal. The promoter can also be a mammalian and tumour specific promoter in cancer gene therapy applications (i.e. promoter of the Glucose Regulated Protein [grp78]). The entire transgene cassette is flanked by Inverted Terminal Repeat sequences (ITRs) from AAV, which form a protective hairpin structure allowing the transgene cassette to be stably maintained as concatameric episomal (extra-chromosomal) DNA in the mammalian cell nucleus transduced by the phagemid particle. The ITRs allow concatamer formation of AAV and subsequently enable AAV transgene cassettes to be stably expressed over a long period of time.

The phagemid is unable to package itself into particles as it lacks structural phage genes. As a result, it requires “rescuing” by a helper virus, as shown in Figure 7, which provides structural (i.e. capsid) proteins required for formation and extrusion of particles from the prokaryotic host. Conventionally speaking, genetic elements in the vector are generic and used widely in genetic engineering.

- 64 -

B) Helper phage

Referring to Figure 7, the helper phage (referred to herein as M13KO7) is a bacteriophage engineered specifically for rescuing phagemid particles (i.e. PAAV) from prokaryotic hosts carrying and/or containing the phagemid genome shown in Figure 3.

5 The helper phage contains a disrupted origin of replication (p15a, medium copy number) and packaging signal, which significantly deters its ability to package itself into phage particles. Consequently, the phagemid genome will outcompete the helper phage in both replication and packaging.

10 In order to give the phagemid targeting properties (or multifunctional properties as described in WO 2014/184528), the genome of the helper phage must be engineered to do so, as it provides the structural capsid proteins for phagemid particle assembly. For example, the helper genome may encode a pIII capsid minor coat protein that is configured to display a cell-targeting ligand for enabling delivery of the resultant

15 PAAVP particle to a desired target cell (e.g. tumour). It can also encode at least one pVIII major coat protein that is configured to display a foreign peptide on the resultant PAAV particle. In one embodiment, therefore, it is desired to induce a 9-amino acid mutation in the pIII minor coat protein to confer specificity to tumour cells and angiogenic tumour-associated endothelial cells that express $\alpha_v\beta_3$ and $\alpha_v\beta_5$ integrin

20 receptors. Thus, referring to Figure 8, the genome of the helper phage comprises the RGD4C peptide (CDCRGDCFC – SEQ ID No: 7) targeting these $\alpha_v\beta_3$ and $\alpha_v\beta_5$ integrins.

Once the PAAV phagemid genome and the Helper phage have been constructed, they are used together to produce, in a prokaryotic host, the Phagemid - AAV Vector (PAAV)

25 particle, as discussed below.

Example 2 – Phagemid - AAV Vector (PAAV) Production

The inventors have devised two different methods (Methods 1 and 2) for producing the Phagemid - AAV Vector (PAAV) particle, and these are illustrated in Figures 9 and 10.

30

Notes:

- TG1: a strain of *E. coli* that carries the fertility factor (F' pilus).
- 2xYT: liquid broth used to culture TG1 *E. coli*.
- Kanamycin: antibiotic resistance selection marker present on the helper phage.
- 35 - Ampicillin: antibiotic resistance selection marker present on the phagemid vector.

- 65 -

- TYE top agar: solid media used to culture TG1 *E. coli*, adapted from 2x TY by the addition of 1.25% bacteriological agar.

Phagemid/AAV Vector (PAAV) Production Method 1: Infective Rescue

5 With reference to Figure 9:

1. Add 4-5 ml of TG1 *E.coli* carrying PAAV genome pre-culture (overnight) to 60 ml 2xYT (100µg/mL Ampicillin) supplemented with 1% glucose.
2. Incubate culture at 37° in shaker (250 RPM).
- 10 3. Once OD₆₀₀ is in the range of 0.5 to 0.8 (log phase), add at least 1×10¹⁰ transducing units of helper phage (M13KO7) to culture.
4. Invert to mix. Incubate at 37° for 30 minutes.
5. Pour the infected starter culture from step 3 in to a 2L flask with 2x YT (100µg/mL Ampicillin + 25µg/mL Kanamycin) supplemented with 1% glucose
- 15 to a final volume of 400-450mL.
6. Incubate overnight in an orbital shaker at 37°, 250rpm for 16-20 hours.
7. Purify phagemid (PAAV) particles from culture supernatant.

The benefits of Method 1 are its very high yields.

20

Phagemid/AAV Vector (PAAV) Production Method 2: Stable producer cell-line

With reference to Figure 10:

Part 1: Competent producer cell-line production

- 25 1. Transform and plate TG1 competent *E.coli* (Zymo Research, USA) with ssDNA genome from helper hage M13KO7 in TYE top agar (50µg/mL Kanamycin)
1. Pick individual colonies and inoculate 5mL 2xYT media (50µg/mL Kanamycin) supplemented with 1% glucose.
2. Incubate overnight in an orbital shaker at 37°, 250rpm for 16-20 hours
- 30 3. Check for true positive transformants by extracting DNA from the 5mL overnight cultures using a commercial extraction kit (QIAGEN, Netherlands) and run on 1% agarose gel (100volts, 2.5mA) against a DNA ladder.
4. Prepare chemically competent cells from the correct transformant identified in step 4 using a published protocol (adapted from that published by Krantz et al.,
- 35 UC Berkeley)

Part 2: PAAV Phagemid Particle Production

1. Transform competent cell-line created in Part 1 with a Phagemid/AAV genome and plate on TYE top agar (100µg/mL Ampicillin + 50µg/mL Kanamycin)
2. Pick a colony and inoculate 5mL 2xYT (100µg/mL Ampicillin + 50µg/mL Kanamycin) supplemented with 1% glucose.
3. Incubate in an orbital shaker at 37°, 250rpm for 4 hours
4. Pour the infected starter culture from step 3 in to a 2L flask with 2xYT (100µg/mL Ampicillin + 25µg/mL Kanamycin) supplemented with 1% glucose to a final volume of 400-450mL
5. Incubate overnight in an orbital shaker at 37°, 250rpm for 16-20 hours
6. Purify phagemid particles from culture supernatant

PAAV Phagemid Particle Purification

1. Transfer the warm overnight culture to centrifuge bottles and pellet the bacteria by centrifugation at 3300G, 4° for 30 minutes.
2. Discard the pellet and transfer supernatant to a clean centrifuge bottle.
3. Add 30% volume of supernatant in each bottle with ice-cold 20% PEG-8000/2.5M NaCl and swirl to mix.
4. Incubate on ice for 4-24 hours
5. Precipitate phagemid particles by centrifugation at 10000G, 4° for 30 minutes. Discard the supernatant.
6. Dry the phagemid particle pellet by centrifugation at 10000G, 4° for 1 minute.
7. Remove remaining supernatant with PEG/NaCl
8. Resuspend the phagemid particle pellet in 0.5-2mL PBS
9. Filter the resuspended phagemid particle preparation using a 0.45 micron filter.
10. Keep the preparation at 4°. The preparation is stable for up to 2 years 4°. A 25% glycerol stock can be stored indefinitely at -80°.

Example 3 – Use of Phagemid - AAV Vector (PAAV) for gene therapy techniques

Examples 1 and 2 describe the components of the invention (i.e. phagemid genome shown in Figure 3 and helper phage shown in Figure 7) required to produce the Phagemid - AAV Vector (PAAV) particle and two methods of production. Once produced and purified, the PAAV particles can have a range of uses, such as in gene therapy.

- 67 -

As an example, the PAAV particles described herein carry the GFP transgene, as it is readily detectable in known assays to show successful delivery to a target cell. In therapy, any transgene may be selected and engineered into the phagemid genome shown in Figure 3, to be carried in the resultant PAAV particles. For example, the transgene may be any gene encoding a protein, which may have therapeutic or industrial utility. For example, the transgene may encode one or more antigen for recognition by adoptively transferred T cells, such as CAR T cells. The transgene may also encode a short hairpin/small interfering/short guiding RNA molecule using in RNAi therapy. The transgene may encode multiple polypeptides, nucleic acids, or a combination of both, fused together using an internal ribosomal entry site (IRES) or a viral fusion peptide (T2A peptides for in-frame fusion).

Example 4 – Use of Phagemid - AAV Vector (PAAV) for in vitro AAV production

In addition to gene therapy, the PAAV particles described herein can be used in novel methods for producing adeno-associated virus (AAV). Phage-guided AAV production utilizes the ability of the phagemid particles to package large amounts of dsDNA. A typical AAV production system consists of three major elements: rAAV, rep-cap and adenohelper genes, which function together to production recombinant AAV particles. The inventors have devised two different strategies.

With reference to Figure 11, the first strategy employed is to produce three different phagemid vectors that carry the rAAV-producing elements. These are the Phagemid - AAV Vector (PAAV) (see Figure 3), the adenohelper phagemid particle (see Figure 12), and the rep-cap phagemid particle (see Figure 13). The basic structures of these particles are similar, as they contain two origins of replication and a selection marker, as described in the phagemid/AAV construction section. The key difference, however, is the transgene cassette. While the Phagemid - AAV (PAAV) genome contains an AAV transgene cassette, as shown in Figure 3, the adenohelper and rep-cap particles contain the adenohelper transgene or rep-cap transgene, as shown in Figures 12 and 13, respectively.

In another embodiment, the inventors have genetically engineered a so-called “unified construct” that contains all of the required elements inside a single vector genome, as shown in Figures 14 and 15.

- 68 -

When introduced into the same mammalian producer cell (see Figures 11 and 14), either on separate vectors or on the same unified vector, the rep-cap and adeno-helper genes behave as trans-acting elements that facilitate packaging of the rAAV genome in the phagemid/AAV vector. This production process is comparable to transient co-

5 transfection of three plasmids. However, in this case, the plasmids are replaced with phagemid vectors carrying the very same elements.

Below is described a protocol for PAAV phagemid-guided production of adeno-associated virus (AAV).

10

Notes:

DMEM: Dulbecco's Modified Eagle Medium.

FBS: Foetal Bovine Serum, a growth supplement.

Complete media: DMEM + 10% FBS.

15 EDTA: Ethyl-diamine tetra-acetic acid, an ion chelator used to dissociate cells by sequestering calcium ions required for tight junction formation.

GlutaMax: a growth supplement, analogue of L-Glutamine.

Protocol for phagemid-guided AAV production:

- 20 1. Seed and grow HEK293 cells in complete media (DMEM supplemented with 10% FBS, 20mM GlutaMax, Penicillin/Streptomycin and Non-Essential Amino Acids) in a 15cm tissue culture plate for a minimum of 48 hours until 80% confluence is achieved.
- 25 2. Mix Phagemid/AAV, rep-cap phagemid and adeno-helper phagemid to achieve a 1:1:1 transducing unit ratio under 5mL total volume OR Aliquot a unified vector (single vector containing all three elements in a single particle) to achieve 1million transducing units per cell.
3. Add an equal volume of serum-free DMEM (supplemented with 20mM GlutaMax) to the transduction mixture made in step 3.
- 30 4. Invert to mix. Incubate at room temperature for 15 minutes.
5. Wash the HEK293 cells plated in step 1 with PBS, repeat 3 times.
6. Add the transduction mixture and swirl gently to distribute the mixture evenly.
7. Incubate at 37°, 5% CO₂ in a cell culture incubator for 72 hours
- 35 a. After 6 hours of incubation with the transduction mixture, supplement with an equal volume of complete media (DMEM supplemented with 10% FBS, 20mM GlutaMax, Penicillin/Streptomycin and Non-Essential

- 69 -

Amino Acids).

- b. After 24 hours, replace media with complete media (DMEM supplemented with 10% FBS, 20mM GlutaMax, Penicillin/Streptomycin and Non-Essential Amino Acids).

5

rAAV Purification:

1. Add 0.5M EDTA solution to the medium in the tissue culture plate to a final concentration of 0.010M, incubate for 5 minutes at room temperature.
2. Collect the cells and media by aspiration and trituration and transfer to a 50mL centrifuge tube.
3. Pellet the cells by centrifugation at 1500RPM, 5 minutes, Room temperature.
 - a. Optional: collect the supernatant for further AAV purification.
4. Resuspend the cell pellet in 2-5mL serum-free DMEM.
5. Lyse the cells in the suspension by subjecting to 4 freeze-thaw cycles in an ethanol-dry ice bath and a water bath set to 37°.
6. Centrifuge the cell lysate at 10000G, 10 minutes at Room temperature.
 - a. Aliquot the supernatant for quantification/further purification/concentration.
 - b. Discard the pellet (debris).

20

Example 5 – Use of Phagemid - AAV Vector (PAAV) for in situ AAV production

Referring to Figure 16, the inventors have devised a method for the in situ production of AAV particles using the PAAV.

- 25 Firstly, an optimal dose (or multiple doses) of the three phagemid vectors or the unified vector are introduced in vivo through intravenous/thecal/peritoneal or intramuscular/subcutaneous (or any of the aforementioned routes of administration). The diseased tissue is a tumour displaying the relevant integrins and so the targeting moiety on the phagemid PAAV particles is the RGD4C sequence. The tumour should
 - 30 start to produce rAAV containing the viral transgene encoded in the hybrid phagemid particle and not wild-type AAV. These AAV therapeutic particles should autoinfect nearby sites, as they naturally have high affinity to mammalian tissue, and eradicate the tumour over a given time.

Example 6 - Engineering Pseudovirions for Large-scale Targeted Gene Transfer and Recombinant Adeno-associated Virus Production

Transmission Electron Microscopy

In characterising the particles, the inventors imaged PAAV particles to show that vector
 5 size is substantially reduced when using the phagemid-based vector system. Using
 Transmission Electron Microscopy, the inventors imaged and measured the length of
 PAAV of the invention and known AAVP particles on mesh copper TEM grids after
 negative staining with uranyl acetate (see Figure 17). It was found that the average
 AAVP particle was 1455.02nm in length (Fig. 17A), while a typical PAAV particle
 10 according to the invention is only 729.96nm in length (Fig. 17B) – which equates to
 approximately 50% reduction in particle size. Compared to the helper phage that is
 used to produce PAAV particles (typically 1186.03nm, Fig. 17B), the relative vector size
 is approximately 38% shorter than the helper virus.

15 The difference in vector size forms the basis of the theory that PAAV may be more
 efficient as a gene delivery vector than the AAVP, not only in terms of production yield,
 but also in subsequent infection processes when entering and expressing genes in
 mammalian cells. As such, the inventors probed vector efficiency at various stages of
 infection, including binding, internalisation, and gene expression in 293AAV (a
 20 derivative of Human Embryonic Kidney 293) and U87 glioblastoma cell lines.

Vector Internalisation

Following binding, vectors undergo receptor-mediated endocytosis by the target cell.
 To investigate potential differences in vector internalisation, the inventors assayed the
 25 number of internalised vectors in target cells at two time-points (2 hours, 2H; 4 hours,
 4H) using flow cytometry (see Fig. 18). It was found that PAAV vectors were
 internalised more efficiently at 2 hours (Median Fluorescence Intensity (MFI) = 1031.7,
 335 higher than AAVP, $p < 0.05$) and to a greater overall extent at 4 hours when
 compared to AAVP in both cell lines. The MFI at 2 hours for PAAV was significantly
 30 higher than AAVP by 335 for 293AAV and 207 for U87 cells ($p < 0.05$). At 4 hours post-
 transduction, this difference became substantially greater for 293AAV (829 MFI,
 $p < 0.05$), but less so for U87 (157 MFI, non-significant). Overall, the MFI peaked at
 2092 (293AAV, $p < 0.05$, Fig 18A) and 1137 (U87, Fig 18B) for PAAV1-treated cells,
 which was significantly higher than AAVP, which respectively peaked at 1063 (293AAV)
 35 and 980 (U87). The data demonstrates that PAAV performed consistently better than
 AAVP in rate and extent of internalisation for both time-points in both cell-lines.

Green Fluorescent Protein Expression following AAVP and PAAV-mediated Gene Transfer

To investigate whether the differences in vector internalisation translates to increased gene expression, the inventors performed a GFP-expression assay using RGD and NT PAAV.GFP and AAVP.GFP vectors (see Fig 19). In this experiment, they also tested whether addition of the cationic polymer DEAE.DEXTRAN (Dex) could enhance gene transfer by increasing the bioavailability and endosome-escape of PAAV vectors, as described in WO2014/184529. Nine days post-transduction, cells were trypsinised, and counted and analysed using a flow cytometer. It was found that transgene expression was generally higher in 293AAV cells than U87, regardless of whether Dex was used to assist vector transduction. When vector alone is used, the targeted RGD.PAAV.GFP vector transduces target cells with higher efficacy (7.7%, $p < 0.01$ and 1.4%, $p < 0.05$ GFP +ve cells in 293AAV and U87 cells, respectively) – compared to AAVP, this translates to a 2.44 and 1.56 fold increase respectively in 293AAV and U87 cells (Fig 19A, C).

When Dex is added however, gene expression increases dramatically for RGD.AAVP and RGD.PAAV vectors. In 293AAV cells, GFP expression in RGD.AAVP.GFP treated cells increased to 25% while RGD. PAAV.GFP treated cells experience a substantial increase to 50% (all $p < 0.01$); addition of Dex resulted in an increase in gene expression of 7.9-fold for RGD.AAVP and 6.5-fold for RGD. PAAV (Fig 19B, D). In U87 cells, which is regarded as highly resilient to transduction, Dex was able to augment gene expression by over 3.6-fold in RGD.PAAV.GFP to 4.8% GFP+ve cells ($p < 0.01$) – this was not the case for RGD.PAAV.GFP, as Dex increased gene expression by only 1.5-fold to 1.3% GFP+ve cells ($p < 0.05$). Interestingly, Dex enabled transduction by NT. PAAV (non-targeted) vectors in 293AAV cells (7.34%), but not with U87.

Phagemid-guided Recombinant Adeno-associated Virus Production

To assess whether PAAV and phagemid-derived vectors could be used to produce rAAV in a commercial producer cell-line, the inventors transduced 293AAV cells with three targeted vectors, which are normally plasmids that require transfection for gene transfer. They were able to harvest rAAV particles from the cell lysate and quantify the rAAV gene copy number (GC) per mL over three time-points after phagemid-guided transduction (Fig. 20A). When compared to conventional transfection with FuGene6 (transfection reagent, 3.99×10^{11} GC/mL, Fig 20B), phagemid-guided rAAV production provides over 1.9-fold increase at 168 hours (7.69×10^{11} GC/mL, Fig 21A) in rAAV yield.

- 72 -

Because phagemid-guided gene transfer requires extensive intracellular processing (unlike transfection), it requires a longer time for viral genes to be expressed and packaged in to functional particles. When yields are compared at the same 72-hour time-point however, transfection produced 1.76e11 GC/mL higher than phage-guided rAAV production. The rAAV yield per mL culture supernatant from transfection or phagemid-guided production dishes at all time points were approx. 8-9e10 GC/mL with no observable trends (data not shown).

Example 7 – Construction and uses of RGD4C-phagemid

The tripeptide, RGD, is found in proteins of the extracellular matrix, including fibronectin. The integrins act as receptors for fibronectin by binding to the RGD motif located in fibronectin in the site of cell attachment to $\alpha_v\beta_3$ integrin, and so the inventors induced a 9-amino acid mutation in the pIII minor coat protein of the recombinant phagemid particle in order to confer its specificity to tumour cells and angiogenic tumour-associated endothelial cells that express $\alpha_v\beta_3$ and $\alpha_v\beta_5$ integrins. Thus, the genome of the second vector comprises the RGD4C targeting peptide (CDCRGDCFC – SEQ ID No: 7).

Referring to Figure 21, there is shown immunofluorescence staining of UW228 and DAOY human medulloblastoma cells, which demonstrates the expression of α_v , β_3 and β_5 integrin subunits, receptor for RGD4C-phagemid. These data demonstrate that the phagemid vector containing the RGD4C targeting peptide can be used for targeted gene delivery and gene therapy in the paediatric brain tumor, medulloblastoma.

Referring to Figure 22, there is shown targeted gene delivery to paediatric medulloblastoma cells by the RGD4C-phagemid, over a time course of 4 days. The data show that RGD4C-phagemid mediated efficient and selective gene delivery that increased overtime in medulloblastoma.

Figure 23 shows Western blot analyses showing down-regulation of the mammalian target of rapamycin (mTOR) expression in paediatric UW228 and DAOY medulloblastoma cells following treatment with RGD4C-phagemid carrying a sequence encoding the mTOR/shRNA (RGD4C-mTOR/shRNA)). These data demonstrate that the RGD4C-phagemid can be successfully used to deliver shRNA in tumour cells to knock down expression of the therapeutic target mTOR in a selective and efficient way.

- 73 -

Figure 24 shows combination treatment of temozolomide (TMZ) and RGD4C-phagemid carrying a sequence encoding shRNA for mTOR in medulloblastoma cells, known for their resistance to temozolomide. The data demonstrate that targeted the RGD4C-mTOR/shRNA can re-sensitize medulloblastoma cells to TMZ and achieve
5 complete tumour cell eradication. Therefore, targeted knockdown of mTOR expression by the RGD4C-phagemid is an efficient strategy to use in combination with temozolomide against chemoresistant tumour cells, such as medulloblastoma.

Figure 25 shows treatment of medulloblastoma cells with TNF α vectors. Therefore,
10 RGD4C/TNF α has therapeutic potential for use in targeted tumour killing such as medulloblastoma. Figure 26 shows immunofluorescence staining of DIPG cells to demonstrate expression of α_v , β_3 and β_5 integrin subunits, receptor for RGD4C-phagemid. These data demonstrate that the phagemid vector containing the RGD4C targeting peptide can be used for targeted gene delivery and gene therapy in the
15 paediatric brain tumours, DIPG.

Figure 27 shows selective and dose dependent delivery of gene expression to UW288, DAOY, or DIPG cells by RGD4C-phagemid/AAV. These data prove that RGD4C-phagemid can successfully deliver gene expression to DIPG in a dose-dependent and
20 selective way. These data also indicate that RGD4C-PAAV shows efficient gene transfer to medulloblastoma *in vitro* that increased over time. There was no non-specific uptake in the cells transduced with the control (non-targeted PAAV-Luc). The transduction efficiency was enhanced with the cationic polymer DEAE dextran for medulloblastoma cell lines.

25 Figure 28 shows treatment with RGD4C-phagemid-TNF α . These data demonstrate that RGD4C-phagemid can successfully deliver TNF α to DIPG in a selective manner, resulting in apoptosis induction. Therefore, RGD4C-phagemid-TNF α has therapeutic potential for use in targeted therapy against DIPG. Figure 28 also shows that
30 medulloblastoma is a good candidate for treatment with RGD4C-phagemid-TNF α , as the treatment resulted in tumour cell killing when tested with either of the cell lines UW288 or DAOY. For instance, UW288 showed about 60% cell death on day 6 relative to the control. Tumour cell killing was further enhanced with the cationic polymer DEAE dextran.

35

Example 8 – Luciferase expression of RGD4C-phagemidProtocol:

HEK cells were plated in a 48-well plate in complete media (DMEM, 10% FBS, 1% glutamine, 1% penicillin/streptomycin) and incubated for at least 48 hours until 70-
 5 80% confluence was reached. Cells were then washed with PBS and transduced with hybrid phage/phagemid vectors suspended in serum-free media (DMEM) for 12 hours before the media was supplemented with complete media. Luciferase expression was measured by adding 10uL of culture media to 50uL of prepared Quanti-luc (InvivoGen, USA) reagent. The emission of photos was measured using a plate reader equipped
 10 with a luminometer (promega, USA).

Figure 29 shows luciferase expression after transduction with RGD.PAAV at various concentrations of transducing units. The graph demonstrates a dose-dependent exponential relationship between time and expression of luciferase after incubation
 15 with hybrid phage/phagemid vectors at various concentrations. The figure demonstrates that quantifiable gene expression can be achieved by phagemid vectors via an assay for secreted luciferase.

Example 9 – Binding of RGD.PAAV vector to 293 AAV cellsProtocol:

293AAV cells were seeded on 24-well plates in complete media (DMEM +10%FBS, 1%Glutamine, 1% Penicillin/Streptomycin), and were left to reach 70-90% confluence for a minimum of 48 hours. The cells were washed twice with 500uL PBS and placed on ice before being transduced with 200000 TU/cell (transducing units/cell) of PAAV
 25 vectors suspended in 200uL of serum-free DMEM. After 1 hour of incubation on ice, the media was recovered from the wells and the amount of phagemid particles were titrated on TG1 *E.coli* and quantified by colony-counting.

Referring to Figure 30, there is shown the percentage of PAAV vectors bound to the cell
 30 surface of 293 AAV cells. RGD.PAAV vectors had 58.2% binding efficiency, whereas M13. PAAV vectors had 7.1% binding efficiency relative to their respective controls.

Example 10 – Transduction of tumour cells by PAAV to express either MUC1 or PSMA antigen on their cell surface, such that they can be targeted by specific CAR T cells.

35 The conventional treatment for cancer currently consists of one or more of the following three options: surgery, chemotherapy and radiotherapy. Although the disease

- 75 -

can sometimes be cured by these interventions, in many cases the cancer cells are not completely eliminated, and so the recurrence rate is high. To make matters worse, chemotherapy and radiotherapy are associated with unpleasant side effects. As a result, there is a great interest in the development of alternative approaches for cancer treatment. One of the most promising of these new therapeutic techniques is cancer immunotherapy, which aims to harness the power and specificity of patients' own immune system to eliminate cancer cells. Cancer immunotherapy is an evolving avenue of treatment. Two main strategies involve active immunotherapy targeting tumour-associated antigens (TAAs) and passive immunotherapies that enhance existing anti-tumour responses.

Examples of cancers include paediatric brain tumours, such as medulloblastoma and Diffuse Intrinsic Pontine Glioma (DIPG). Medulloblastoma is the most common brain tumour and originates in the cerebellum with a five years survival rate following the current therapeutic strategy that consists of surgical resection, radiotherapy, and chemotherapy (Rudin et al., 2009). However, the survivors often have long term endocrinological and neurocognitive side effects. Therefore, development of novel therapeutic approaches that are non-invasive, tumour specific, safer, cost-effective and efficient is urgently needed to avoid the long-term side-effects from current treatment. On the other hand, diffuse intrinsic pontine glioma (DIPG) is the most aggressive brain tumour that arises exclusively in children with poor survival of only 6-10% beyond two years. Due to its diffuse nature, there is no effective therapeutic strategy for this type of cancer (Jansen et al., 2012, Mueller and Chang, 2009).

Due to the immune system's unique properties and its central and universal role in the organism, immunotherapy possesses the great potential to treat cancer and offers long-term protection while potentially providing fewer side effects than other treatments. One particular approach, adoptive cell therapy (ACT), involves the transfer of immune cells that have anti-tumour activity. These cells can be T cells that already exist in a tumour, known as tumour-infiltrating lymphocytes (TIL), some of which will be specific for TAAs. These cells can be isolated from excised tumour tissue, cultivated, activated and expanded *ex vivo*, then re-infused into patients. Other types of cells that are useful for ACT include genetically engineered T cells that express either a modified T cell receptor (TCR) or a chimeric antigen receptor (CAR). These artificial receptors specifically direct the T cells to target antigens expressed by tumour cells (Blankenstein T, *et al.* The determinants of tumour immunogenicity. Nat Rev Cancer. 2012;12(4):307-

13.; Sharpe M and Mount N. Genetically modified T cells in cancer therapy: opportunities and challenges. *Dis Model Mech.* 2015;8(4):337-50.).

CAR proteins are expressed on the surface of T cells, and contain extracellular binding
 5 domains which bind strongly to specific tumour antigens, a hinge region linking
 between extracellular domains and transmembrane domains, a transmembrane
 domain, and intracellular signalling domains (also called co-stimulatory domains) such
 as CD28 and OX40 (a tumour necrosis factor receptor). Co-stimulatory signals
 mediated by those domains enable efficiency and prolong the anti-tumour activity of
 10 the T cells (Sharpe M and Mount N. Genetically modified T cells in cancer therapy:
 opportunities and challenges. *Dis Model Mech.* 2015;8(4):337-50; Till BG, *et al.* CD20-
 specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with
 both CD28 and 4-1BB domains: pilot clinical trial results. *Blood.* 2012;119(17):3940-50;
 Koehler H, *et al.* CD28 co-stimulation overcomes transforming growth factor-beta-
 15 mediated repression of proliferation of redirected human CD4+ and CD8+ T cells in an
 antitumor cell attack. *Cancer Res.* 2007;67(5):2265-73). CAR T cells can be designed to
 recognise broad types of antigen, which may be expressed on tumour's cell surface.
 Potential target antigens include proteins, carbohydrates, and glycolipids. CAR T cells
 do not need the antigen to be processed and presented by MHC, unlike conventional T
 20 cells and transgenic TCR T cells. Therefore, the same CAR-based strategy can be
 applied in all patients expressing the same tumour antigen regardless of the patient's
 MHC haplotype (Sharpe M and Mount N. Genetically modified T cells in cancer
 therapy: opportunities and challenges. *Dis Model Mech.* 2015;8(4):337-50, Haji-
 Fatahaliha M, *et al.* CAR-modified T-cell therapy for cancer: an updated review. *Artif*
 25 *Cells Nanomed Biotechnol.* 2015;1-11).

Despite having many advantages, CAR T cell therapy has some limitations. For
 instance, the tumour may not express a suitable target antigen. This may occur for a
 variety of reasons such as the neo-antigens being unknown, expressed at inappropriate
 30 levels, expressed only on a sub-population of tumour cells, also expressed on non-
 tumour tissues, not expressed in a manner that is suitable for the targeting of CAR T
 cells to the tissue, or if expression of the antigen by the tumour is likely to be reduced or
 lost during treatment.

35 For example, it has been reported that some CAR T cell therapies have unwanted
 toxicity in both animal models and in clinical trials. The problem can occur when the

antigen recognised by the CAR T cell is not merely expressed on tumour cells but also presented on normal cells leading to damage of healthy tissue (Palmer DC, *et al.* Effective tumour treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity (Proc Natl Acad Sci U S A. 2008;105(23):8061-6; Morgan RA, *et al.* Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010;18(4):843-51; Lamers CHJ, *et al.* Treatment of Metastatic Renal Cell Carcinoma With Autologous T-Lymphocytes Genetically Retargeted Against Carbonic Anhydrase IX: First Clinical Experience. Journal of Clinical Oncology. 2006;24(13):e20-e2; Grupp SA, *et al.* Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16):1509-18.). Therefore, the availability and selection of the target antigen are challenging. Ideally, the antigen presented exclusively by the tumour cells or alternatively by normal cells that is not essential for survival (Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 2015;348(6230):62-8). At present, many CAR T cells have successfully been developed against various tumour antigens, such as mucin 1 (MUC1) for the treatment of prostate cancer and breast cancer (Sanchez C, *et al.* Combining T-cell immunotherapy and anti-androgen therapy for prostate cancer. Prostate Cancer Prostatic Dis. 2013;16(2):123-31, S1; Wilkie S, *et al.* Retargeting of Human T Cells to Tumor-Associated MUC1: The Evolution of a Chimeric Antigen Receptor. The Journal of Immunology. 2008;180(7):4901-9), prostate-specific membrane antigen (PSMA) for the treatment of prostate cancer (Maher J, *et al.* Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCR[zeta] /CD28 receptor. Nat Biotech. 2002;20(1):70-5.), CD19 and CD20 for the treatment of B-cell malignancies (Brentjens RJ, *et al.* Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood. 2011;118(18):4817-28.) and estrogen-related receptor beta type 2 (ErRB2) for the treatment of prostate and breast cancer (Pinthus JH, *et al.* Immuno-Gene Therapy of Established Prostate Tumors Using Chimeric Receptor-redirected Human Lymphocytes. Cancer Research. 2003;63(10):2470-6.). Furthermore, to pursue a higher selectivity on tumour cell, T cells have been developed through several strategies including dual-CARs T cells that are modified to express two CARs targeting specifically two different antigens expressed on the same tumour cell (Kloss CC, *et al.* Combinatorial antigen recognition with balanced signalling promotes selective tumor eradication by engineered T cells. Nat Biotechnol. 2013;31(1):71-5; Wilkie S, *et al.* Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors

engineered to provide complementary signalling. J Clin Immunol. 2012;32(5):1059-70.).

Molecular cloning and genetic engineering

5 Each PAAV-CMV-CD28-IL4, PAAV-CMV-GPI-IL4 and PAAV-CMV-PSMA (Fig. 32f) were constructed by combining PAAV-CMV-GFP plasmid (Fig. 3) with either pUC57-CD28-IL4 plasmid, pUC57-GPI-IL4 or pUC57-PSMA plasmid while PAAV-Grp78-GFP plasmid was combined with either pUC57-CD28-IL4 plasmid, pUC57-GPI-IL4 or pUC57-PSMA plasmid to construct PAAV-Grp78-CD28-IL4, PAAV-Grp78-GPI-IL4 and
10 PAAV-Grp78-PSMA.

The new plasmids; PAAV.CMV.MUC1.CD28.IL4, PAAV.CMV.MUC1.GPI.IL4, PAAV.CMV.PSMA, PAAV.Grp78.MUC1.CD28.IL4, PAAV.Grp78.MUC1.GPI.IL4 and PAAV.Grp78.PSMA, were conducted by restriction enzyme digestion and ligation,
15 transformed into TG1 competent E. coli and plated on 2xYT top agar with ampicillin. All constructs were validated firstly by restriction digestion and gel electrophoresis, and secondly by DNA sequencing (MRC CSC Genomics Core Laboratory, UK).

Figure 31 shows schematic diagrams of embodiments of the expression plasmid
20 constructs for bacteriophage-guided CAR T cell therapy; 32a represents MUC1-CD28.IL4 expression plasmid driven by CMV promoter, 32b represents MUC1-GPI.IL4 expression plasmid driven by CMV promoter, 32c represents PSMA expression plasmid driven by CMV promoter, 32d represents MUC1-CD28.IL4 expression plasmid driven by Grp78 promoter, 32e represents MUC1-GPI.IL4 expression plasmid driven by Grp78
25 promoter and 32f represents PSMA expression plasmid driven by Grp78 promoter.

CD28, GPI and PSMA antigen expression

HEK 293 cells at approximately 60% confluent in 12-well plate were incubated 24 hours with each vector (1,000,000 TU/cell) in complete media consisting of Dulbecco's
30 Modified Eagle's Medium (DMEM) supplemented with 10% Fetal Bovine Serum (FBS), L-Glutamine (2mM, Sigma), penicillin (100 units/ml, Sigma), and streptomycin (100 mg/ml, Sigma). Untreated cells were used as a negative control. Next day, all vectors was removed from the culture and the cells were maintained in a humidified incubator at 37 °C in 5% CO₂ as monolayers in complete medium. The medium was renewed
35 every two days.

- 79 -

At day 6 post-transduction, the cells were harvested with cell dissociation buffer (Invitrogen), washed in washing buffer (PBS containing 2%FBS and 0.1%NaN₃) and incubated in Clear Back (human Fc receptor blocking agent, MBL) for 20 minutes at room temperature. The cells were subsequently incubated with either HMFG2 antibody
 5 provided by Dr. John Maher (King's College London, UK) or PSMA antibody (MBL) diluted in washing buffer at 4 °C overnight. Next day, the cells were washed in washing buffer and incubated for 30 minutes at room temperature with anti-mouse IgG Alexa fluor 488 conjugated secondary antibodies (Invitrogen). The cells were finally washed in washing buffer and subjected to FACs calibur Flow cytometer (BD Biosciences). The
 10 mean fluorescence intensity was measured for at least 20,000 gated cells per triplicate well. Results were analyzed using Flowjo (TreeStar) software.

MUC-1.CD28, MUC-1.GPI and PSMA antigen expression on day 6 post-transduction
 HEK 293 cells were transduced by either 10⁶ TU/cell of RGD targeted PAAV (RGD) or
 15 non-targeted PAAV (NT). Figure 33 shows the resultant data. Untreated HEK 293 cells (Ctrl) and, targeted PAAV transduced-HEK 293 cells with only 488 secondary antibody staining (Ant.488) were shown as control. (A) represents the MUC-1 or PSMA expression of HEK 293 cells transduced by CMV promoter-driven PAAV vector. DEAE-dextran was added. (B) represents the MUC-1 or PSMA expression of HEK 293 cells
 20 transduced by CMV promoter-driven PAAV vector without DEAE dextran added. (C) represents the MUC-1 expression of HEK 293 cells transduced by Grp78 promoter-driven PAAV vector without DEAE dextran added.

Stable cell line selection

25 To select the stable cell line expressing MUC-1.CD28, MUC-1.GPI or PSMA antigen on their cell surfaces', puromycin resistant sequence was inserted in PAAV-CMV-CD28-IL4, PAAV-CMV-GPI-IL4, PAAV-CMV-PSMA, PAAV-Grp78-CD28-IL4, PAAV-Grp78-GPI-IL4 and PAAV-Grp78-PSMA plasmids.

30 **Figure 34** shows schematic diagrams of the expression plasmid constructs with puromycin resistant gene for stable cell line selection bacteriophage-guided CAR T cell therapy therapy; 34a represents MUC1-CD28.IL4 expression plasmid driven by CMV promoter, 34b represents MUC1-GPI.IL4 expression plasmid driven by CMV promoter, 34c represents PSMA expression plasmid driven by CMV promoter, 34d represents
 35 MUC1-CD28.IL4 expression plasmid driven by Grp78 promoter, 34e represents MUC1-

- 80 -

GPI.II4 expression plasmid driven by Grp78 promoter and 34f represents PSMA expression plasmid driven by Grp78 promoter.

5 The new plasmid was conducted by restriction enzyme digestion and ligation, transformed into TG1 competent E. coli and plated on 2xYT top agar with ampicillin. All construct was validated firstly by restriction digestion and gel electrophoresis, and secondly by DNA sequencing (MRC CSC Genomics Core Laboratory, UK)

Results

10 PAAV vectors encoding either MUC1 or PSMA transgene were produced using the helper phage system. These transgene products are subjected to display on tumour cell surface after being transduced by PAAV. MUC1 and PSMA antigens are specifically recognised by MUC1-CAR T cells and PSMA-CAR T cells.

15 Presented herein are data showing that the phagemid particles of the invention can be used to transduce cancer cells, and that the cancer cells subsequently stably display the delivered antigens in a manner suitable for use as the target of an adoptively transferred T cell.

20 Discussion

There is strong evidence to suggest that targeted PAAV vectors are more efficient than AAVP vectors at gene transduction in both commercial and disease cell lines. Both internalisation and gene expression data concordantly indicate that PAAV are more efficient than AAVP. Evidence is also provided to suggest a strong synergistic effect
25 between DEAE-Dex and PAAV vectors on gene transduction that surpasses that of AAVP. Although these data suggest that PAAV are superior to AAVP, it must also be considered that PAAV vector samples contain helper phage contamination. Despite efforts in optimising experimental conditions during vector production, helper phage contamination (in this case, approx. 1/10) is unavoidable and will competitively inhibit
30 transduction as it too displays the RGD targeting sequence on its minor coat protein. Taking this into account, the internalisation and gene expression data may very well be underestimating the 'true' efficacy of RGD.PAAV. Additionally, because the internalisation assay utilises staining of intracellular phage capsid for signal detection, the smaller overall size (and available capsid protein per particle) of the PAAV means
35 that the proportional number of particles internalised cannot be compared directly to that of AAVP, which we have shown using TEM is twice in length compared to PAAV

- 81 -

particles. Accordingly, methods of the invention involve a purification step (e.g. FPLC) to remove the helper phage.

It is essential that in addition to providing mechanistic insight, future work must encompass replication of all experiments using pure PAAV samples. In particular, phagemid-guided rAAV production may benefit greatly from decreased competitive inhibition by helper phage contamination and yield multiple fold higher rAAV particles compared to conventional transfection protocols.

10 Summary

Hybrid phagemid vectors that are highly efficient at gene transfer to mammalian cells are described. These phagemid/AAV (PAAV) vectors have very large cloning capacities and are targeted to mammalian cells, meaning transfection reagents are not required. This platform allows the production of vectors that are suitable for therapeutic gene therapy. Evidence is provided that this platform can deliver genes, including antigens suitable for targeting by adoptive T cell transfer therapy or CAR T cell therapy, to tumour cells.

20 Example 11 - Superior phagemid/AAV hybrid vector for guided delivery of TRAIL gene to paediatric DIPG cells.

The use of cytokines in gene therapy was investigated as they serve diverse functions as differentiation, proliferation, activation or induction of cell death by apoptosis. The tumour necrosis factor (TNF) superfamily is one such group of molecules that are of interest because of their ability to induce death of tumour cells. Members of the TNF superfamily including Fas ligand (FasL), CD95 ligand (CD95L) and TNF α have been identified as important therapeutic agents for cancer biological therapy. Their administration can induce apoptosis in different cancer cells but also cause severe toxicity to liver, preventing their application in the clinic.

30 Given the dilemma of systemic toxicity, another member of the TNF superfamily, TRAIL, is rising as a promising cancer therapeutic agent. Preclinical and early clinical trials using recombinant TRAIL and antibodies against TRAIL receptors have shown that TRAIL has preferential toxicity toward tumour cells with generally little or no toxicity to normal tissues while retaining its anti-tumour properties. TRAIL is constitutively present in many tissues at the level of mRNA, most predominately in

35

- 82 -

spleen, lung and prostate, and is expressed mainly by cells of the immune system such as natural killer (NK) cells and macrophages.

TRAIL is synthesized as a Type II transmembrane protein that can also be
5 proteolytically cleaved by a cysteine protease to generate a secreted form⁷. The
membrane-bound conformation appears to be more potent, as TRAIL is biologically
active as a homotrimer and this specific conformation presumably facilitates cross-
linking of ligand-receptor complexes, thereby increasing signalling strength. The
secreted form is less potent, but effects can be enhanced by engineering an extracellular
10 domain fused to motifs such as a leucine zipper, which helps with stabilisation and
formation of homotrimers.

Like other TNF superfamily members, TRAIL induces apoptosis through interacting
with cross-linked receptor molecules on the surface of the target cells^{5,10}. There are 5
15 receptors that have been identified: TRAIL R-1 and R-2 are death receptors that
contain a cytoplasmic sequence death domain (DD) which triggers apoptosis, while
TRAIL R-3, R-4 and osteoprotegrin are decoy receptors that prevent apoptosis^{5,6,10}.

When homotrimer TRAIL binds to death receptors, the receptors form a trimer and
20 recruit adaptor protein Fas-associated death domain (FADD). FADD recruits initiator
caspases 8 or 10, forming the death inducing signal complex (DISC), where initiator
caspases are auto-activated by proteolysis. Activated caspase 8 or 10 then cleave the
effector caspase 3, causing cleavage of death substrates and cell death. If TRAIL binds
to the decoy receptors instead, FADD is not recruited and apoptosis is not triggered.
25 Even in cells resistant to TRAIL-induced apoptosis, TRAIL can induce necroptosis¹¹.
The TRAIL-receptor system can induce direct killing of tumour-supportive immune
cells and its expression on NK cells is an important mechanism used by the immune
system to kill cancer cells.

30 Current clinical trials to deliver agonists of those in the TNF superfamily, including
recombinant TRAIL or agonist antibodies against TRAIL receptors, have unfortunately
failed to produce a clinical benefit in cancer patients, partly due to insufficient agonistic
activity and short half-life of the drugs. Additionally, often these drugs are limited in
their efficacy from design due to concerns that systemic delivery of stronger agents can
35 induce lethal adverse effects. In order to ensure the delivery of TRAIL at optimal

- 83 -

concentrations to produce clinical results, a suitable vector is required to selectively target and transport TRAIL to cancer cells.

Using phage display-based technology, viral vectors that display ligands that target and
5 bind receptors selectively expressed in tumour tissues can be used to deliver TRAIL.
Most research has focused on the use of eukaryotic viruses such as retrovirus and
adenovirus as vectors as they provide superior transgene delivery. However, they have
had limited success in systemic gene therapy due to their wide tropism for mammalian
10 cell-membrane receptors, leading to undesired uptake by the liver, reticuloendothelial
system and unwanted tissues, as well as immunogenicity. In contrast, prokaryotic
viruses are advantageous, as they do not require ablation of native tropism for use in
mammalian cells, are cost effective and readily produced in high titres. As they lack
tropism, they are inherently poor vehicles for mammalian cell transduction¹³.
However, by altering their coat proteins to display selective ligand peptide motifs,
15 phages can be internalised into cells.

Effective administration of treatment solely to the tumour for prolonged effects without
systemic toxicity can be achieved using vectors based on bacterial viruses,
bacteriophage or phage. These bacteriophage-based vectors can be engineered to
20 display selective ligand peptide motifs on its coat proteins to allow viral binding to
targeted cells and subsequent internalisation for ligand-directed delivery of genes¹⁹. By
combining the favourable biological attributes of eukaryotic and prokaryotic viruses, a
chimeric virus vector was constructed comprising of recombinant adeno-associated
virus (AAV) and M13-derived filamentous phage, named AAV/Phage or AAVP13. The
25 pIII coat protein of the phage was engineered to display the double-cyclic peptide
CDCRGDCFC (RGD-4C, SEQ ID NO: 7), which binds to specific α v integrin receptors
(α v β 3 or α v β 5) that are over-expressed in both tumour and supporting angiogenic
vaculature. This allows for superior ligand-directed delivery and cellular transduction
of therapeutic transgenes as a targeted platform and these functional attributes have
30 been confirmed in preclinical models of several cancers including prostate, breast
cancer and soft-tissue sarcomas.

The inventors have improved known vector platforms by using the phagemid system to
produce the next-generation vector known as Phagemid-AAV (PAAV) (Figure 43).
35 PAAV vector is a chimeric virus – a M13 filamentous phage containing a hybrid genome
constructed using DNA sequences from the AAV serotype 2. The gene of interest is

- 84 -

regulated by the constitutively active cytomegalovirus, CMV promoter and flanked by full-length inverted terminal repeats (ITRs). The phagemid contains an f1 origin of replication, which is used for single stranded replication and packaging into phage particles; as well as an origin of replication for double stranded replication once it enters the target cell. It can be selected with ampicillin during cloning and production of virus vector.

In this hybrid vector model, most of the phage genome is removed which allows for longer DNA sequences to be accommodated, but necessitates the use of helper viruses to provide the capsid and other phage components. RGD-4C peptide motif is first displayed on the pIII coat protein of the M13 bacteriophage to produce a targeted backbone helper virus. The helper virus is then used to transduce TG1 E.coli bacteria containing the engineered phagemid, and selection of the targeted vectors containing phagemid can be conducted using selection pressure with antibiotics. The new model was able to accommodate longer DNA sequences, had higher transduction efficiency and could be produced at higher titre over the original AAVP.

Without wishing to be bound to any particular theory, further improvements to transduction efficiency can be achieved via two methods. First, by engineering the RGD-4C peptide to display on pVIII instead of pIII coat protein. pVIII, being the major coat protein, is expressed in up to 2700 copies while pIII is only expressed up to 5 copies. A greater number of RGD-4C ligands that are available for targeting and binding integrins are therefore thought to be have higher efficiency at binding and transducing cells.

Without wishing to be bound to any particular theory, another strategy to enhance efficiency is by displaying the histidine rich H5W ligand, an endosomal escape peptide on the recombinant pVIII coat proteins. Intracellular barriers such as endosomes can limit the rate of gene expression even if the efficiency of internalisation is high, by trapping vectors and preventing it from exerting its therapeutic effects. The histidine side chain can form zwitterions, allowing it to act as a proton sponge and buffer the low pH in the endosome following ligand-directed endocytosis of the phage vector. When protons enter the endosome, water is drawn into the endosome via a vacuolar membrane proton pump, causing pores to form on the endosome and thereby releasing the phage vector.

The aim of this study was to develop a superior PAAV vector with optimal transduction efficiency of DIPG cells, by altering the peptides displayed on the vector's coat proteins. Next, the most suitable PAAV vector was used to deliver the TRAIL transgene to assess the effectiveness of TRAIL as a therapeutic gene in the treatment of DIPG.

5

Without being bound to any particular theory, the inventors hypothesised that:

1. Specificity of targeting and efficacy of genetic transfer can be enhanced by displaying the RGD-4C ligand on pVIII coat proteins or H5W peptide on the recombinant pVIII coat proteins
- 10 2. TRAIL is an effective therapeutic gene to specifically induce DIPG cell death in in vitro experiments and in an in vivo orthotopic DIPG animal model

Aims of study

1. Design and produce a viral vector for specific targeting of DIPG cells with optimal expression of the desired gene.
- 15 2. Assess and investigate the killing potential of therapeutic gene TRAIL against DIPG
3. To assess the specificity of targeting TRAIL expression to DIPG in vivo and investigate the therapeutic efficacy following intravenous administration of vector to immunodeficient mice with established orthotopic human DIPG.
- 20

Protocol

Cell culture

HEK293T cell lines were maintained in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% foetal bovine serum (FBS) and 1% penicillin and streptomycin. DIPG tumour cell lines were obtained from Hospital Saint Joan de Déu Barcelona. They were maintained in Tumour Stem Medium (TSM) Base supplemented with 10% FBS. TSM is made according the recipe provided (Table XXX).

30 *Integrin staining*

DIPG cells were seeded on poly-D-lysine coated coverslips in 24-well plates and grown until 60-70% confluent. 5 wells were used to stain for: control, secondary antibody only, α v, β 3 and β 5 integrins. Cells were washed and fixed in 4% formaldehyde for 10 minutes at room temperature (RT). Cells were washed three times in PBS and incubated with 50mM ammonium chloride for 5 minutes. Cell were washed again with PBS for three times and blocked for 30 minutes in 2% bovine serum album (BSA-PBS).

35

Subsequently, cells were incubated with primary antibodies anti- α v (1:100), anti- β 3 (1:50) and anti- β 5 integrins (1:100) diluted in 1% BSA-PBS for one day and kept in a moist chamber at 4°C. Following which, cells were washed with three times with 1% BSA-PBS and incubated for 1 hour with secondary Alex Fluor 488-conjugated
 5 antibodies (1:750) and 4',6-diamidino-2-phenylindole (DAPI, 1:2000). Coverslips were washed three times with 1% BSA-PBS, three times with PBS and once with sterile water. After air-drying, coverslips were mounted in Mowiol mounting medium. Cells were viewed and images were taken with a fluorescence microscope.

10 *Production, purification and titration of helper phage with RGD-4C ligand displayed on pVIII coat proteins (Figure 44)*

Wild-type M13 phage DNA was modified to express RGD-4C on pVIII coat proteins by polymerase chain reaction (PCR). The primers used in the PCR were designed by a colleague (Sajee Waramit) prior to the start of this project. PCR product was ligated
 15 using T4 DNA ligase (NEB) and transformed into DH5 α bacteria for cloning. Plasmids are extracted by Miniprep (QIAGEN), validated by restriction digestion and gel electrophoresis and then sent for sequencing to ensure integrity of DNA sequences (MRC CSC Genomics Core). The selected clone was then transformed into TG1 competent E.coli (Zymo research) and plated on 2xYT (Sigma) agar with 50 μ g/ml
 20 kanamycin overnight in an incubator at 37°C.

After colonies form, a single colony is selected and grown in 1L of 2xYT media with kanamycin in a shaking incubator (32°C, 220 rpm) for 18 hours. The overnight culture was centrifuged at 6000g for 30 minutes at 4°C. Phage supernatant was collected and
 25 20%v/v PEG/NaCl (20% PEG 6000, 2.5M NaCl) was added and mixed thoroughly. After incubation in the cold room overnight, the supernatant was centrifuged again at 10000g for 30 minutes at 4°C. Phage pellet was re-suspended in 16mL phosphate buffer saline (PBS) and 20%v/v PEG/NaCl and kept in the cold room overnight. The final phage suspension was centrifuged at 10,000g for 30 minutes at 4°C and the
 30 supernatant discarded. The purified phage pellet was re-suspended in 1-2 mL of PBS (depending on the pellet size) and sterile-filtered through a 0.45 μ m filter cartridge.

Titration was carried out using serial dilutions of 10-fold increments. 5 μ L of each dilution of phage was used to infect 500 μ L of naïve TG1 E.coli that has been grown to
 35 log phase (OD₆₀₀=0.45-0.50) by incubating them for 30 minutes at 37°C. Following incubation, 100 μ L of the bacteria was plated on 2xYT agar with kanamycin overnight in

an incubator at 37°C. Colonies were counted on the following morning after 18 hours of incubation and virus titre estimated and expressed as bacterial transducing units (TU).

Production, purification and titration of RGD pVIII vectors containing reporter genes (Green Fluorescent Protein [GFP] and lucia luciferase [lucia]) (Figure 45)

To assess efficiency in transduction of DIPG cells, vectors were constructed containing phagemids with the reporter genes green fluorescent protein (GFP) and lucia (InvivoGen). GFP expression can be detected via fluorescent microscopy, while lucia is a secreted luciferase that can be quantified with its substrate Quanti-Luc by measuring Relative Luciferase Units (RLUs). The following protocol uses PAAV-GFP plasmid or PAAV-lucia plasmids.

Plasmids were first transformed into TG1 competent E.coli (Zymo research) and plated on 2xYT (Sigma) agar with 50µg/ml ampicillin overnight in an incubator at 37°C. After colonies form, a single colony is selected and grown in 2xYT media with ampicillin in a shaking incubator (32°C, 220 rpm). 100mL of the bacteria is grown to log phase (OD600=0.45-0.50), following which 15-20µL of the RGD pVIII helper phage is added and incubated in a shaking incubator (32°C, 150 rpm). The bacteria are then grown in 1L of 2xYT media containing kanamycin and ampicillin in a shaking incubator (32°C, 150 rpm) for 18 hours. Purification was carried out as per previous investigation. Titration was carried out by growing bacteria on 2xYT with ampicillin only and on another plate with kanamycin only, in order to estimate titre of reporter gene vector and helper phage respectively.

Production, purification and titration of H5W peptide RGD pIII vectors containing reporter gene (lucia)

H5W RGD pIII helper phage was produced by a colleague (Sajee Waramit) prior to the start of this project. Production was largely similar to previous stated protocol, with the exception that 1mM isopropyl β-D-1-thiogalactopyranoside (IPTG) was also added to select for H5W RGD pIII vectors. Purification and titration of vectors were carried out as per previous investigation.

Transduction of vector into cells

Cells used in transduction (HEK293T or DIPG) were seeded in plates until 60-70% confluent. The media is then removed and cells were incubated overnight with vectors diluted in OptiMEM, the amount of which is derived based on the virus titre obtained

from titration. The transduction media is then removed and replaced with complete media. For cells transduced with GFP, at indicated time points the cell is viewed under fluorescence and images taken to look for cells expressing GFP. For cells transduced with lucia, at indicated time points 10µl of cell media and 25µl of Quanti-Luc (InvivoGen), the substrate for the lucia, were mixed in a white polystyrene 96-well plate then incubated for 5 minutes at RT. Luciferase expression was quantified using a Promega Glomax microplate reader.

Assess and investigate the killing potential of therapeutic gene TRAIL against DIPG

Production of PAAV-human TRAIL (hTRAIL) plasmid for transfection (Figure 46)

The GFP sequence in a PAAV-GFP plasmid was replaced by the hTRAIL gene sequence by PCR. hTRAIL gene was amplified and designed to contain restriction sites for EcoRI and SalI at the ends by cloning pUNO1-hTRAIL (InvivoGen) using specific primers (Table 1). Molecular cloning, plasmid extraction and DNA sequence validation were carried out as per previous investigation. The selected clone was then transformed into TG1 bacteria for amplification, then extracted via Maxiprep (QIAGEN).

Table 1: Primer sequences (Invitrogen) used to produce hTRAIL fragment with restrictions sites (EcoRI/SalI) using pUNO1-hTRAIL and PCR.

Forward primer 5' – 3'
GAG TGA ATT CGC TGT GAC CGG CGC CTA C – SEQ ID NO: 24
Reverse primer 5' – 3'
GCT CGT CGA CTC ATG TCT GGC CAG CTA GCT TAG CC – SEQ ID NO: 25

Transfection of plasmids into cells

DIPG cells were seeded in 48 well-plates until 60-70% confluent. Prior to start of experiment, cells were incubated in OptiMEM low serum media for 1-2 hours. For 48-well plates, the FuGENE HD transfection protocol (Promega) the protocol advises to aim for a media volume of 0.5-2.0ml, FuGENE volume of 0.6-1.8µl and DNA amount of 0.2-0.6µg. Transfection efficiency depends on the ration of FuGENE to DNA, in this case a ratio of 3:1 is used.

Eppendorf tubes were prepared and labelled for use in the experiment. OptiMEM was added to each tube up to 20µl, depending on the volume of FuGENE to be used. FuGENE is then directly added into the medium without contact with the walls of the

- 89 -

plastic tube, and the mixture is incubated for 5 minutes at RT. Plasmid DNA is added to the tubes and the transfection reagent:DNA complex is incubated for 15 minutes at RT. The complex is then added to DIPG cells in a drop-wise manner and the plate swirled to ensure even distribution. Cells were incubated at 37°C for 6 hours, following which the
 5 transfection media is changed TSM media supplemented with FBS without antibiotic. Cells are replaced in the incubator and observed for cell viability in the next 24-48 hours.

Results

10 *DIPG cells express integrin receptors for RGD-4C ligand binding*

To establish the suitability of this vector model in this cell line for targeted gene delivery, cells were first investigated for expression of the integrins $\alpha\beta 3$ and $\alpha\beta 5$, by means of fluorescence microscopy. As shown in Figure 47, DIPG cells tested were positive for expression for α , $\beta 3$ and $\beta 5$ units, with no fluorescence observed in cells
 15 incubated without antibodies or secondary antibody alone.

RGD-4C ligand as displayed on pIII coat protein produced higher transduction efficiency and gene expression levels than pVIII coat protein

Previous data from the inventor's lab has shown that targeted RGD-4C pIII vector
 20 mediated gene delivery and expression was selective and efficient as compared to un-targeted vector. In order to optimise transduction, one of the hypotheses was to display the RGD-4C on the pVIII coat protein in order to increase the number of copies of ligand per phage (Figure 48).

25 Using reporter gene vectors (GFP or lucia), transduction efficiency was compared using human kidney embryonic cells, HEK293T, a cellular model that was continuously used to characterise phage vectors. Cells were incubated with un-targeted vector (control lacking RGD-4C), targeted RGD pIII PAAV-GFP or RGD pVIII PAAV-GFP vectors and viewed under fluorescent microscopy (Figure 49). Across all TUs, the highest GFP
 30 expression was seen in cells transduced with RGD pIII PAAV-GFP.

Similarly, in HEK293T cells transduced with un-targeted, RGD pIII PAAV-lucia or RGD pVIII PAAV-lucia vectors, the highest RLU is observed in RGD pIII PAAV-lucia (Figure 50). This suggested that RGD displayed on pIII was superior to pVIII in
 35 transduction and gene expression.

H5W peptide as displayed on recombinant pVIII coat protein improves transduction efficiency and gene expression

An alternative strategy to optimise the vector was to display H5W peptide on recombinant pVIII coat protein. Previous data from the lab showed that in a transduction experiment using vectors containing reporter gene lucia (Sajee Waramit, unpublished data), display of H5W peptide increases luciferase expression in HEK293T cells as compared to RGD pIII alone (Figure 51).

To investigate if this finding could be applied to DIPG cells, DIPG cells were incubated with un-targeted, RGD pIII PAAV-lucia or H5W RGD pIII PAAV-lucia vectors. Consistent with that of HEK293T data, the highest RLU in DIPG cells is observed in H5W RGD pIII PAAV-lucia (Figure 52). This suggested that H5W peptide was able to improve vector efficiency in DIPG cells and should be used in the final vector construct.

Transfection of PAAV-hTRAIL plasmid into DIPG cells induced cell death

Following optimisation of vector and before further experiments were conducted, it was essential to determine if the selected gene of interest, human TRAIL (hTRAIL), was able to induce cell death in DIPG cells via transfection.

DIPG cells were transfected with either PAAV-hTRAIL or control PAAV-GFP plasmid. There was significantly more cell death in cells transfected with PAAV-hTRAIL according to microscopic images taken 18 hours post-transfection at all DNA concentrations (Figure 53).

Discussion

Without wishing to be being bound to any given theory, the data thus far show that vectors expressing H5W and RGD-4C on pIII coat proteins were most optimal in targeting and inducing expression of desired genes in DIPG cells. Data from transfection experiments also suggests that the therapeutic gene TRAIL is able to induce DIPG cell death, which warrants further investigation.

Example 12 – hybrid IL2-TNF α

To increase targeted loco-regional production of TNF α within the tumour site, the inventors constructed a phagemid encoding a secreted TNF α by inserting a signal peptide from IL-2 to precede the TNF α sequence lacking the transmembrane domain. To the inventor's knowledge this is the first time that a hybrid IL2-TNF α was designed

and their data suggest that preceding TNF α gene with the IL2 signal peptide sequence significantly enhanced expression and secretion of TNF α in cancer cells. Such modifications represent a significant advance in the technique available for targeted production and release of TNF α in the tumour microenvironment and should be
 5 considered for increasing the therapeutic levels of TNF α .

Protocol

PAAV.Grp78.IL-2SP.hTNF α construction

The coding therapeutic sequence inserted in the phagemid is a hybrid sequence that
 10 contained a tumour specific promoter of the Glucose Regulated protein (Grp78), signal peptide (SP) sequence from IL-2 (Figure 57) and human sequence of TNF α . The *Grp78* promoter is stress-inducible and is strongly activated by conditions of glucose deprivation, chronic anoxia, and acidic pH that persist within aggressive and poorly perfused tumours. Moreover, the *Grp78* promoter is induced in a wide variety of
 15 tumours and thus makes it an attractive candidate for use in gene therapy. Previous studies have demonstrated several advantages of this promoter over viral promoters. The safety and tumour specificity of this promoter have also been elegantly reported in transgenic mice carrying a *LacZ* transgene. High *LacZ* expression was shown in tumours established in these transgenic mice, while no promoter activity was detected
 20 in major normal tissues. Furthermore, unlike viral promoters used in gene therapy vectors, mammalian promoters such as *Grp78* are not silenced in eukaryotic cells. In the inventor's previously published work, they reported that the double-targeted RGD4C/phage-*Grp78* provides persistent transgene expression over RGD4C/Phage-*CMV* carrying the cytomegalovirus *CMV* promoter. Inclusion of both RGD4C ligand
 25 and *Grp78* promoter generates a vector with dual tumour targeting at both cell entry and transcriptional levels.

The TNF α ₁ is transmembrane, to generate a secreted TNF α ₂ with better availability for its receptor on the cell surface of tumour cells, we generated a secreted form of TNF α ,
 30 by removing the transmembrane domain of TNF α ₁ and replacing it with the signal peptide of interleukin-2 (IL-2). The IL-2 was previously used as an effective signal peptide tested in various studies to enhance the secretion of other cytokines or growth factors into the extracellular milieu and subsequently increased their efficacy and availability for their corresponding receptors. IL-2 signal peptide sequence flanked by
 35 *BamHI* and *EcoRI* restriction sites (Thermoscientific, UK) was ligated to PAAV.Grp78

backbone. hTNF α sequence flanked by *EcoRI* and *Sall* restriction sites was provided from pUNO1-hTNF α plasmid (Invivogen, France) by polymerase chain reaction (PCR), then ligated to PAAV.Grp78.IL-2 backbone. Molecular cloning steps were conducted using restriction enzyme digestion (NEB, UK) and quick T4 DNA ligase for ligation (NEB, UK). The modified plasmid was transformed into TG1 competent *E. coli* (Zymo research, USA). The bacteria carrying the plasmid were then selected by ampicillin selection on 2xYT agar plate. The construct was validated by restriction digestion and gel electrophoresis, and DNA sequencing (MRC CSC Genomics Core Laboratory, UK) see Figure 58.

10

Example 13 - Application of PAAV-delivered TNF α cytokine gene therapy in DIPG

Introduction

Diffuse intrinsic pontine glioma (DIPG) is the most aggressive brain tumour that arise exclusively in children with poor survival of only 6-10% beyond two years. Due to its diffuse nature and its sensitive location in the brainstem, surgical removal is not feasible and there is no effective therapeutic strategy for this type of cancer. The current standard treatment for DIPG is radiotherapy, which is not showing any success, as all children relapse afterwards, even in combination with radio-sensitizers. Many clinical trials have tested the effect of chemotherapy in combination with the conventional radiotherapy, yet no improvement on increasing the overall survival even when combining high doses of chemotherapeutic drugs. This resistance to chemotherapy is due to the intact blood brain barrier as well as the anatomical location of DIPG in the pons makes it more difficult for any drug to reach the targeted location. To overcome this issue, a clinical trial has applied the use of convection-enhanced delivery (CED) to deliver the chemodrug, topotecan, for the treatment of DIPG in 2 children. In this pilot study, both patients died after treatment although initially there was a reduction in tumour size. CED is a technique that directs the delivery of chemotherapeutic drugs to the brain tumours through sustained flow. This technique is being used lately by clinical trials to overcome the drug delivery challenges by bypassing the blood brain barrier.

30

Targeted therapy for DIPG seems to be the best solution due to its diffuse nature and sensitive location. In an attempt to target DIPG tumour, an ongoing clinical trial applying the concept of targeted radiation through labelling a radioactive substance,¹²⁴I, with 8H9 antibody, which is known to bind selectively to cancer cells sparing the healthy brain cells (clinicaltrials.gov ID NCT01502917) [8]. Another

35

candidate to target brain tumours, as suggested by our group (Hajitou's lab) and showed high selectivity in glioblastoma, are the integrins $\alpha v \beta 3$ and $\alpha v \beta 5$ through the binding of RGD4C peptide as discussed in chapter 3. In fact, RGD4C targeting DIPG is currently being used in an ongoing phase I clinical trial (clinicaltrials.gov ID

5 NCT03178032). In this trial an oncolytic adenovirus, DNX2401, is used to target tumour cells and induce cell death. Among thirty ongoing clinical trials for DIPG, the majority are focused on testing different drugs and radiotherapy, other treatments including gene therapy has not yet been applied. TNF α is an inflammatory cytokine that is known for its anticancer properties by mediating apoptosis, necrosis, and

10 immune cell activation. Depending on the cell context, it can also induce cell proliferation and angiogenesis. Its anti-tumour activity has been studied in many solid tumours including colon cancer, oesophageal adenocarcinoma, melanoma, pancreatic cancer and many others. Yet, the efficiency as a therapeutic agent was very limited due to its significant toxicities when introduced systemically. This limited the clinical use of

15 TNF α in the clinic as a therapeutic agent for cancer to be used for soft tissue sarcoma, melanoma and other irresectable tumours confined to the limb in the form of isolated limb perfusion (ILP) to avoid limb amputation. Indeed, TNF α works synergistically with chemotherapeutic drugs in vivo through targeting tumour vasculature disrupting the VE-cadherins and thus increase the penetration of the chemotherapeutic drugs to

20 tumour environment. Thus, efforts to overcome the limitation of systemic toxicity are required to enhance therapeutic efficacy of TNF α . One strategy was made to decrease TNF α toxicity and yet retain its anti-tumour activity by making a mutant form of TNF α . This mutated TNF α was further targeted to the tumour environment by the signalling peptide RGD4C and enhanced the efficiency of the chemotherapeutic drugs in

25 hepatoma and sarcoma allografts.

In vitro studies for DIPG are very limited with little human tissue available for study, restricting the understanding of this devastating type of brain cancer. Therapeutic applications, other than chemotherapeutic drugs and radiotherapy, are also hindered

30 due to the lack of in vitro applications and understanding. Thus, in the inventors investigated the therapeutic effect of two forms of TNF α , transmembrane (tmTNF α) and secreted (sTNF α), against DIPG. TNF α was used in the form of gene therapy to be expressed and delivered to the cells using PAAV targeted by the signalling peptide RGD4C. Without wishing to be bound to any particular theory, the use of RGD4C-

35 targeted PAAV as a therapeutic gene delivery vehicle to the tumour site will ensure safer, selective and efficient gene transfer for the treatment of DIPG.

In order to understand the mechanism of cell death induced by TNF α , the inventors studied the viability and apoptotic activity in response to transduction of PAAV carrying two different forms of TNF α , tmTNF α and sTNF α . The apoptotic activity was
5 determined by measuring the activity of caspase3/7, caspase 8, and caspase 9.

Finally, the effect of chemotherapeutic drug, cisplatin, in enhancing gene therapy was studied. Thus, two different promoters, GRP78 and CMV, upstream of TNF α were used to understand the synergistic effect of gene therapy with cisplatin. Lucia reporter gene
10 under the control of GRP78 and CMV promoters was used for quantitative analysis for gene expression after cisplatin treatment and further understand the role of cisplatin in enhancing gene expression.

Results

15 *Transduction of DIPG with PAAV carrying the transmembrane tmTNF α and secreted sTNF α transgene:*

Transmembrane TNF α gene and secreted TNF α were cloned into PAAV vector, PAAV-tmTNF α and PAAV-sTNF α (comprising the vector as shown in example 12), followed by the production of targeted (RGD4C) and non-targeted (M13/control) viruses. DIPG
20 cells were transduced and cell viability was measured at day 7 post-transduction. The transduction efficiency was further enhanced with 40ng/ μ g of phage protein DEAE dextran. DIPG cells showed better response to PAAV-sTNF α in inducing cell death compared to PAAV-tmTNF α , where the former shows about 50% cell death on day 7 compared to only 20% cell death that was induced by the transmembrane form as
25 shown in figure 59. Together, these data suggest that sTNF α is a good candidate for the treatment of DIPG.

Gene delivery and TNF α expression after transduction with PAAV:

The efficiency of PAAV gene delivery was assessed by measuring mRNA levels after
30 transduction. Both forms of TNF α were expressed in the transduced cells with high specificity as the non-targeted (M13) form shows negligible mRNA expression of TNF α compared to the targeted PAAV (RGD4C) as shown in figure 60A. At the protein level, Transduction of PAAV- tmTNF α did not lead to the secretion of TNF α in the medium as was detected by ELISA (figure 60B). Although transduction with both forms shows
35 TNF α expression at the mRNA level, only the secreted form was related to the level of TNF α protein. This further confirms that the transduction of the transgene was

- 95 -

efficient and may suggest that the inefficiency of inducing cell death by the transmembrane form is due to the lack of soluble secreted protein. As the release of sTNF α from the initial membrane bound form requires the enzymatic activity or expression of TNF α converting enzyme (TACE). Thus, TACE enzyme expression was
5 measured by western blot and compared with other paediatric brain tumour cells (medulloblastoma). DIPG expression of TACE enzyme was 4X lower than the expression level of UW228 and 2X lower than the expression level of Daoy cells.

CLAIMS

1. A recombinant phagemid particle for expressing a transgene in a target tumour cell transduced with the particle, for use in a method for treating, preventing,
5 or ameliorating cancer, wherein the phagemid particle comprises at least one transgene expression cassette comprising a nucleic acid sequence encoding one or more cytokine, and comprises a genome which lacks at least 50% of its bacteriophage genome, and wherein the method comprises delivering the nucleic acid sequence to at least adjacent to the tumour cell, such that one or
10 more cytokine is expressed.
2. The recombinant phagemid particle for use according to claim 1, wherein the transgene expression cassette encodes a cytokine which has the effect of apoptosis induction in the tumour cell, alternation of the tumour cell to
15 promote endogenous anti-tumour responses, alternation of the tumour cell to facilitate other therapies, or alternation of the tumour microenvironment to facilitate therapy.
3. The recombinant phagemid particle for use according to either claim 1 or 2,
20 wherein the cytokine is IL-4, IL-12, IL-15, TNF α , TRAIL, IFN- γ , or any combination thereof, optionally wherein the cytokine is IL-15.
4. The recombinant phagemid particle for use according to any preceding claim,
25 wherein the cytokine is a hybrid cytokine comprising a non-endogenous signal peptide configured to increase expression and/or secretion of the cytokine.
5. The recombinant phagemid particle for use according to claim 4, wherein the non-endogenous signal peptide is an IL-2 signal peptide.
- 30 6. The recombinant phagemid particle for use according to claim 5, wherein the hybrid cytokine is a hybrid TNF α comprising a IL-2 signal peptide configured to increase expression and/or secretion of TNF α .
- 35 7. The recombinant phagemid particle for use according to claim 6, wherein the hybrid TNF α comprises an amino acid sequence substantially as set out in SEQ ID No: 22 or a fragment or variant thereof.

8. The recombinant phagemid particle for use according to either claim 6 or 7, wherein the hybrid TNF α is encoded by a nucleic acid sequence comprising SEQ ID No: 23 or a fragment or variant thereof.
- 5
9. The recombinant phagemid particle for use according to any preceding claim, for use in treating, preventing or ameliorating paediatric brain tumours, optionally diffuse intrinsic pontine glioma (DIPG) or medulloblastoma.
- 10
10. A system for producing a recombinant phagemid particle from a prokaryotic host, the system comprising:-
- (i) a first vector configured to persist inside a prokaryotic host, and comprising at least one transgene expression cassette comprising a nucleic acid sequence encoding one or more cytokine, and a packaging signal for enabling replication of the vector into single-stranded DNA; and
- 15
- (ii) a second vector comprising nucleic acid encoding structural proteins required for packaging the single-stranded DNA, resulting in the formation and extrusion of a recombinant phagemid particle from the prokaryotic host.
- 20
11. A method for producing a recombinant phagemid particle from a prokaryotic host, the method comprising:-
- i) introducing, into a prokaryotic host cell, a first vector configured to persist inside the prokaryotic host, and comprising at least one transgene expression cassette comprising a nucleic acid sequence encoding one or more cytokine, and a packaging signal for enabling replication of the vector into single-stranded DNA;
- 25
- ii) introducing, into the host, a helper phage comprising nucleic acid encoding bacteriophage structural proteins; and
- 30
- iii) culturing the host under conditions which result in the single-stranded DNA being packaged by the structural proteins to form and extrude a recombinant phagemid particle from the prokaryotic host.
- 35
12. A method for producing a recombinant phagemid particle from a prokaryotic host, the method comprising:-

- 98 -

- 5 i) introducing into a prokaryotic host cell: (a) a first vector configured to persist inside the prokaryotic host, and comprising at least one transgene expression cassette comprising a nucleic acid sequence encoding one or more cytokine, and a packaging signal for enabling replication of the vector into single-stranded DNA, and (b) a second vector comprising nucleic acid encoding structural proteins required for packaging the single-stranded DNA; and
- 10 ii) culturing the host under conditions which result in the single-stranded DNA being packaged by the structural proteins to form and extrude a recombinant phagemid particle from the prokaryotic host.
13. A pharmaceutical composition comprising the recombinant phagemid viral particle produced by the system according to claim 10, or produced by the method of claim 11 or 12, and a pharmaceutically acceptable vehicle.
- 15 14. A process for making the pharmaceutical composition according to claim 13, the process comprising contacting a therapeutically effective amount of the recombinant phagemid particle produced by the system according to claim 10, or produced by the method of claim 11 or 12, and a pharmaceutically acceptable vehicle.
- 20 15. A recombinant phagemid particle for expressing a transgene in a target tumour cell transduced with the particle, wherein the phagemid particle comprises at least one transgene expression cassette comprising a nucleic acid sequence encoding one or more cytokine, and comprises a genome which lacks at least 50% of its bacteriophage genome, and wherein, in use, the particle is configured to deliver the nucleic acid sequence to at least adjacent to the tumour cell, such that one or more cytokine is expressed, and wherein the cytokine is any one of IL-4, IL-12, IL-15, TRAIL, IFN- γ , hybrid TNF α or any combination thereof, optionally wherein the cytokine is IL-15.
- 25 30 16. The recombinant phagemid particle of claim 15, for use in therapy or diagnosis.
- 35 17. A recombinant phagemid particle for expressing at least one antigen in a target tumour cell transduced with the particle, the phagemid particle comprising at least one transgene expression cassette comprising a nucleic acid sequence

- 99 -

encoding one or more cytokine, and comprising a genome which lacks at least 50% of its bacteriophage genome, and wherein, in use, the particle is configured to deliver the nucleic acid sequence to at least adjacent to the target tumour cell, such that the one or more cytokine is expressed.

5

18. The recombinant phagemid particle according to claim 17, for use in therapy or diagnosis.

10

19. The recombinant phagemid particle according to claim 17, for use in treating, preventing or ameliorating cancer.

20. Use of a helper phage comprising nucleic acid encoding viral vector structural proteins to produce the recombinant phagemid particle according to claim 17 from a prokaryotic host.

15

21. A recombinant phagemid viral particle according to claim 17, produced by the system of claim 10, produced by the methods of claim 11 or 12, or produced according to the use of claim 20, wherein the recombinant phagemid particle is for production of a recombinant viral vector comprising or derived from the viral genome within the genome of the phagemid particle, wherein the recombinant viral vector is used for delivering the nucleic acid sequence encoding one or more antigen, to at least adjacent to the tumour cell, such that one or more cytokine is expressed.

20

25

22. A recombinant vector comprising rAAV, rep-cap, adenohelper genes, and a nucleic acid sequence encoding one or more antigen or cytokine, for use in the treatment, prevention, or amelioration of cancer.

30

23. A recombinant phagemid particle comprising the vector of claim 22, for use in a method for the treatment, prevention, or amelioration of cancer.

35

24. The recombinant phagemid particle according to claim 15 or 17, or produced by the system of claim 10, or produced by the methods of claim 11 or 12, or produced according to the use of claim 20 or 21, or for use according to any of claims 1-9 and 22-23, or according to the pharmaceutical composition of claim 13, or according to the process for making the pharmaceutical composition of

- 100 -

claim 14, wherein the phagemid particle is configured to deliver the transgene expression cassette to the target tumour cell.

- 5 25. A particle according to claims 15, 17 or 24, or produced by the system of claim 10, produced by the methods of claim 11 or 12, or produced according to the use of claim 20 or 21, or for use according to any of claims 1-9 and 22-23, or according to the pharmaceutical composition of claim 13, or according to the process for making the pharmaceutical composition of claim 14, wherein the genome of the recombinant phagemid particle comprises a packaging signal for enabling replication of the phagemid genome into single-stranded DNA, which can subsequently be packaged into the phagemid particle inside a prokaryotic host, optionally wherein the packaging signal comprises an origin of replication, optionally an F1 ori.
- 10 26. A particle according to claims 15, 17, 24 or 25, or produced by the system of claim 10, or produced by the methods of claim 11 or 12, or produced according to the use of claim 20 or 21, or for use according to any of claims 1-9 and 22-23, or according to the pharmaceutical composition of claim 13, or according to the process for making the pharmaceutical composition of claim 14, wherein the genome of the recombinant phagemid particle comprises an origin of replication for enabling replication of double-stranded vector inside a prokaryotic host, optionally a pUC ori.
- 15 27. A particle according to any one of claims 15, 17, 24-26, or produced by the system of claim 10, or produced by the methods of claim 11 or 12, or produced according to the use of claim 20 or 21, or for use according to any of claims 1-9 and 22-23, or according to the pharmaceutical composition of claim 13, or according to the process for making the pharmaceutical composition of claim 14, wherein the genome of the recombinant phagemid particle comprises one or more DNA sequence, which favours targeted integration into a host genome.
- 20 28. A particle according to any one of claims 15, 17, 24-27, or produced by the system of claim 10, or produced by the methods of claim 11 or 12, or produced according to the use of claim 20 or 21, or for use according to any of claims 1-9 and 22-23, or according to the pharmaceutical composition of claim 13, or according to the process for making the pharmaceutical composition of claim
- 25 30 35

- 101 -

14, wherein the at least one transgene expression cassette comprises a viral transgene expression cassette.

5 29. A particle according to any one of claims 15, 17, 24-28, or produced by the system of claim 10, or produced by the methods of claim 11 or 12, or produced according to the use of claim 20, or for use according to any of claims 1-9 and 22-23, or according to the pharmaceutical composition of claim 13, or according to the process for making the pharmaceutical composition of claim 14, comprising multiple transgene expression cassettes.

10

30. A particle according to any one of claims 15, 17, 24-29, or produced by the system of claim 10, produced by the methods of claim 11 or 12, or produced according to the use of claim 20 or 21, or for use according to any of claims 1-9 and 22-23, or according to the pharmaceutical composition of claim 13, or
15 according to the process for making the pharmaceutical composition of claim 14, wherein the at least one transgene expression cassette comprises a mammalian viral transgene expression cassette.

20 31. A particle according to any one of claims 15, 17, 24-30, or produced by the system of claim 10, or produced by the methods of claim 11 or 12, or produced according to the use of claim 20 or 21, or for use according to any of claims 1-9 and 22-23, or according to the pharmaceutical composition of claim 13, or according to the process for making the pharmaceutical composition of claim 14, wherein the transgene expression cassette comprises one or more
25 functional elements required for expression of the nucleic acid in the target cell selected from the groups consisting of: a promoter, nucleic acid for encoding a polyA tail attachable to the expressed agent, and either left and/or right Inverted Terminal Repeat sequences (ITRs) or left and/or right Long Terminal repeat sequences (LTRs).

30

32. A particle according to any one of claims 15, 17, 24-31, or produced by the system of claim 10, or produced by the methods of claim 11 or 12, or produced according to the use of claim 20 or 21, or for use according to any of claims 1-9 and 22-23, or according to the pharmaceutical composition of claim 13, or
35 according to the process for making the pharmaceutical composition of claim 14, wherein the at least one transgene expression cassette comprises a

- 102 -

lentivirus transgene expression cassette.

- 5 33. A particle according to any one of claims 15, 17, 24-32, or produced by the system of claim 10, or produced by the methods of claim 11 or 12, or produced according to the use of claim 20 or 21, or for use according to any of claims 1-9 and 22-23, or according to the pharmaceutical composition of claim 13, or according to the process for making the pharmaceutical composition of claim 14, wherein the at least one transgene expression cassette comprises an adeno-associated virus (AAV) transgene expression cassette.
- 10 34. A particle according to any one of claims 15, 17, 24-33, or produced by the system of claim 10, or produced by the methods of claim 11 or 12, or produced according to the use of claim 20 or 21, for use according to any of claims 1-9 and 22-23, or according to the pharmaceutical composition of claim 13, or
- 15 according to the process for making the pharmaceutical composition of claim 14, wherein the transgene expression cassette further comprises a nucleic acid encoding an agent, which has therapeutic or industrial utility in the target cell or tissue, optionally wherein the agent encoded by the nucleic acid is polypeptide or protein.
- 20 35. A particle according to any one of claims 15, 17, 24-34, or produced by the system of claim 10, or produced by the methods of claim 11 or 12, or produced according to the use of claim 20 or 21, or for use according to any of claims 1-9 and 22-23, or according to the pharmaceutical composition of claim 13, or
- 25 according to the process for making the pharmaceutical composition of claim 14, wherein the recombinant phagemid particle comprises one or more capsid minor coat protein, optionally wherein the recombinant phagemid particle comprises a pIII capsid minor coat protein that is configured to display a cell-targeting ligand for enabling delivery of the particle to the target tumour cell.
- 30 36. A particle according to any one of claims 15, 17, 24-35, or produced by the system of claim 10, or produced by the methods of claim 11 or 12, or produced according to the use of claim 20 or 21, or for use according to any of claims 1-9 and 22-23, or according to the pharmaceutical composition of claim 13, or
- 35 according to the process for making the pharmaceutical composition of claim 14, wherein the recombinant phagemid particle comprises one or more capsid

major coat protein, optionally wherein the recombinant phagemid particle comprises at least one pVIII capsid major coat protein that is configured to display a foreign peptide thereon.

- 5 37. A particle according to any one of claims 15, 17, 24-36, or produced by the system of claim 10, or produced by the methods of claim 11 or 12, or produced according to the use of claim 20 or 21, or for use according to any of claims 1-9 and 22-23, or according to the pharmaceutical composition of claim 13, or according to the process for making the pharmaceutical composition of claim 10 14, wherein the recombinant phagemid particle is combined with a cationic polymer to form a complex having a net positive charge, optionally wherein the cationic polymer is selected from a group consisting of: chitosan; poly-D-lysine (PDL); diethylaminoethyl (DEAE); diethylaminoethyl-dextran (DEAE.DEX); polyethyleneimine (PEI); polybrene; protamine sulphate; 5 and a cationic lipid.
- 15 38. A particle according to any one of claims 15, 17, 24-37, or produced by the system of claim 10, or produced by the methods of claim 11 or 12, or produced according to the use of claim 20 or 21, or for use according to any of claims 1-9 and 22-23, or according to the pharmaceutical composition of claim 13, or 20 according to the process for making the pharmaceutical composition of claim 14, wherein:
- a. the genome of the recombinant phagemid particle lacks at least 60%, 70%, or at least 80% of the bacteriophage genome from which it is derived;
 - 25 b. a particle according to any preceding claim, wherein the genome of the recombinant phagemid particle lacks at least 90%, 95%, or at least 99% of the bacteriophage genome from which it is derived; or
 - c. a particle according to any preceding claim, wherein the phagemid particle lacks bacteriophage structural genes in its genome required for 30 the formation, packaging or extrusion of the particle from a prokaryotic host, preferably structural genes which encode the capsid proteins.

Figure 1

Comparing AAVP and PAAV

	Next-generation PAAV vectors
Relative genome size	c. 6000 bases (42% of AAVP)
Relative virus size	~50% shorter than AAVP
Production yield	up to 100,000X current AAVP yields
Payloads per particle	Multiple (AAVP can only carry 1 payload)
Biodistribution	<i>Potentially better</i>





Figure 2

***Phagemid/Adeno-associated
Virion (PAAV)***


Figure 3

Figure 4




Figure 5




Figure 6




Figure 7




Figure 8

[illegible]

Figure 9





Figure 9 continued

Figure 10




Figure 10 continued




Figure 11

Phagemid-guided rAAV production – methodology




Figure 12




Figure 13





Figure 14


Figure 15

Figure 16





Figure 17

Figure 18





Figure 19

Figure 20





Figure 21

Figure 22




Figure 23




Figure 24




Figure 25





Figure 26

Figure 27A






Figure 27B**Figure 27C**


Figure 28


Figure 28 (cont)

Figure 29




Figure 30




Figure 31a

Created with SnapGene®




Figure 31b

Created with SnapGene®




Figure 31c

Created with SnapGene®




Figure 31d

Created with SnapGene®




Figure 31e

Created with SnapGene®




Figure 31f

Created with SnapGene®




Figure 32




Figure 33a

Created with SnapGene®




Figure 33b

Created with SnapGene®




Figure 33c

Created with SnapGene®




Figure 33d

Created with SnapGene®




Figure 33e

Created with SnapGene®




Figure 33f




Figure 34





Figure 35


Figure 36

Figure 37




Figure 37 continued

A Cloud with a Secret





Figure 38

A.



B.





Figure 39


Figure 40

Figure 41




Figure 42




Figure 43





Figure 44


Figure 45

Figure 46





Figure 46 continued

Amplified hTRAIL EcoRI SalI
921 bp

PCR ↑ Amplify 527 .. 1427 using:
forward primer human TRAIL
reverse primer human TRAIL



pUNO1-hTRAIL
4026 bp

Figure 47





Figure 48

Figure 49




Figure 50




Figure 51




Figure 52




Figure 53




Figure 54




Figure 55




Figure 56




Figure 57




Figure 58




Figure 59




Figure 60







Figure 2



***Phagemid/Adeno-associated
Virion (PAAV)***